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REGULATION OF TUMOR CELL METASTASIS BY CD151
TRENIS PALMER
Dissertation under the direction of Professor Andries Zijlstra
  Our lab has demonstrated that clustering of the tetraspanin CD151 on the sur-
face of tumor cells inhibits cell migration and cancer metastasis. As a member of the tet-
raspanin superfamily CD151 associates with a number of proteins on the cell surface 
and functions as a molecular scaffolding protein when clustered into protein rich com-
plexes known as Tetraspanin Enriched Microdomains (TERM). Treatment of tumor cells 
with the anti-CD151 monoclonal antibody (MAb) 1A5 promotes the localization of CD151 
to the areas of cell-cell contact to promote adhesion and inhibit migration and metastasis 
through TERM formation. Due to the published associations with the laminin binding in-
tegrins (primarily α3β1), combined with the ability of CD151 to regulate α3β1-mediated 
adhesion, we hypothesized that it would be involved in the inhibition of migration and 
metastasis mediated by the clustering of CD151. We present data demonstrating that 
1A5 recognizes the integrin-association epitope of CD151 and binds to integrin free 
CD151 (CD151free). Additionally, we demonstrate that the expression of integrin α3 is not 
required for the ability of CD151 to control motility. We found the expression of CD151free 
increasingly present in the tumor tissue of patients with aggressive prostate cancer fur-
thermore, CD151free staining functions an independent prognostic indicator of survival. 
The demonstration that α3β1 is not functionally involved in the regulation of migration by 
CD151 suggests that there are functions of CD151 related to motility that are independ-
ent of integrin associations. By proteomic analysis we elucidated the components of the 
CD151TERM complex and pulled down ALCAM/CD166. We demonstrate that ALCAM is 
required for the inhibition of migration as a component of the CD151-TERM complex. 
Mechanistically, the CD151/ALCAM immobility complex signals through Protein Kinase 
xiv
Cα to activate the small GTPase Rap1A to control motility. Ultimately, sustained activa-
tion of Rap1 is sufficient to inhibit metastasis. This thesis defines the role of CD151 as a 
molecular integrator of migration and regulator of metastasis through its ability to control 
both cell-cell and cell-matrix adhesion.
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CHAPTER I
INTRODUCTION
Tumor Cell Metastasis
 Metastasis is the primary cause of cancer-related mortality. While we have made 
significant advances in the treatment of cancer, there are few if any treatments designed 
to target metastatic disease. Derived from the Greek word meaning displacement or 
movement, metastasis is traditionally defined as the spread of cancer cells from one or-
gan to another non-adjacent organ or tissue. This is an overly simplistic definition but it 
offers a foundation for exactly what metastatic disease: a disease of mis-regulated cell 
motility. There are two principles reasons why treating metastasis has proved difficult: 1) 
the complexity of the metastatic process summarized in Figure 1,(1,2) and 2) the overall 
inefficiency of metastasis, for which it has been suggested that less than <0.001% of all 
circulating tumor cells give rise to secondary metastases(3). The process of metastasis 
is a cyclic process and each sequential step of the cascade must be completed in order 
for a tumor cell to form a metastatic lesion in a distant site. It begins with departure of 
cells from the primary tumor, a process that can be motivated by a number of factors in-
cluding but not limited to the availability of oxygen and nutrient in the tumor microenvi-
ronment, space constraints mediated by rapid growth of the tumor and soluble factors 
that are able to serve as chemoattractants at the secondary site. Following successful 
departure from the primary tumor, disseminating tumors cells must be able to enter the 
vasculature (intravasate) and survive transport through the vascular system. Those cells 
that are able to successfully persist in the vasculature, be able to arrest in a capillary 
bed,and subsequently extravasate at the secondary site. Finally, the secondary site must 
be conducive to tumor growth before the disseminating tumor cells can establish a-
1
Fig.1. Cancer metastasis requires a complex series of events. Cancer 
cells must gain access to blood and lymphatic vessels, survive the trip to dis-
tant locations, move back into the tissues and initiate a new tumor. Because 
each of these steps is required the successful metastatic cell is rare com-
pared with the huge numbers of cancer cells at the primary site. Conse-
quently, metastasis usually only occurs late in cancer evolution. This figure 
modified and adapted from (2).
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metastatic colony of tumor cells. Each step in the metastatic cascade requires unique 
properties not present in every tumor cell. The absence of specific traits or the inability to 
adapt leads to the elimination of tumor cells at each sequential step in this cascade. Al-
though the disease is clearly pathological, the regulation of cell migration is inherent in 
the biology of normal cells. during non-pathological processes such as development and 
wound healing. This is demonstrated experimentally as many of the same processes 
that regulate the motility of normal cells are also involved in the acquisition of the motile 
metastatic phenotype of tumor cells. Therefore, we cannot discuss metastasis without an 
understanding of the process of cell migration in normal cells.
The Process of Cell Migration
 Cell migration is required for development, wound healing, proper immune sys-
tem function, and tumor cell metastasis . The steps of the migration cycle depicted in 
figure 2 can be summarized in five steps: 1). protrusion at the front of the cell 2). adher-
ence to the substrate at the front of the cell which generates tractional force across the 
cell body 3). cell surface proteolysis of cell to matrix proteins 4). contraction of the cell 
body and 5). the release of cell-substrate adhesion at the rear of the cell(4). Although 
this is a very simplistic view of the process of cell motility like the metastatic cascade it is 
a highly coordinated process and in order for a cell to become motile the process must 
be completed successfully. Normal cells such as those that maintain the structural integ-
rity of organs and those involved in maintaining epithelial cell barriers would prefer to 
stay immobile. Similarly, tumor cells would also prefer to remain non-motile. In normal 
and tumor cells the non-motile phenotype is primarily controlled by the expression of cell 
to cell adhesion molecules like E-cadherin. E is an important protein 
3
Fig. 2. Generalized model of Cell Motility. The steps in the cell motility cy-
cle can be divided into steps which include 1). protrusion 2). adhesion to the 
substrate 3). cell surface proteolysis 4). contraction of the cell body and 5) de-
adhesion at the rear cell which completes the migration cycle. This figure 
modified and adapted from (4).
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the processes and development and metastasis. Its expression regulates cohesive na-
ture of epithelial cells and their ability to respond to pro-migratory stimuli. While much of 
what we know about cell motility has been generated from analyses of single cell migra-
tion, this thesis will primarily focus on the migration of epithelial cells that are engaged in 
cell-cell interactions.
The Epithelial Mesenchymal Transition and Metastasis
 For most tumors the progression toward metastatic behavior involves digression 
away from its original epithelial behavior and gain a certain level of phenotypic plasticity. 
This plasticity can occur through de- or trans-differentiation which can be accomplished 
by undergoing a cellar program of Epithelial-to-Mesenchymal cell Transition (EMT). EMT 
is primarily associated with the loss or mis-localization of the epithelial cadherin (E-
cadherin). E-cadherin is highly expressed at epithelial cell-cell junctions and is involved 
in the maintenance of epithelial cell architecture. During embryonic development E-
cadherin is expression is necessary for a number of processes including gastrulation 
and organ morphogenesis(5). It was initially characterized as a “invasion suppressor” 
because its loss is routinely associated with the promotion of tumor cell motility and in-
vasion(6). The loss of E-cadherin is generally considered an early step in the progres-
sion to metastatic disease and in patient samples of invasive/metastatic tumors E-
cadherin expression is either loss or mis-localized further supporting the role of E-
cadherin as a regulator of metastasis (7,8). Although E-cadherin is a prominent example 
of a protein that regulates the motility of normal cells, there are many cell adhesion 
molecules involved in the process of tumor cell metastasis.
Involvement of Cell Motility Processes in Metastasis
 Investigations into the phenomenon of EMT and an analysis of the cellular be-
haviors associated with the loss of E-cadherin provide clues to suggest that motility is 
involved in cancer cell metastasis. One of the major consequences associated with EMT 
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is an increase in cell motility. Additionally a wealth of experimental data generated both 
in vitro and in vivo has demonstrated that the expression of motility-related genes in 
cancer cells is sufficient to drive metastasis in many cell lines and tumor models(9). In 
the following sections this concept will be supported by expounding upon the steps in-
volved in migration while also making connections to the overall metastatic process.
Cell protrusion and re-arrangement of the actin cytoskeleton
 The initial steps involved in the regulation of motility are associated with re-
arrangement of the actin cytoskeleton. Examples of proteins involved in this process in-
clude Arp 2/3, cortactin, and N-WASP. Re-arrangement of the actin cytoskeleton is pri-
marily associated with the formation of two actin rich structures filopodia and lamellapo-
dia, two structures with well defined functions. Filipodia formation is involved in the sens-
ing of extracellular cues and surveillance of the extracellular microenvironment. Lamelli-
podia are thought to be the actual motors that pull the cell along the substratum. Arp2/3 
is a seven subunit protein complex that serves as a site for actin nucleation and is be-
lieved to be important for regulating protrusive events at the front of the cell. It can be 
activated by a number of proteins including Wiskott Aldrich Syndrome Proteins (WASP) 
and cortactin. Arp2/3 activity and expression is involved in the regulation of fibroblast mi-
gration and-expression of Arp 2 and 3 is sufficient to promote the migration of gastric 
cancer cells(10). Arp2/3 expression is up-regulated in many tumors including; 
breast,colorectal, and lung. Additionally, the knockdown of Arp2/3 is sufficient to inhibit 
cancer cell invasiveness (11). Cortactin is an Arp2/3 binding protein routinely up-
regulated in head and neck small squamous cell carcinoma (HNSCC), breast and lung 
cancer. It is involved in the formation of invadapodia, actin-rich structures involved in ex-
tracellular matrix degradation. Phosphorylation of cortactin is thought to be required for 
its ability to regulate migration. The WASP family of proteins also bind Arp2/3 binding 
protein and activate the complex in response to signals that induce migration. The family 
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consists of five proteins all of which are involved in some aspect of tumor cell motility at 
the front of the cell (12). One member of the family N-WASP, is decreased in metastatic 
breast cancer and is inversely correlated with poor patient outcome.
Cell-extracellular matrix interactions
 Cell-ECM interactions stabilize newly synthesized protrusions at the leading edge  
of the migrating cell. These interactions with the matrix are largely controlled adhesion 
receptors such as members of the integrin family. Integrins are heterodimeric cell sur-
face receptors consisting of an α and β subunit and, upon activation, are able to bind to 
their cognate matrix ligands and subsequently control adhesion. In addition to their abili-
ties to control migration integrins by modulating cell-to-cell and cell-to-matrix adhe-
sion(13,14), they are also able to control changes in morphology, survival and prolifera-
tion. They are abundantly expressed in numerous cells and tissues in all organisms 
while some cells express multiple integrins. Integrin activation is regulated by two princi-
ple mechanisms: 1). outside in activation and 2). inside out activation. Outside-in integrin 
activation is primarily associated with integrin binding to its extracellular matrix ligand. 
ECM binding promotes signal transduction mechanisms related to changes in cell mor-
phology and migration. Epithelial cells express a number of different integrins on the sur-
face including α2β1, α6β4, α3β1 and αvβ3 (14,15). The expression of these integrins 
have been analyzed in different human cancers including: breast, melanoma , and ovar-
ian. While the phenotypes associated with their expression may vary, they are generally 
implicated in the regulation of invasive disease processes.
Cell-cell adhesion
 As mentioned earlier, cell-cell adhesion is important for maintaining epithelial in-
tegrity and also for controlling tumor cell escape from the primary tumor. Cell-to-cell ad-
hesion can be mediated by three classes of adhesion receptors: cadherins, integrins and 
member of the immunoglobulin super-family (IgG-Sf)(16). Members of the IgG-Sf have 
been implicated in the progression of a number of cancers including: melanoma, pros-
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tate, ovarian, colon and breast. Members of this family include ALCAM, VCAM and L1-
CAM(17). Structurally IgG proteins are characterized by the presence of at least one N-
terminal extracellular IgG-like domain and a very short C-terminal tail(18). They can form 
two types of interactions on the cell surface homotypic and heterotypic. Homotypic inter-
actions involve the association of the IgG-SF protein with itself on adjacent cells while, 
heterotypic interactions occur between IgG-SF and known ligands While E-cadherin is 
routinely loss IgSF members are routinely upregulated especially in migrating sheets of 
tumor cells. The up-regulation of IgSF proteins is especially important in the progression 
of metastasis and colonization at the secondary site.
Detachment and de-adhesion at the rear of the celll
 The mechanisms associated with detachment at the rear of the cell and rear re-
traction remain poorly understood. It has been suggested that rear detachment is primar-
ily due to to integrin inactivation and subsequent endocytosis. Furthermore, the loss of 
integrin interaction with the actin cytoskeleton is potentially involved as well. Although 
the process is not completely understood some of the proteins involved are known. In 
migrating fibroblasts the endocytosis of αvβ3 integrin appears to be involved. Addition-
ally, in some cell types Rho/Rock activity is believed to be required. Myosin IIa has been 
demonstrated to act downstream of the Rho/ROCK activity to regulate actinomyosin 
contraction. The calpain family of cell surface proteases are responsible for the cleavage 
of a number of cell surface proteins that make up the integrin adhesive networks includ-
ing Talin and FAK to regulate de-adhesion at the rear of the cell. 
Adhesion controls migration and metastasis
 The loss of cell-cell adhesion in epithelial derived cancers can ultimately deter-
mine whether or not a tumor cell becomes motile and departs the primary tumor. Inde-
pendent of other pro-migratory factors in the tumor microenvironment the loss of cell-cell 
contact is required. An in-depth analysis of the metastatic cascade demonstrates that at 
various steps in the cascade the promotion or inhibition of cell-cell adhesion could be 
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important .This fact has not been demonstrated any more clearly than with experiments 
focusing on the loss or over-expression of E-cadherin in tumor cells. Equally important 
are the cell specific interactions with the extracellular matrix. The matrix can be both 
supportive and inhibitory to the migration and the metastasis of tumor cells. The role of 
adhesion to adjacent cells and to the matrix as a tumor cell progresses through the 
metastatic cascade is depicted in Figure 3.While some adhesion is important, too much 
adhesion to the matrix can inhibit cell motility.The balance of adhesion must be properly 
regulated such that it is optimal. This fact is depicted in the bell-shaped curve of cell mo-
tility (Fig 4) which demonstrates that in instances where neither minimal adhesion nor 
maximal adhesion facilitates motility(19). Indeed, migration is maximal when a dynamic 
optimal adhesion has been accomplished. Overall, adhesion is a key factor in the regula-
tion of cell motility and tumor cell metastasis, although there maybe some debate as to 
how important individual adhesive mechanisms are to the overall process of metastasis. 
In this thesis I will introduce the idea that the cell surface protein CD151 can control nu-
merous aspects of adhesion and regulate migration and metastasis by connecting two 
seemingly divergent molecules to function as a molecular integrator of cell migration. 
The Tetraspanin CD151
 CD151, a member of the tetraspanin family was initially isolated as a platelet cell 
surface antigen. It is expressed in a number of cells and tissues in addition to platelets 
including epithelial cells, endothelial cells, and megakaryocytes(20,21). CD151 is con-
sidered a metastasis promoter gene. It is routinely up-regulated at the invasive front of 
migratory cells and its expression is able to promote cell motility. In a mouse model of 
spontaneous prostate cancer development on a CD151 null background metastasis is 
diminished further demonstrating that the expression of CD151 promotes metastasis. As 
a member of the tetraspanin family CD151 interacts with a number of proteins on the cell 
surface forming macromolecular cell surface complexes known as Tetraspanin Enriched 
Microdomains (TERMS). The most well-known interactions involve the laminin binding 
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Fig.3.Cell-cell adhesion in the metastatic cascade: I). Adhesion molecules 
stabilize the interactions between normal cells, II). Tumors cells adhere to each 
other and normal cells in the microenvironment III). Cell to cell interactions in the 
tumor continue to be relatively high. IV). During the process of matrix invasion 
and degradation adhesion is decreased to a certain extent in order to allow mi-
gration some cells leave as single cells, adhesion is maintained between sheets 
of migrating cells. V). Migrating tumor cells interact with fibroblasts which can 
generate tracks for tumor cells to migrate on VI).During intravasation adhesion is 
minimal although the tumor cells can adhere to the endothelium VII). During 
transit in the vasculature tumor cells can interact with other blood cells including 
white blood cells, platelets, and fibroblasts. Cell to cell adhesion is high. VIII). At 
the secondary site prior to extravasation the tumors arrest by adhering to the 
blood vessel wall. IX). During the process of extravasation adhesion is de-
creased in order to allow for the tumor cells to transendothelial migrate. X). In 
the secondary site adhesion cell to cell adhesion is increased in order to allow 
colonization and growth This figure created by Andries Zijlstra 2013.
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Fig. 4. Relationship between adhesion and migration po-
tential. In order for tumor cells to migrate their must be a 
balance between adhesion and migration. Too little adhesion 
can inhibit migration but so can too much adhesion This fig-
ure modified and adapted from (19).
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integrins α3β1 and α6β4. Through interactions with these proteins CD151 is involved in 
the regulation of cell-matrix adhesion and motility. The CD151 TERM complex contains a 
number of proteins in addition to the laminin binding integrins including: cadherins and 
immunoglobulin proteins(22). Recently, it was demonstrated that CD151 interacts with 
and regulates the function of the matrix metalloprotease MMP-14 ((23) demonstrating 
another role for CD151 in motility and migration by regulating matrix degradation. 
Purpose of this study
 The purpose of this study was two fold 1). to determine the molecular mecha-
nisms associated with the regulation of motility and metastasis by clustering of CD151 
and 2). determine the protein components of the CD151TERM complex on the cell sur-
face in oder to elucidate the protein(s) involved in the regulation of motility and metasta-
sis through association with CD151. Due to the published associations of CD151 with 
α3β1 I that it would be an attractive target, I further hypothesized that clustered CD151 
associates with the integrin and through this association motility and metastasis are in-
hibited (Fig. 5). This thesis will also focus on the potential of targeting molecular mecha-
nisms of motility in metastasis using CD151 as an example.
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Fig. 5. Hypothesis: CD151 controls migration via the laminin binding in-
tegrins. On the tumor cell surface CD151 forms a complex with a3b1 integrin. 
I hypothesize that the ability of CD151 to inhibit migration and metastasis is 
due to its association with α3β1 integrin. Furthermore, I hypothesize that 
CD151 clustering of CD151 promotes its association with α3β1 integrin and 
facilitate adhesion to laminin.
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Summary
 We have previously demonstrated that a CD151-specific monoclonal antibody 
(1A5) can inhibit tumor cell migration in vitro as well as metastasis in vivo (24). It was 
subsequently demonstrated that this antibody inhibits motility and metastasis by prevent-
ing de-adhesion at the rear of the cell. Herein, I demonstrate that this antibody repre-
sents a class of antibodies that are specific for the integrin-binding site of CD151. 
 Their specificity for the integrin-binding site makes these antibodies specific for 
integrin-free CD151 (CD151free). I demonstrated that CD151free is clustered by antibodies 
to the integrin-binding site which leads to a pro-adhesive state of the target cell. In a ret-
rospective study I demonstrate that CD151free recognized by the 1A5 antibody has clini-
cal significance in the progression of prostate cancer (Chapter 4). In chapter 5 I demon-
strate that targeting CD151free promotes tumor cell adhesion and inhibit cell motility. I ex-
plored the mechanism of action by identifying partners of CD151free using the antibody 
1A5 among which was the the novel CD151-associated protein Activated Leukocyte Cell 
Adhesion Molecule (ALCAM). Together these molecules are able to activate the GTPase 
Rap1A in a PKCα-dependent manner. Perpetual Rap1A activation is sufficient to prevent 
migration of tumor cells. Collectively, these data support the role of CD151 as a regulator 
of not only cell-cell adhesion but cell-matrix adhesion to inhibit tumor cell migration.  
14
CHAPTER II
TARGETING CELL MOTILITY TO PREVENT METASTASIS*
Summary
 Mortality and morbidity in patients with solid tumors invariably results from the 
disruption of normal biological function caused by the physical infiltration and destruction 
by disseminating tumor cells. Tumor cell migration is under intense investigation as the 
underlying cause of cancer metastasis. The need for tumor cell motility in the progres-
sion of metastasis has been established experimentally and is supported empirically by 
basic and clinical research implicating a large collection of migration-related genes. 
However, there are few clinical interventions designed to specifically target the motility of  
tumor cells and adjuvant therapy to specifically prevent cancer cell dissemination is se-
verely limited. In an attempt to define motility targets suitable for treating metastasis, we 
have parsed the molecular determinants of tumor cell motility into five underlying princi-
ples including cell autonomous ability, soluble communication, cell-cell adhesion, cell-
matrix adhesion, and the integration of the previous four on molecular scaffolds. The cur-
rent challenge is to implement meaningful and sustainable inhibition of metastasis by 
developing clinically viable disruption of molecular targets that control these fundamental 
capabilities.
Introduction
 Metastatic disease remains the primary cause for cancer-related deaths (25). 
Whether it is present at the time of diagnosis, develops during treatment, or occurs at 
the time of disease relapse the dissemination of tumor cells from the primary lesion is 
the principle reason for mortality and morbidity of cancer patients. Surgical resection of 
the primary lesion, along with cytotoxic and cytostatic systemic therapy
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has been relatively successful in treating benign, localized cancer and preventing its 
progression to metastatic disease. Metastases however, remain difficult to treat and ren-
der the disease incurable. Paradoxically, the more effective cancer treatment is at pro-
longing life, the greater the risk of metastasis. To combat the risk for eventual metasta-
sis, many patients  are over-treated with the intent of preventing dissemination of their 
disease. Therapies that specifically target the motility of tumor cells could significantly 
improve cancer treatment by removing the threat of systemic disease and decreasing 
the dependency on therapeutics with detrimental side effects. For the past 5 decades 
the processes involved in tumor cell metastasis have been micro-dissected in an attempt 
to identify therapeutically viable targets. The central, defining process of metastatic dis-
ease is its ability to mobilize, invade, and cross normally non-permissive tissue barriers. 
This has greatly intensified the investigation into molecular mechanisms of motility and 
their contribution to metastasis (Fig. 6). Here, we provide an overview of these investiga-
tions and examine the potential for targeting of tumor cell motility in the treatment of me-
tastasis.
 The migration of adherent cells is defined as the translocation of cells from one 
location to another. Detailed discussion is available from the Cell Migration Consortium 
on the Cell Migration Gateway (www.cellmigration.org). Typically, migration is parsed into 
five component processes: polarization, protrusion, adhesion, translocation of the cell 
body, and retraction of the rear (Fig. 7, [2,(26). Although it is mechanistically convenient 
and sometimes necessary to define cell migration in this manner, the movement of cells 
within a living organism is highly complex, tightly regulated, and carefully coordinated. 
The physiology of cell migration is also very diverse. Some cell types such as activated 
hemopoietic cells exhibit a highly individualized “ameboid” movement with little adhesion 
and no matrix remodeling. Fibroblasts, and melanocytes generally migrate in a “mesen-
chymal” fashion as individual which are highly adherent and require 
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Fig.6. Publications on migration and metastasis: Total and annual 
number of Pubmed listed publications targeting migration and metas-
tasis. www.pubmed.gov was searched for articles with the keywords 
“Migration” and “Metastasis” in the title or abstract. The data is pre-
sented as the number of publications/year (blue) and the cumulative 
number of articles in the field up to and including the indicated year.
Annual Publications Evaluating the Role of Migration and Metastasis
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Fig. 7 Cell migration: A basic representation of  cellular behavior during migration. Mi-
gration is parsed into five components processes: polarization, (de)adhesion, transloca-
tion of the cell body, and retraction of the rear. Successful motility can be accomplished 
as isolated, individual cells (3a) or collectively as a group of cells (3b). This figure modi-
fied and adapted from (1)
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proteolytic remodeling of the matrix. The migration of neuronal and smooth muscle cells 
is collective, directionally coordinated, and mechanistically integrated. Epithelial cells, 
the cell type from which most cancers originate, can exhibit multiple migration pheno-
types. While epithelial cells are generally present as stationary, tightly interconnected 
sheets of cells, they can be mobilized during development, physiological homeostasis, 
and wound repair. Depending on their developmental differentiation, environmental stim-
uli, and surrounding tissue architecture, epithelial cells can migrate as collective sheets, 
clusters, tubular structures, or as individual cells (reviewed by Friedl and colleagues in 
[4,(27) and Rørth et al. in (28). Interestingly, in patients with malignant disease, tumor 
cells are found as both individual cells and organized collective sheets or clusters, sug-
gesting that tumor cells in vivo exhibit the plasticity to switch between single and collec-
tive cell migration.
 Tumorigenesis is largely driven by the subversion of normal cellular processes 
that control cell proliferation and cell death. It is therefore not entirely surprising that mo-
lecular mechanisms that control cellular motility in normal physiology reappear in meta-
static cancer. However, unlike normal migrating cells, metastatic tumor cells no longer 
respond to contact inhibition and are capable of crossing barriers that are non-
permissive to normal cells.
Tumor cell motility is a therapeutically viable target for the treatment of metastasis
 Despite the growing evidence implicating tumor cell motility in metastasis, there 
remains uncertainty about the viability of targeting motility with the intent of treating me-
tastasis. There is evidence for both active and passive mechanisms of cancer dissemi-
nation (29,30). Further-more it has been suggested that the transient contribution of tu-
mor cell motility to metastasis does not make it a suitable clinical target (29). These fac-
tors raise the question: can the inhibition of motility contribute therapeutically to the 
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treatment of metastatic cancer? Here we have synthesized data in the field and suggest 
that the answer is “yes”.
 Experimental, empirical, and clinical findings indicate that therapies targeting mo-
tility would be effective at treating metastasis. In the clinic, much of the metastatic risk 
assessment is based on the potential for the cancer to mobilize and cross non-
permissive tissue barriers. In basic research, the migration machinery has been shown 
to promote dissemination. Most importantly, there is a strong correlation between the 
molecular mechanisms of migration and the progression to systemic disease (31). Thus, 
the molecular mechanisms that promote tumor cell motility offer several inroads for novel 
drug design and clinical intervention designed to limit cancer progression towards overt 
metastasis and to treat existing metastatic disease. These include:
 1. Anti-migration therapy may support active surveillance in the clinic. Cancer pa-
tients at risk for developing systemic disease are treated aggressively. This strategy is 
associated with high morbidity, poor quality of life, and elevated risk of treatment compli-
cations. Targeting motility could be implemented as a preventative measure to enable 
the physician to keep a patient under active surveillance without risking the appearance 
of systemic disease.
 2. Targeting tumor cell motility within the primary tumor could limit local invasion. 
Invasive neoplasia, such as glioblastoma and pancreatic cancer aggressively infiltrate 
adjacent tissues and can be incurable even in the absence of overt metastasis to distant 
organs. Surgical intervention is frequently ineffective and disease often recurs. Targeting 
motility could improve therapy of these malignancies by preventing further infiltration and 
expansion into normal tissues.
 3. Patients with overt metastases may benefit from treatments that block further 
dissemination. The paradigm suggesting that dissemination to the lymph nodes is the 
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first step in a metastatic cascade (32) has been challenged in the clinic by the absence 
of improved survival after removal of regional lymph nodes (33) In fact, it was demon-
strated that occult micrometastases are not indicative of disease free survival (34). 
These observations suggest that the cells responsible for metastases have yet to be 
mobilized from the primary site and would therefore remain susceptible to anti-migration 
therapy.
 4. Restricting tumor cell motility may limit “evolution” towards an increasingly 
metastatic phenotype. Tumor cells exhibit an epigenetic diversity and plasticity that con-
tributes to the selective evolution of metastatic abilities. This is evident from the pro-
motility gene expression profiles seen in metastatic cells (35) and the in vivo selection of 
tumor cells with increasing metastatic ability (36),(37). Once tumor cells disseminate 
away from the primary site, these two elements support the evolution and expansion of 
metastatic cells.
 The role of motility in the evolution of a metastatic phenotype is supported by 
evidence of the primary tumor re-seeding itself with circulating tumor cells (38). Similarly, 
existing metastases can reseed to unaffected tissues expanding the burden of meta-
static disease (reviewed extensively in (39). Preventing the dissemination of tumor cells 
may therefore limit the Darwinian evolution of the metastatic phenotype. Anti-motility 
strategies provide a unique mechanism to prevent the development of systemic disease 
and limit cancer-related death. Equally important, a successful anti-motility strategy may 
diminish the need for overly aggressive cytotoxic therapies currently used to avert the 
risk of metastatic dissemination.
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Metastasis and the role of tumor cell motility
 In order for a tumor cell to disseminate to a distant site, it must detach from the 
primary lesion, invade locally, and travel to a distant site where it can survive and prolif-
erate (Fig. 8). Dissemination occurs via three avenues: 1) local invasion of normal tis-
sues adjacent to the tumor, 2) infiltration of the draining lymphatic system, or 3) hema-
togenous metastasis through the vasculature (29). Although large numbers of circulating 
tumor cells can be detected in tumor-bearing animals, metastatic colonization is re-
markably inefficient (37). The metastatic inefficiency of cancer cells is, in part, because 
successful metastatic dissemination requires the completion of each step in a complex 
sequence of events (Fig. 8). The interrelated and sequential nature of this metastatic 
cascade greatly diminish the probability that any single tumor cell will give rise to a 
metastatic lesion.
 The inefficiency of metastasis has raised the question of whether tumor cells dis-
seminate via passive or active migration-dependent mechanisms (29). Three basic prin-
ciples appear to determine the efficiency by which clinically overt metastases are 
formed: 1) Tumor–host inter- actions: tumor–host interactions control metastatic pro-
gression as tumor cells depart the primary lesion and enter a new environment, 2) Tis-
sue structure and biomechanics: tissue structure and the biomechanics of the vascula-
ture determine the route and distribution of circulating tumor cells, and 3) Pro-metastatic 
molecular determinants: the acquisition of pro-metastatic molecular determinants previ-
ously absent in the primary tumor. The latter can be acquired through a transient epige-
netic plasticity such as the epithelial–mesenchymal transition (EMT) (40,41) or an evolu-
tionary selection of epigenetic and genetic changes. (35)
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Fig.8. The metastatic cascade: Malignant tumor cells become mobilized and in-
vade the local microenvironment (1a)and intravasate into the tumor vasculature 
(1b). Circulating tumor cells travel to a secondary tissue (bone) via the blood supply 
(2) and arrest in the venous supply of the recipient organ (3). Arrested tumor cells 
subsequently extravasate (4) and invade the bone microenvironment (5). Within the 
bone, tumor cells can enter a protective niche where it remains as occult or dormant 
disease. When the tumor cell engages a favorable microenvironment it can engage 
the osteoblasts and initiates feedforward loop (vicious cycle) that promotes growth 
and further infiltration of the bone microenvironment (6) This picture modified and 
adapted from (1).
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Tumor–host interactions
 In 1889, Paget hypothesized that disseminating tumor cells, which he called 
seeds, could reach most, if not all, organs but that successful metastasis was deter-
mined by selective growth in specific (the soil) (42). This became known as the “seed–
to–soil” hypothesis. In subsequent years, extensive interrogation of tissue-specific me-
tastasis validated this hypothesis (reviewed in depth by Weiss (43) and Fidler (36). Re-
ciprocal interactions between tumor and host cells can establish a positive feed-forward 
loop that supports tumor expansion. Consequently, normal tissue containing tumor cells 
can support metastatic growth. For instance, bone is a preferred metastatic site for both 
prostate and breast cancer metastases (44) while lung is preferred by metastatic cells 
from melanoma and renal cancer. The reciprocal interaction between tumor and host 
has been investigated extensively in recent years. At the primary site, tumor-associated 
fibroblasts and inflammatory cells contribute to an environment that supports malignant 
cancer (45-47). Similarly, reciprocal communication between cancer cells, osteoblasts, 
and osteoclasts establishes a feed-forward loop in which tumor cells promote the de-
struction of bone and the release of tumor-supporting growth factors from the bone (44). 
More recently, it was demonstrated that systemic communication between the primary 
cancer, the bone marrow, and future metastatic sites can result in the formation of tumor-
supportive conditions (pre-metastatic niche) prior to the arrival of metastatic cells (Fig. 8) 
(48). There is, in fact, increasing evidence to suggest that motility in the local microenvi-
ronment and systemically across the circulatory system involves intricate tumor–host 
communication.
Tissue structure and biomechanics
 Systemic dissemination requires that tumor cells access the vasculature and 
travel via the circulatory system to a distant site where the cells extravasate and estab-
lish secondary tumor growth (reviewed comprehensively by Weiss (43) and Fidler (36). 
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Ewing and colleagues postulated that metastatic inefficiency was related to the location 
of the tumor within the body, the anatomic structure of the vasculature, and the biome-
chanics of tumor cell transportation. The contribution of tissue biomechanics to cancer 
metastasis and to the randomness of colonization were further explored by Weiss 
(43,49). Indeed, gross anatomical evaluation shows that colorectal cancer metastasizes 
predominantly to the nearest vascular bed in the liver, pancreatic cancer invades ag-
gressively to adjacent organs and the surrounding viscera, and ovarian cancer cell dis-
semination is almost exclusively restricted to the peritoneal cavity. While it is certainly 
true that the capillary bed immediately downstream of the primary tumor is exposed to a 
greater number of circulating tumor cells, overt metastasis from numerous types of can-
cer is predominately site specific. This was conclusively, albeit inadvertently, shown in 
patients with metastatic ovarian cancer (50). These patients received peritoneovenous 
shunts to alleviate tumor-induce ascites but they developed no overt distant metastases 
in spite of the circulating, malignant cells. These observations confirm that mere, inad-
vertent, passive access to the circulatory system is not sufficient to accomplish meta-
static growth.
The acquisition of pro-metastatic molecular determinants
 The identity of genes responsible for tumor cell metastasis and tissue tropism 
has been the subject of intense investigation. These studies aim to develop a mechanis-
tic understanding and identify clinically viable targets for the treatment of metastatic dis-
ease. Expression analysis of clinical specimens and experimental models with divergent 
metastatic abilities identified a very large number of genetic determinants that control the 
metastatic process (35). Furthermore, an evaluation of cancer's epigenetic plasticity re-
vealed an inherent ability of metastatic cells to alter the expression of these determi-
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nants in a changing environment. The Epithelial–Mesenchymal Transition (EMT) is an 
example of cancer cell plasticity in which epithelial-derived cancers adopt a mesenchy-
mal behavior. During EMT, the adhesive repertoire is significantly altered and includes a 
reduction in E-cadherin, a gain of N-Cadherin, as well as changes in cytoskeletal organ-
izing proteins, and the expression of developmental transcription factors to gain migra-
tory and invasive properties (41). These epigenetic changes often occur transiently in 
response to growth factor stimuli such as TGFβ and HGF. More permanent changes can 
clearly evolve within the heterogenous tumor cell population. In vitro and in vivo selec-
tion reveals relatively stable epigenetic changes that support metastatic behavior and 
tissue-specific metastasis. These changes presumably arise as a consequence of altera-
tions in DNA accessibility through changes in DNA methylation, histone modification, and 
genomic imprinting (51,52). Unlike the transforming events of carcinogenesis, genetic 
alterations are relatively rare during metastasis. Instead, metastasis is associated with 
the accumulation of multiple epigenetic modifications. Many of these modifications drive 
the mobilization of metastatic tumor cells.
Tumor cell motility
 The contribution of tumor cell motility to metastasis is evident in each of the three 
principles discussed above:
 I. Tumor–host interactions can promote tumor cell motility by providing chemotac-
tic stimuli (53), remodeling the tissue to alleviate its non-permissive and motility-
suppressive characteristics, and providing guidance cues to promote directional migra-
tion (54)
 II. The vascular anatomy and architecture of tumor vasculature are responsible 
for creating hypoxic regions, oxygen, and nutrient gradients as well as preferred points 
of vascular entry/exit (54),36]. Moreover, recent investigations into mechano-
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transduction demonstrate that tissue rigidity in the primary tumor and the bone contrib-
utes to the motility of tumor cells (55-57).
 III. Molecular determinants that enable cell autonomous motility are seen in al-
most every expression profiling of metastatic cells. Although a large number of changes 
occur in the transition from benign to invasive disease, a signature of motility-related 
genes is evident both in experimental models and patient specimens. In some instances 
these pro-migratory gene profiles are transiently induced by the environment of the pri-
mary tumor or the metastatic site while in other instances the profile is the product of a 
more persistent reprogramming of the tumor cell (35,54,58-61).
 Ultimately, it is the contribution of these three principles that determines the mo-
bility and metastatic ability of a tumor cell. The key to targeting tumor cell motility for 
therapeutic means lies in the identification of a molecular mechanism required for tumor 
cell motility that is sufficiently cancer specific to prevent disruption of normal physiology.
Mechanisms that regulate cell motility
 Cell migration broadly refers to processes involved in the movement of cells from 
one location to another. For adherent cells, translocation requires dissociation at the 
point of origin, physical displacement of the cell body, and re-adherence in another loca-
tion. While this process appears relatively simple, it is in fact a process of immense bio-
logical complexity. Cell migration requires the integration of numerous molecular mecha-
nisms that allow a cell to coordinate the formation of new adhesions while disengaging 
existing adhesions and simultaneously exerting force to move the cell body. Among the 
adhesion receptors alone there are four large families: the immunoglobulin superfamily 
cell adhesion molecules, the integrins, the cadherins, and the selectins (15,62,63). 
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These adhesion receptors engage immobilized ligands including structural and matricel-
lular proteins of the extracellular matrix or cell-surface ligands on adjacent cells. Scaf-
folding proteins and signaling molecules mediate intracellular connections of the cyto-
skeleton with the cytoplasmic tail of adhesion receptors (64,65). Subsequent remodeling 
of the cytoskeleton transmits force between distant portions of the cell allowing the cell 
body to migrate to a new location where new adhesions are established. Extracellular 
stimuli such as cytokines are generally required to initiate and sustain activation of the 
molecular migration machinery. When a tumor cell encounters a non-permissive barrier 
such as a basement membrane, the production of proteolytic enzymes, a change in ad-
hesion receptors, and the expression of a pro-migratory matrix can enable a cell to 
penetrate the barrier and disseminate from the tissue in which it was originally retained 
(66,67). Close coordination of these adaptations is necessary for successful metastatic 
dissemination.
 Considering the complexity of migration, it is impossible to rigorously review all 
the molecular determinants of migration and identify all of the potential areas for clinical 
intervention. Rather than adding increasing layers of complexity to the existing literature 
we parsed the molecular determinants into five underlying principles that collectively dic-
tate tumor cell motility (Fig. 9).
These include:
1) Cell autonomous ability
2) Soluble communication
3) Cell–cell adhesion
4) Cell–matrix adhesion
5) Integrating mechanisms of migration
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Fig. 9 Classification of cell migration determinants. The innumerable molecu-
lar determinants thats contribute to tumor cell motility can be classified in one of 
five underlying principles. Cell autonomous migratory ability includes the intrinsic 
determinants that enable a cell to move. Soluble communication includes auto-
crine and paracrine communication. Cell-cell adhesion includes those determi-
nants responsible for physical cell-cell adhesion and communication. Cell-matrix 
adhesion includes those determinants responsible for adhesion to and migration 
on the ECM. Molecular integration includes the molecular scaffolding compo-
nents that allow for the integration of all molecular determinants of migration. This 
figure modified and adapted from (1).
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The following sections discuss in detail the broad functional contribution of each principle 
category, we provide representative examples that are possible targets suitable for in-
vention in Tables 1–5, and we provide an extensive overview in Table 6 of ongoing trans-
lational work attempting to target tumor cell migration in the clinic.
Cell autonomous ability 
 Within the human body, each cell type exhibits a distinct autonomous ability to 
migrate that varies depending upon the molecular mechanisms that remain available to it 
after developmental differentiation (reviewed extensively by Friedl et al. (27,68) and Ta-
ble 1). During metastasis, the cell's autonomous migratory ability appears to be driven by 
the activation of latent mechanisms, the aberrant recruitment of endogenous mecha-
nisms, and/or the ectopic expression of developmentally suppressed migratory mecha-
nisms.
 The cell's autonomous migration potential is most apparent in its ability to re-
model its cytoskeleton. Of the three cytoskeletal filaments (microfilaments, intermediate 
filaments, and microtubules) remodeling actin microfilaments is the most studied. This 
innate, autonomous ability involves hundreds of molecular determinants that control ac-
tin polymerization, extension, stabilization, and depolymerization. During migration, 
these filaments influence cell shape, transmit force, and support cargo trafficking. Key 
molecular determinants of the endogenous migratory ability include the small GTPases 
(Rho, Rac, CDC42) (68)] which initiate cytoskeleton remodeling, while members of the 
Actin Related Proteins (Arp2/3) mediate actin remodeling, and motor proteins of the my-
osin family control cell protrusion, contraction and cargo motoring. The extent to which 
autonomous migration contributes to motility was elegantly revealed by Lämmermann 
and colleagues in a study of 3D-migration of leukocytes from which all integrins were 
ablated (69). Surprisingly, the integrin-negative leukocytes are perfectly capable of mi-
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grating in vitro and in vivo. These cells migrate by the sole force of actin-network expan-
sion, which promotes protrusive flowing of the leading edge (70). Thus the ability to 
regulate the cell's cytoskeletal structure can determine its inherent migratory capacity 
and contribute to the metastatic potential of cancer (Table 1).
 The non-receptor tyrosine kinase Src is another example of a cell- autonomous 
molecular determinant that is frequently and aberrantly activated in malignant cancer. 
Discovered originally as a viral oncogene(71), Src is over-expressed and ectopically ac-
tivated in a myriad of cancers (72). Experimental evidence and current clinical trials indi-
cate that this kinase is a fundamental driver of cell motility and tissue invasion. Src influ-
ences tumor biology by driving proliferation, altering gene transcription, and regulating 
adhesion, invasion and motility. Src mediates these functions through activation of a 
large number of substrates including key components of thefocal adhesion complex, 
(vinculin, cortactin, talin, paxillin, FAK, tensin, ezrin and p130Cas), junctional proteins, (β 
- and γ -catenin, ZO-1, occludin, p120ctn, connexin 43, nectin-2) (70,73,74), enzymes 
involved in phospholipid metabolism, (PLC-γ, p85 subunit of PI3-kinase) and signaling 
molecules (p190RhoGAP, p120rasGAP, Eps8)(73,75,76).
 Unlike its enzymatically active counterparts, the Wiskott-Aldrich Syndrome family 
of proteins including WASP and WAVE (77) promote actin remodeling through the acti-
vation of Actin Related Proteins (ARPs). Together, members of these protein families fa-
cilitate the polymerization of new actin strands and promote protrusion of the cell's lead-
ing edge. Individual family members are selectively expressed and ectopic expression 
increases cell autonomous and facilitates metastatic dissemination (12).Although indi-
vidual molecular determinants are often emphasized, it is increasingly evident that entire 
pro-migration gene signatures occur in metastatic cells (54).
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Table I: Targeting molecular mechanisms that support cell autonomous migration.
Target Molecular Mechanism
Ras/Rho/
CDC42
Small GTPases involved in the reorganization of actin and microtubulin 
network formation that controls cell protrusions (lamellipodia and filopodia) 
Snail, Twist Transcription factors that functions as a regulators of the EMT phenotype promote migration and tumor cell motility
SATB1
Transcriptional regulator (chromatin organizer and transcription factor) that 
integrates higher-order chromatin architecture with gene regulation. Ec-
topic SATB1 expression promotes aggressive phenotype while its down-
regulation promotes E-cadherin expression and inhibits the transcription 
factors Snail and Twist.
Src A non-receptor tyrosine kinase that transmits integrin-dependent signals central to cell movement and proliferation
WAVE3
An actin nucleation/polymerizing factor that binds actin and the Arp2/3 
complex. It is an effector molecule involved in the transmission of signals 
from tyrosine kinase receptors and small GTPases to the actin cytoskele-
ton. Normally expressed in ovary in brain but ectopic expression can oc-
cur at high levels in diverse cancers where it promotes motility and metas-
tasis.
miRNA-10b, 
miR34a
microRNA can regulate expression of a large group of genes that control 
migration. Both upregulation of migration promoters and down regulation 
of migration inhibitors has been observed.
Molecules included here are representative molecular determinants of the underlying 
principle which can be found in (61,71,78-87).
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Transcriptional regulators influence cell autonomous motility by controlling the protein 
pools available for cytoskeletal rearrangements by regulating their expression. The aber-
rant and ectopic expression of transcription regulators are recurring themes in cancer 
metastasis. Snail, Twist (79), and SATB1 (82) reappear in metastatic cells and drive a 
motility-promoting expression profile that enables tumor cells to mobilize. Conversely, 
broad regulation of motility genes by microRNA was identified recently (88). Upregulation 
of the miRNA-10b may reduce expression of motility suppressor genes such as 
HOXD10 [43] while genomic loss of miRNA101 [66] results in the overexpression of me-
tastasis associated histone methyltransferase EZH2. Similarly, reduced expression of 
miR34a is apparent in aggressive prostate cancer. This miR has been evaluated pre-
clinically as a therapeutic agent against prostate cancer metastasis [67]. Targeting mi-
croRNA may be clinically efficacious because this treatment impacts cellular behavior by 
altering expression for a group of genes that collectively control migration.
Soluble communication 
 Soluble mediators, ranging from small molecules to macromolecular protein 
complexes, enable communication between tumor cells and their environment without 
direct contact. Mediators produced by tumor and host cells within the local microenvi-
ronment provide paracrine and autocrine support for cellular movement (Table 2). Solu-
ble factors produced within the tumor tissue also act systemically to mobilize cells from 
the bone marrow or to influence host cells in a putative metastatic site. Conversely, the 
host can provide systemic soluble mediators that influence cellular behavior in the pri-
mary tumor and the metastatic lesions.
Tumor-derived mediators 
 Tumor cells produce a myriad of cytokines that influence the biology of the tumor 
as well as the local host stroma. EGF, HGF, and generated by the tumor act in autocrine
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Table II: Targeting molecular mechanisms that enable soluble communication.
Target Molecular Mechanism
TGFβ
TGFβ ligands (a 40-member superfamily that incudes TGFβ1, 2, and 3) 
control cellular growth, differentiation, and motility through heteromeric 
signaling complexes composed of the TGFβ type I, II, and III receptors. 
Neutralizing antibodies can diminish metastasis. 
VEGF
Ligands that belong to the VEGF-PDGF super family where the VEGF 
gene yields five isoforms (A-D) that bind to four receptors (Flt-1, Flk-1, 
neuropilin-1, and Flt-4). 
EGF
The EGF family includes ten ligands that bind to dimeric ERBB 
receptors to induce pro-migratory signaling via receptor tyrosine 
kinase activity. Currently a target of many anti-cancer therapeu-
tics ,EGF receptor is upregulated in many cancers (breast, colo-
rectal, lung).
SDF-1
A soluble cytokine that binds to its cognate receptor CXCR4. First 
recognized for its broad impact on immune functions and ability 
to control homing of bone marrow  cells, it is also involved in the 
homing of tumor cells to distant sites.
TNFα
The most studied member of the tumor necrosis family of cytokines first 
recognized as a regulator of the immune response. It is produced by a 
large number of human tumors. The highest levels of TNF-α is  secreted 
by foreign leukocytes present in the tumor microenvironment. Plays a 
dual role as about both a tumor suppressor and tumor promoter. High 
serum expression in patients is associated with a poor prognosis.    
Molecules included here are representative molecular determinants of the underlying 
principle which can be found in (53,89-102).
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and paracrine fashion to mobilize both tumor and host cells. In many instances tumor-
derived cytokines promote motility indirectly via the host stroma. The exposure of fibro 
blasts to the pro-inflammatory cytokine TNF-α promotes their differentiation into cancer-
associated fibroblasts (CAFs, (102)). CAF promote tumor cell motility through the in-
duced expression of paracrine acting cytokines and by physically encouraging the inva-
sion of tumor cells {144)..Tumor-derived mediators can also have a significant systemic 
influence on metastasis. Specific cytokines, such as VEGF-A, placental growth factor 
(PLGF), granulocyte colony stimulating factor (G-CSF), stromal cell derived factor-1 
(SDF1) and osteopontin, secreted by the growing tumor can impinge upon the bone 
marrow (BM) via the peripheral circulation. These factors can switch the quiescent mi-
croenvironment in the BM compartment to a highly pro-angiogenic and pro- tumorigenic 
state that promotes the expansion and mobilization of progenitor cells into the peripheral 
circulation. These cells engage the primary tumor and develop a favorable metastatic 
environment in distant organs (premetastatic niche) in response to SDF-1, TNFα, TGFβ, 
and PLGF (48,103).
Host-derived mediators 
 Tumors recruit a wide variety of stomal cells including endothelial cells, fibro-
blasts, inflammatory cells, and bone marrow derived cells such as mesenchymal stem 
cells. These stomal cells can promote tumor cell motility through the production of a va-
riety of soluble mediators like EGF, HGF, TGFβ, HGF, and CCL5 (103,104). In many in-
stances, a pro-metastatic reciprocal interaction supports paracrine signaling between 
tumor and host. Tumor cells recruit mesenchymal stem cells which promote tumor cell 
motility through the production of CCL5 (105). Macrophages are similarly recruited to the 
invasive front by tumor-derived CSF-1 where they induce tumor cell chemotaxis through 
the release of EGF (53).
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 Collectively, host and tumor derived soluble factors enable communication be-
tween the cancer and its environment. It is the activation or suppression of the migration 
machinery in response to these soluble factors that regulates the motility and dissemina-
tion of tumor cells.
Cell–cell interactions 
 While cell–cell interactions generally promote tissue cohesion, adhesive contacts 
between adjacent cells can both promote and inhibit motility. Cell–cell interactions are 
controlled at multiple levels, including the expression, localization, and surface presenta-
tion of cell adhesion molecules (Table 3). Cell to cell adhesion receptors include mem-
bers of the immunoglobulin superfamily (IgSF), cadherins, integrins, selectins, ephrins, 
and the tight junction proteins claudins and occludins. Tissue specific ex- pression of ad-
hesion proteins creates a characteristic expression signature in cancers that reflects 
their tissue of origin. However, adhesive characteristics change in metastatic disease. A 
loss of firm adhesion promotes motility and metastasis which is evident in the loss or 
mis-localization of cadherins and tight junction proteins (63). However, adhesion is rarely 
lost completely during metastasis, and new adhesive proteins are frequently upregulated 
or newly expressed to displace previously migration-suppressive adhesions. Such inter-
actions include EpCAM, which can abrogate E-cadherin-mediated adhesion (106). Cad-
herin switching from E-cadherin to N-cadherin can promote motility during epitheli-
al–mesenchymal transition. The expression of even low levels of Ephrin A2 can promote 
motility and mediate metastasis by influencing other pro-migratory signaling events such 
as Src activation (107). Several members of the immunoglobulin superfamily contribute 
to the motile behavior of tumor cells. ICAM, EpCAM, L1CAM, and ALCAM have all been 
associated with metastatic behavior (106),75,(108). New understanding of
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Table III: Targeting molecular mechanisms that support cell-cell interactions.
Target Molecular Mechanism
E-Cadherin
Cell-Cell adhesion molecule of the cadherin family involved in the 
regulation of epithelial cell-cell adhesion. Routinely mislocalized or lost 
in patients with metastatic disease. Experimental over expression can 
inhibit migration while knock down or cellular relocalization in re-
sponse to pro-migratory cytokines can promote motility and migration. 
Generally considered a negative regulator of cell motility.
N-Cadherin
Cell-Cell adhesion molecule of the cadherin family involved in the 
regulation of epithelial cell-cell adhesion. Expressed during epithelial-
mesenchymal transition and upregulated in metastatic disease. 
Upregulation frequently co-incides with the loss of E-Cadherin. Asso-
ciation with FGFR-1 enhances receptor signaling and provides a pro-
metastatic mechanism of motility
EpCam
Cell-Cell adhesion molecule of the immunoglobulin super family. Can 
function as a tumor suppressor or oncogene because it inhibit motility 
but also abrogate E-cadherin mediated adhesion to promote tumor 
cell motility.
ALCAM
Cell-Cell adhesion molecule of the immunogobulin super family. Can 
inhibit motility when engaged in cell-cell interactions or promote motil-
ity when cleaved by ADAM17. Expression is upregulated in prostate, 
pancreatic, and colorectal cancer but down regulated in breast cancer. 
Shedding is elevated in all cancers and the shed ectodomain is being 
explored as a biomarker of metastasis.
Claudin 1, 4, 
and 7
Cell-Cell adhesion molecule of the Claudin family involved in transmit-
ting cell-cell contact to the actin cytoskeleton within the tight junction. 
Loss of Claudins enhances motility and metastasis.
EphA2
Cell-Cell adhesion molecule of the ephrin family capable of  promoting 
motility and metastasis. Integrates with Src, Akt, and HGF-mediated 
signaling. 
Molecules included here are representative molecular determinants of  the underly-
ing principle which can be found in (17,41,58,106,107,109-119).
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IgSF shedding suggests that these adhesion molecules are selectively favored in cancer 
metastasis because their adhesion dynamic is readily augmented by pro-migratory stim-
uli (62). Thus, changes to cellular adhesion that facilitate cell migration eventually pro-
mote cancer metastasis.
Cell–matrix interactions 
 The dynamic interaction between a cell and its external matrix heavily influences 
cell migration and the invasive behavior of cancer cells. Cell–matrix interactions are 
formed between adhesive proteins on the surface of the migrating cell and the structural 
components of the extracellular matrix. These factors influence both the motility and mi-
gratory capacity of normal cells, and the metastasis of tumor cells (Table 4 and (45).
 The best studied family of proteins that regulate cell–matrix interactions are in-
tegrins, a family of heterodimeric cell-surface proteins, which contain an extracellular al-
pha and beta subunit. Similar to cell–cell adhesion molecules, some integrins suppress 
metastasis while others promote dissemination. Integrin α2β1 was recently identified as 
a metastasis suppressor. It is lost in mouse models of breast cancer and in breast can-
cer patients (120). Conversely, the integrin αvβ3 promotes cancer metastasis 
(15,121).Non-integrin receptors are also involved in the migration of metastatic cells. 
Syndecan-1 is diminished in some cancers and upregulated in others, yet its ability to 
regulate adhesion and migration is primarily controlled by shedding (122). Conversely, a 
change in splice variants of the hyaluronic acid receptor CD44 facilitates motility and me-
tastasis by promoting matrix remodeling (123).In addition to changing their adhesion re-
ceptor profile, metastatic tumor cells can cross non-permissive tissue barriers by remod-
eling the matrix that surrounds them.
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Table IV: Targeting molecular mechanisms that support cell-matrix inter-
actions.
Target Molecular Mechanism
Integrin 
αvβ3
Matrix adhesion receptor of the integrin family involved in the ad-
hesion to a wide variety of matrix components that exhibit the 
RGD sequence. These include collagen, vitronectin, and fi-
bronectin. This integrin is also extensively expressed by the host 
vasculature and hemopoietic cells.
Integrin 
α2β1
Matrix adhesion receptor of the integrin family involved in the ad-
hesion to collagen and a few additional substrates. While the re-
ceptor facilitates motility on collagen it actually inhibits migration 
on non-collagen substrates and suppresses metastasis.
Syndecan-1
Transmembrane proteoglycan  of the immunoglobulin super fam-
ily. Syndecans have previously been considered as ligand gather-
ers, working as co-receptors in collaboration with signalling recep-
tors but they can also signal independently. Syndecan-1 interacts 
with the ECM through its glycosaminoglycan side chains. Some 
reports suggest it can also engage in cell-cell adhesion. Loss of 
Syndecan-1  is specifically associated with metastasis.
MMP14
Transmembrane metalloproteinase of the MMP family. MMP14 is 
a collagenase but also capable of cleaving aggrecan, elastin, fi-
bronectin, gelatin, tenascin, nidogen, perlecan, fibrillin, and 
laminin. It can also cause shedding of Syndecan-1, and betagly-
can (TBRIII). It can activate the MMP2 and MMP-13 activation. Its 
activity can be reguated by ALCAM and CD151. MMP14 is ex-
pressed in many metastatic cells and facilitates invasion. How-
ever, it is not required for metastasis.
CD44
Transmembrane  receptor for hyaluronic acid and can also inter-
act with other ligands, such as osteopontin, collagens, and matrix 
metalloproteinases (MMPs). Splice variant expression is corre-
lated with motility and metastasis. Splice variant-induced changes 
in adhesion can facilitate migration and metastasis.
Molecules included here are representative molecular determinants of the un-
derlying principle which can be found in (120,124-132).
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Matrix remodeling is accomplished through degrading existing matrix, producing new 
matrix components, and (re) organizing both new and existing matrix proteins within the 
existing tissue architecture. Matrix metalloproteases (MMPs), including MMP2, 9, and 
14, were among the first matrix remodeling enzymes found to be capable of promoting 
metastasis by degrading the matrix (66,68,133). Along with serine proteases, MMPs are 
among the enzymes that enable tumor cells to penetrate the extracellular matrix by 
cleaving multiple matrix components including collagens, vitronectin, fibrinogen, and 
laminin. In some instances, cleavage of the matrix protein creates a pro-migratory stimu-
lus (66). This can be seen for laminin-332 cleaved by the serine protease Hepsin (134). 
Conversely, the expression, deposition, and assembly of new, permissive extracellular 
matrix by the invading tumor cells that enable their migration further facilitates the me-
tastasis of tumor cells. This is seen in the deposition of tenasin-C isoforms (135,136), 
fibronectin isoforms (137), collagen (138) and fibrin. Incorporation of new matrix and re-
modeling of the tumor extracellular matrix also changes the three-dimensional rigidity of 
tissues, frequently making the tissue less pliable. With this increasing rigidity, the motility 
of tumor cells can increase (56) leading to increased invasion and cancer malignancy 
(55). Although the extracellular matrix was initially perceived as a barrier to tumor cell 
dissemination, it is increasingly evident that the architecture and the matrix composition 
of the microenvironment can promote tumor cell dissemination.
Molecular integration 
 Although a large number of molecular determinants influence migration, the con-
tribution of any single component is regulated through its integration into the migration 
machinery. There are thousands of molecular determinants that can contribute to cell 
migration. Their integration occurs primarily at the level of molecular scaffolds that allow 
for a convergence of these individual mechanisms. A molecular scaffold generally con-
sists of an adaptor protein capable of interacting simultaneously with several proteins 
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which, together, regulate a single biological process. Adaptor proteins are found at every 
cellular level including the cytoplasm (P130CAS), the membrane (CD151), and the ex-
tracellular matrix (SPARC). Among all the therapeutic strategies currently under evalua-
tion (Table 5) there is only one molecular scaffold (FAK) because it is a kinase that is 
also drug-able. However, the clinical focus on integration mechanisms is likely to inten-
sify as our understanding of molecular scaffolds is rapidly increasing and their uniquely 
critical participation in migration may improve therapeutic efficacy. To emphasize its im-
portance, four points of integration are presented below.Integration of cell–matrix adhe-
sion with cell-autonomous ability.
  Molecular integration of  integrins with the cell autonomous migration machinery 
occurs primarily through Talin and Focal Adhesion Kinase (FAK). Talin is a scaffolding 
protein that binds the cytoplasmic domain of β integrin subunit and links integrins to the 
actin cytoskeleton while complexing Vinculin and FAK into a functional complex that con-
trols inside-out activation of  the integrin and outside-in signaling resulting from matrix 
binding. As a non- receptor tyrosine kinase, FAK integrates with integrin associated 
complexes through the binding of Talin and Paxillin where it engages and controls the 
activity of  a wide variety of cell autonomous signaling molecules including src, PI3K, 
Shc, PLCγ, RhoGEF, GRB2.
Integration of cell–cell adhesion with cell-autonomous ability
 P120 is an adaptor protein of the catenin family and is frequently lost or mutated 
in cancer. Loss of P120 activity disrupts the function of E-cadherin and facilitates a pro-
migratory phenotype. P120 interacts directly with the cytoplasmic tail of E-Cadherin and 
integrates cadherin, src, and RTK signaling through scaffolding of intracellular signaling 
molecules (139,140). Its interaction with the zinc-finger 
transcription factor kaiso allows P120 to regulate gene transcription (141) 
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Table V: Targeting mechanisms that support molecular integration.
Target Molecular Mechanism
CD151
Transmembrane scaffolding protein of the Tetraspanin Super Family. 
CD151 interacts with other tertraspanins as wel as unique partners includ-
ing integrins α3β1 and α6β1, MMP14, MMP7, PKC, PI4K and other. 
These tetraspanin-partner dimers are incorporated into macromolecular 
complexes known as tetraspanin-enriched microdomains through the 
homo- and hetero-dimerization of the tetraspanins.
Talin-1
Integrin adaptor protein that binds to the cytoplasmic tail of the β subunit 
tail and links the integrin to the actin cytoskeleton and complexes Vinculin 
and FAK into a functional complex that controls inside-out activation of the 
integrin and outside-in signaling resulting from matrix binding. Silencing 
Talin reduces metastasis
FAK
Non-receptor tyrosine kinase that binds to Focal Adhesion Complexes by 
binding Talin and Paxillin. It interacts with a wide variety of signaling mole-
cules including src, PI3K, Shc, PLCγ, P130Cas, RhoGEF,GRB2, and 
more. Phosphorylation of its partners by FAK regulates motility.
P120 Catenin
Intracellular scaffolding protein of the catenin family that stabilizes the 
formation of E-Cadherin based adhesions and integrates cadherin, src, 
and RTK signaling through scaffolding of intracellular signaling molecules. 
P120 is frequently lost or mutated in cancer thereby disrupting the function 
of E-cadherin and other, currently undefined, signaling components.
Cortactin
Actin binding protein that also binds to WASP, MIM, Hax-1, TEM7, Dy-
namin 2, CD2AP, and Cadherins. Cortactin seems to be important for in-
vasive activity associated with invadapodia present in invasive cells. 
Cortactin is strongly correlated with cancer progression although its spe-
cific role remains unclear.
SPARC
Matricellular protein capable of interacting with collagen, fibronectin, EGF, 
TGFβ, and the β1 integrin. It alters the composition, assembly, and matu-
ration of ECM. SPARC is upregulated in a large number of cancers al-
though its biological contribution to metastasis is very context dependent.
P130 CAS
Intracellular scaffolding protein defined as an integrin adaptor molecule. 
P130cas is capable of binding a very broad range of cytoplasmic signaling 
molecules including FAK, PYK2, FRNK, PTPNI2, RAPGEF1, CRK, NCK, 
SFK, Aurora A, and PI3K. It is participates in both transformation and mi-
gration.
Molecules included here are representative molecular determinants of the underlying 
principle which can be found in (24,87,139,140,142-149).
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regulation of GTPase signaling via P120 catenins has been established(150) but the 
identity of partners is currently unknown.
Integration of soluble communication and cell–matrix adhesion with cell-autonomous 
ability 
 P130CAS is a classic molecular scaffold that controls the integration of signaling 
between integrins, receptor tyrosine kinases (RTK), and Src. p130CAS binds to twelve 
known partners and is phosphorylated by both Src and FAK. Stimuli from cell–matrix ad-
hesion (integrins), soluble communication (RTK), and cell autonomous ability (Src) each 
change the phosphorylation, localization, and activity/ availability of P130CAS binding 
partners. Ultimately, the composition and activity of the macromolecular complex that 
contains P130CAS determine its ability to influence actin cytoskeleton remodeling, gene 
expression, and cellular survival (151).
Integration at the membrane with molecular scaffolds 
 The interactions between the cell periphery and its extracellular micro- environ-
ment {92} are organized through macrodomains within the membrane such as focal ad-
hesions (152,153), tight junctions(111), lipid rafts (154), and tetraspanin-enriched micro-
domains (147,155,156). Together with their partner proteins, membranes scaffolding pro-
teins arrange themselves into organized structures within the plane of lipid bilayer. This 
high-order structure controls availability as well as activity of partners associated with the 
scaffolding proteins (157). 
 Of the membrane scaffolding proteins, the 33-member family of tetraspanins is 
most prominently involved in cancer biology. Tspan 1, 7, 8, 13, 24, 27, 28, 29, 30, and 31 
are involved in tumor progression (156). Metastasis seems to be specifically promoted 
by Tspan24 (CD151), (156),101) and suppressed by Tspan27 (CD82), (158). Tetraspan-
ins function as membrane scaffolding proteins by organizing a large selection of partner 
proteins into higher order structures usually referred to as tetraspanin-enriched micro-
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domains (TERM (147)). CD151 is an important regulator of tumor cell motility (156). It 
interacts and organizes integrins (including α3β1 and α6β1), MMPs (including MMP7 
and MMP14), tetraspanins (including CD9, CD81, CD82, and CD151), cytoplasmic sig-
naling molecules (including PKC and PI4K) (Reviewed in detail in [101](159)]. Tetras-
panin expression is frequently altered in cancer (155) and direct targeting of CD151 can, 
in fact, inhibit metastasis (24). The ability of CD151 to control motility and metastasis will 
be the central topic of the remaining chapters of this thesis and it is my hope that it pro-
vides some insight into the targeting of molecular scaffolding proteins in the treatment of 
metastatic disease. 
 The central organizing function of molecular scaffolds and adaptor proteins 
makes them very attractive clinical targets. Considering the limited success of cancer 
therapies that target individual proteases, growth factors, and kinases, altering the mo-
lecular integration of such prominent pro-migratory stimuli may prove to be most effec-
tive strategy for targeting motility and preventing metastasis.
Therapeutic targeting of tumor cell motility
 Therapy that targets tumor cell migration has tremendous potential in the clinic. 
Ideally targeted therapy limits, intervenes, or disrupts a molecular process that supports 
the pathology without disrupting normal physiological function. Successful targeting of 
tumor cell motility with the intent of disrupting metastasis will require the specific target-
ing of molecular mechanisms involved in metastatic dissemination without disrupting 
normal migratory processes such as inflammation and wound healing (160).
 The principal obstacle to developing therapy that specifically blocks metastasis is 
the time needed to determine therapeutic efficacy. Current anti-metastasis therapy is 
tested after first line therapy has failed or as an adjuvant to cytotoxic therapies. For 
many cancers these patients will remain disease free for several years thereby extend-
ing the duration of any trial and requiring a large number of patients. Patients subjected 
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to anti-metastasis therapy will have to be under continuous treatment because it is cur-
rently not possible to predict when a cancer becomes metastatic. This chronic treatment 
compounds possible negative side effects such as any impact on immunity or wound 
healing. Lastly, it is not possible to predict if resistance to targeted therapy for motility 
would develop considering that thousands of molecular determinants are involved in the 
motility of tumor cells. The main focus of existing pharmaceutical strategies is to design 
targeted therapies that disrupt molecular processes both central to survival and required 
in the motility of tumor cells. Consequently, all the drugs that are currently under consid-
eration target not only motility but also influence cell viability and proliferation. Although 
to date no therapy targeting tumor cell motility has been approved for clinical use, sev-
eral treatments are promising and under review in ongoing clinical trials. Table 6 pro-
vides a comprehensive representation of targeted therapies.
Future directions
 In 2010 more than 1300 manuscripts were published on the topic of tumor cell 
migration and its contribution to metastasis (Fig. 6). Numerous molecular mechanisms 
involved in this complex process have been described and suggested as potential thera-
peutic targets, yet only a very small fraction have been evaluated clinically for their ability 
to limit metastasis, and none are in clinical use.
 The difficulty of implementing motility-targeting therapeutics should not come en-
tirely as a surprise considering the complications of determining therapeutic efficacy in 
the adjuvant setting with chronic treatment of cancer patients. This is further complicated 
by the central role of motility in normal physiology and therefore the need to determine 
metastasis-specific therapies. Nevertheless, the proof of principle has been presented 
several times in the form of reduced metastasis in preclinical animal models and promis-
ing results from clinical trials. These trails target Src, VEGF, EGF, and TGFβ which have 
broad biological impact and inhibit multiple mechanisms involved in cancer progression 
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to maximize a favorable clinical outcome including the inhibition of both angiogenesis 
and metastasis or the inhibition of both tumor growth and motility.
 Significant progress in the treatment of metastasis is expected to be made as 
therapies targeting specific migratory mechanisms such as SDF-1, c-MET, EpCAM, and 
Rho-kinase progress through their clinical evaluation (Table 6 and 7). The difficulty in 
confirming long-term suppression of metastasis will remain the main obstacle to suc-
cessful clinical translation of any therapy targeting motility. To accelerate the evaluation 
of therapies that target metastasis, it may be necessary to take advantage of short, pre-
operative neo-adjuvant trials and establish new short-term parameters of clinical suc-
cess. These parameters could include the detection of changes in circulating tumor cells 
or a circulating metastasis biomarker. 
 The integrating function of scaffolding proteins is of particular interest because it 
brings together multiple molecular aspects of migration and is therefore less likely to fall 
subject to drug resistance. In addition, it is likely that combination therapies, targeting 
multiple mechanisms belonging to distinct principles presented here, will be developed 
to optimize efficacy and diminish drug resistance. In the past two decades many putative 
targets have been identified. If the first candidates, currently in clinical trials, prove suc-
cessful, then this approach and a new class of targeted therapeutics will define the fu-
ture of treating metastatic
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 Table VI: Migration inhibitors in clinical development
Drug Target Company Clinical Phase
Cell autonomous
Saracatinib (AZD0530) Src AstraZeneca II
Bosutinib (SKI-606) Src Wyeth II, III
Dasatinib (BMS-354825) Src Bristol-Myers Squibb I,II
Fasudil Rho kinase Asahi Kasei I,II,III 
Emodin Cdc42/Rac1 I 
Soluble interactions
CTCE-9908 SDF-1 Chemokine Thera-peutics I, II
MetMAB (PRO143966) Met Roche/Genentech II
AMG 208 Met Amgen I
GC1008 TGF-β family Genzyme I, II
Trabedersen (AP 12009) TGF-β2 Antisense Pharma I, II
Infliximab TNF-α Centocor I, II
EGFR
Herceptin^
(trastuzumab)
Genentech/Roche I,II,III
VEGF Avastin^ Genentech/Roche I,II,III
CXCR-4 CTCE-9908 Chemokine Thera-peutics I,II
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Table VI Continued
Drug Target Company Clinical Phase
Cell-cell interactions
IGN-101 EpCAM Aphton I, II
Exherin (ADH-1) N-cadherin Adherex I, II
Cell-matrix interactions
Cilengitide (EMD121974) αvβ3 and αvβ5 integrins EMD/Merck KGaA II, III
Volociximab (M200) α5β1 integrin PDL/Biogen Idec II
Etaracizumab (Abegrin) αvβ3 integrin MedImmune I, II
ATN-161 Integrins Tactic Pharmaceuti-cals I,II
BMS-275291# MMPs Bristol-Myers Squibb I,II,III
Endostatin MMPs Alchemgen Thera-peutics III
Curcumin MMPs Sabinsa Corpora-tion I, II
Tigapotide (PCK3145) MMP9 Ambrilia Biopharma II
A6 CD44 Angstrom Pharma-ceuticals II
Mesupron (WX-671) uPA Wilex I,II
ATN-658 uPA Tactic Pharmaceuti-cals I
Tempostatin (Halofuginone 
hydrobromide) Stroma
Collgard Pharma-
ceuticals II
PI-88 Heparanase Progen I,II, III
Vitaxin αvβ3 MedImmune II
Molecular integration
CFAK-C4 FAK CureFAKtor Phar-maceuticals I
PF-562271 FAK Pfizer I
References for these indicated studies can be found in (161-178) .
:
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Chapter III
“CD151” 
MEMBRANE ORGANIZATION THROUGH MOLECULAR 
SCAFFOLDING
Summary
 Tetraspanin proteins represent an interesting class of cell surface molecules that 
are able to control numerous cellular functions and processes. Unlike your traditional cell 
surface proteins they do not posses any catalytic activity or functional domains but rather 
act  as scaffolding proteins that are able organize cell surface partner proteins into 
macromolecular signaling complexes. CD151, is potentially the most well-studied mem-
ber of the tetraspanin family. This chapter will serve as an introduction to tetraspanin pro-
teins while primarily focusing on CD151. I will discuss much of what is known about 
CD151 including; its functions, defining characteristics, and its role in regulating cellular 
behaviors. Finally, I will introduce work from our laboratory using a specific anti-CD151 
monoclonal antibody that  served as a basis for this thesis project.
 
Introduction
 CD151, one of 33 members in the mammalian Tetraspanin (Tspan) family, regu-
lates diverse processes associated with adhesion including cell migration, platelet ag-
gregation, tumor cell invasion and metastasis. Structurally, CD151 contains 4 trans-
membrane spanning domains that form 2 extracellular loops leaving two short intracellu-
lar C  and N terminal tails in the cytoplasm. The largest loop is thought to be important 
for interactions with its transmembrane and membrane-proximal partners while the 
transmembrane and cytoplasmic domains engage in interactions with cytoplasmic sig-
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naling molecules such as PKC. Like most Tspans, CD151 functions as a membrane 
scaffolding molecule by promoting the assembly of itself along with its partners into mac-
romolecular protein complexes within the lipid bilayer of membranes. These complexes 
are known as Tetraspanin Enriched Microdomains (TERMs). CD151 interacts with a va-
riety of molecules include integrins (α3 and α6), proteases (MMP14 and MMP7), signal-
ing molecules (PKC and PI4Kinase), adhesion molecules (E-cadherin) and other Tspans 
including itself. It is widely accepted that the Tspan partner incorporated into the TERM 
contributes to the functional role of the tetraspanin in biological systems. Together these 
partner-Tspan interaction which form the TERM are macro molecular complexes that 
regulate complex cellular behavior but are physically and functionally distinct from other 
signaling structures such as lipid rafts and adhesion complexes. One of the key differ-
ences between TERMs lipid rafts is the fact that lipid rafts are disrupted in cholesterol 
depletion experiments while TERMs are maintained(22). CD151 it is almost ubiquitously 
expressed but is predominantly found on epithelial cells, endothelial cells, and platelets. 
While its loss in humans and experimental mouse models leads to phenotypes related to 
basement membrane failures including skin blistering and renal failure, CD151 is fre-
quently upregulated in cancer. In summary, CD151 participates in regulating adhesive 
functions of normal and tumor cells by organizing partner proteins actively involved in 
the adhesive process. 
Protein Function
 CD151 functions principally as a transmembrane scaffolding protein. Like most 
tetraspanins, CD151 interacts with other transmembrane or membrane-proximal proteins 
through its LEL and short cytoplasmic tails. Multimerization of the Tspan and its partner 
proteins leads to the formation of large multi-molecular complexes within the membrane. 
These complexes were originally referred to as the "tetraspanin web" (179-181), how-
ever, the most current literature refers to them as Tetraspanin Enriched Microdomains 
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(TERM or TEM), (147,155). The large extracellular loop (LEL) contains the majority of 
amino acids important for interactions with transmembrane and membrane proximal 
partners while the transmembrane regions and cytoplasmic tails are thought to be re-
quired for intracellular interactions with Tspan-associated cytoplasmic signaling mole-
cules. Specific partners include α3β1, α6β4, PI4K, and PKCα. The molecular mecha-
nism(s) by which this Tspan conveys biological activity remains under investigation. 
CD151 participates in a wide variety of normal physiological processes as well as pa-
thologies including kidney function, angiogenesis, platelet activation, inflammation, 
wound healing, tumor invasion, and metastasis. ;(23,24,180,182-187). It is generally 
considered to be a pro-migratory molecule and is routinely upregulated at the invasive 
front of metastatic tumors. In vitro the forced expression of CD151 is able to promote 
migration while in cells that express high levels of CD151 the knockdown of CD151 has 
been shown to decrease migration. 
CD151 Expression
 CD151 was originally identified as a platelet cell surface antigen (188), (189) it is 
expressed nearly all tissues. It is abundantly expressed in many cells of the vasculature 
system including endothelial cells, megakaryocytes and platelets. It is highly expressed 
in ductal epithelial cells of  the breast, colon and prostate. It is also expressed in the 
glomeruli and tubules of the kidney, the basal epithelia of the skin, cardiomyocytes, and 
Schwann cells of the brain. CD151 is also expressed in most solid tumors and upregu-
lated in many aggressive neoplasia. In contrast, it is distinctly absent from lymphoma. In 
normal tissues and confluent endothelial or epithelial cell cultures CD151 is predomi-
nantly localized to the basolateral surface and to areas of cell-cell contact(189-193). In 
individually cultured cells without cell-cell contact or non-adherent cells, CD151 is fre-
quently internalized into endosomal and lysosomal compartments (21,194) as a compo-
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nent of  the endocytic pathway. In contrast, tumor cells frequently exhibit general cell 
surface distribution and localization in cytoplasmic vesicles. In epithelial cells CD151 is 
also seen in hemidesmosome-like structures where it associates with α6β4 (184,187). 
More recently CD151, along with other tetraspanins, have been shown to be enriched in 
exosomes. (182,147). 
Interactions with ligands and other proteins
 Presently, there is no specific ligand known for CD151. CD151 interacts with a 
large variety of proteins including integrins, other tetraspanins, proteases, and signaling 
molecules. It is has been suggested that Tspans such as CD151 can interact with more 
than 100 proteins (147,156,195). The most well studied CD151 interactions are those 
that involve the laminin binding integrins α3β1 and α6β1(196), these CD151-integrin 
complexes can regulate cell morphology and migration by controlling adhesion and ad-
hesive strengthening (197) and cytoplasmic signaling . The nature, stoichiometry, and 
affinity of tetraspanin-partner interactions have been difficult to assess quantitatively. Di-
rect partners of Tspans are identified through a combination of protein cross-linking, cell-
surface biotinylation, differential detergent extraction, and reciprocal 
immunoprecipitation(179,190,198-200). The α3β1 CD151-integrin complex is one of the 
best defined interactions. This complex can be immunoprecipitated under both mild and 
stringent detergent extraction conditions indicating a strong, primary interaction that is 
defined by the specific QRD binding sequence (196,201). Furthermore, the interaction is 
highly stoichiometric using reversible crosslinking, biotinylation, and reciprocal immuno-
precipitation of the Tspan and its partner (202). Furthermore, the loss of CD151 leads to 
migration deficiencies in laminin-rich matrixes (203-205). In addition to manipulating the 
activity of its integrin partners directly, evidence has been presented that the tetraspanin 
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can regulate partner trafficking (194), glycosylation (206). Together these observations 
provide strong support for both a physical and functional role for CD151 in α3β1 biology. 
The integrin α6β1 and α6β4 are also partners of CD151 although the interaction is not 
as stable as the CD151-α3 interaction(184,207). Disruption of CD151-α6 interaction 
does not alter integrin cell surface expression or cellular adhesion to laminin, however, it 
does diminish alpha 6 dependent cell spreading and integrin-mediated adhesive 
strengthening (197). It is important to note that the regulation of integrin function has 
been demonstrated biochemically and functionally only for laminin-binding integrins α3 
and α6). The molecular mechanism by which CD151 controls migration remains un-
known. In vivo work with anti-CD151 antibody suggests, however, that CD151 can have 
a broad impact on all matrix-binding integrins (24)
CD151 association with intracellular signaling molecules	   CD151 also associates with signaling molecules including PKCα and PI4Kinase 
type IIα (192,200,202). The importance of these interactions are not fully known however 
it reasonable to speculate that the CD151 interactions with these signaling molecules 
could influence intracellular signaling by incorporating them into the TERM. This is par-
ticularly likely for PKCα which only binds to CD151 in its active form. More recently an 
interaction with the E3 ubiquitin ligase GRAIL was identified however, a functional role of 
this interaction has not been explored (208). Several Matrix Metalloproteinases have 
been associated with CD151 including MMP7(209) and MMP14 (23). These studies 
suggest that the tetraspanin may control activation and localization of these proteases. 
The incorporation of CD151 into tetraspanin-enriched microdomains will most likely allow  
it to interact directly and indirectly to a large number of proteins and regulate their func-
tion. The extent to which to this activity influences biological function will have to be de-
termined for each  individual biological system.
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Regulation of Activity
 The activity of CD151 is primarily regulated post-translationally through modifica-
tions of its subcellular distribution or the stability of its interaction with membrane part-
ners. The most common post-translation modification involves the palmitoylation of con-
served cysteine residues in the transmembrane domains by the palmitoyl-acyl transfe-
rase (PAT) DHHC2, one of 23 known mammalian PATs (210). Palmitoylation of Tspan 
proteins such as CD151 affects the assembly and maintenance of TERMS while also 
affecting tetraspanin subcellular distribution, stability during biosynthesis, cell signaling, 
motility, and morphology. It has also been shown that palmitoylation of CD151 is involved 
in the regulation of Tspan-Tspan interaction because palmitoylation-deficient CD151 is 
unable to complex with other Tspan family members (CD9, CD63, CD81) (180,211-213). 
The importance of this modification has been confirmed both by siRNA mediated knock-
down of expression of DHHC2 as well as the expression of palmitoylation-deficient 
CD151 mutants. In addition to palmitoylation on conserved cysteine residues CD151 is 
also routinely glycosylated in its extracellular domain. Glysosylation of CD151 regulates 
the CD151/alpha 3 beta integrin association while also modulating integrin-mediated ad-
hesion and spreading (206). Tspan clustering is the primary mechanism that can influ-
ence their biological activity. Clustering antibodies for CD151 and other tetraspanins 
have demonstrated dramatic phenotypes including complete immobilization of tumor 
cells (24). These experiments demonstrate that mechanisms capable of regulating Tspan 
clustering are potent regulators of Tspan activity.
Clustering of CD151 using monoclonal antibodies
 As I alluded to above monoclonal antibodies have been indispensable to our un-
derstanding of not only tetraspanin functions but also in the identification of tetraspanin 
associated partner proteins. (214,215). Our laboratory has demonstrated that clustering 
of CD151 using the specific anti-CD151 antibody 1A5 promotes tumor cell immobiliza-
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tion and inhibits metastasis in vivo (24). Monoclonal antibody (mAb) 1A5 was isolated in 
a screen for metastasis inhibitory antibodies and was subsequently shown to inhibit me-
tastasis by inhibiting tumor cell intravasation (216). Although the head and neck small 
squamous cell carcinoma cell line (HNSCC) HEp3 served as the immunogen in the sub-
tractive immunization approach used to generate 1A5 clustering of CD151 was able to 
inhibit in vivo metastasis of the fibrosarcoma cell line HT1080. In vitro treatment of tumor 
cells with 1A5 inhibits migration by promoting an increase in adhesion, which inhibits cell 
migration on all matrices tested including laminin, collagen, fibronectin and vitronect-
in(24). Collectively, this demonstrated that the clustering of CD151 controls motility by 
promoting a pan-integrin adhesive phentoype. Many of the functions and mechanisms of  
action related to clustering of CD151 suggested the involvement of the laminin binding 
integrins particularly α3β1 However,herein we present data to suggest that integrin inde-
pendent mechanisms of CD151 exist. Interestingly, integrin free CD151 (CD151free) is 
potentially involved in prostate cancer progression. The expression of CD151free is also 
a predictor of poor overall survival in prostate cancer This work will be presented in the 
following chapter.
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CHAPTER IV
INTEGRIN-FREE TETRASPANIN CD151 CAN INHIBIT TUMOR CELL 
MOTILITY UPON CLUSTERING AND IS A CLINICAL INDICATOR OF 
PROSTATE CANCER PROGRESSION
Summary
! Normal physiology relies on the organization of transmembrane proteins by mo-
lecular scaffolds, such as tetraspanins. Changes in their organization or expression are 
commonly associated with oncogenesis. The tetraspanin CD151 is thought to contribute 
to cancer progression through direct interaction with the laminin-binding integrins α3β1 
and α6β1. However, this interaction cannot explain the ability of CD151 to control migra-
tion in the absence of these integrins nor its regulation of migration on non-laminin sub-
strates. We demonstrate that CD151 can regulate tumor cell migration without direct in-
tegrin binding and that integrin-free CD151 (CD151free) is clinically correlated with tumor 
progression and metastasis. Clustering of CD151free through its integrin-binding domain 
promotes its stable accumulation in areas of cell-cell contact leading to enhanced cell 
adhesion and subsequently inhibition of tumor cell motility in vitro and in vivo. CD151free 
clustering is a strong regulator of motility even in the absence of α3 expression but re-
quires PKCα suggesting that CD151 can control migration independent of its integrin 
associations. The histological detection of CD151free in prostate cancer correlates with 
poor patient outcome. When CD151free is present, patients are more likely to recur after 
radical prostatectomy and progression to metastatic disease is accelerated. Multi-variate 
analysis identifies CD151free as an independent predictor of survival. Moreover, the de-
tection of CD151free can stratify survival among patients with elevated PSA. Cumulatively 
these studies demonstrate that a subpopulation of CD151 exists on the surface of tumor 
cells that can regulate migration independent of its integrin partner. The clinical correla-
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tion of CD151free with prostate cancer progression suggests that this tetraspanin sub-
population may contribute to the disease and could be used to predict cancer progres-
sion.
Introduction
 Cancer metastasis typically involves the migration and invasion of disseminating 
tumor cells. The activity of cytokine receptors, adhesion receptors and proteases re-
sponsible for this migration, is frequently controlled through their organization within the 
cell membrane. Tetraspanins are key membrane scaffolding proteins responsible for this 
organization. Although the tetraspanins lack enzymatic activity and canonical signal-
transducing capacity, their ability to organize macromolecular structures is their primary 
mechanism of action (1). Of the 33 tetraspanin family members, 6 have been implicated 
in cancer (2, 3) and CD151 has been shown to be a particularly important regulator of 
tumor cell motility (4) and metastasis (5, 6). CD151 interacts with several partners in-
cluding MMP14, cadherins, immunoglobulin proteins, and integrin subunits α3 and α6, 
as well as other members of the tetraspanin family (7-9). Consequently, further elucida-
tion of tetraspanin function requires investigation of its molecular organization and the 
role of specific partners. The interaction between CD151 and the laminin binding in-
tegrins α3β1 and α6β1 has been investigated in detail (reviewed in (1) and (10)). Loss of  
CD151(11) diminished migration on laminin while disruption of the integrin-binding do-
main limits spreading on laminin and tubule morphogenesis as well as tumor growth in 
3D laminin-containing matrixes (12, 13). Recently the CD151-integrin-laminin axis has 
been shown to facilitate EGF signaling (14-16). However, a number of biological activi-
ties have been associated with CD151 that are likely to involve different molecular 
mechanisms. These include migration on non-laminin substrates, platelet function and 
cell-cell adhesion. Effective approaches to investigating these functions have included 
genomic ablation (16-18), mutational analysis (12, 19, 20) and CD151-specific antibod-
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ies (6, 21-24). These studies suggest that both integrin-dependent and integrin-
independent roles exist for CD151 in tumor progression.
 CD151 can be targeted to inhibit tumor cell motility and metastasis using the an-
tibody mAB 1A5 (6). Treatment with mAB 1A5 prevents de-adhesion at the rear of mi-
grating cells resulting in their immobilization and subsequent inhibition of metastatic dis-
semination(6). MAB 1A5, like most anti-CD151 antibodies, was generated in mice 
against a human antigen(25, 26). Consequently these antibodies primarily recognize an-
tigenic differences between human and mouse CD151. Some CD151 antibodies exhibit 
differential staining patterns in human tissues most likely because certain epitopes are 
masked by protein-protein interactions of the CD151 complex(12, 22, 27-29). Epitope 
mapping allows these antibodies to identify the composition of a CD151 complex. Ya-
mada et al., (23) used flow cytometry to map epitope binding of CD151 antibodies on 
CD151 mutants with substitutions at amino acid residues that are not conserved be-
tween human and mouse CD151. These studies demonstrated that several antibodies 
recognize an epitope on CD151 required for binding integrins including α3β1 (12). Inter-
estingly the knockdown of α3 reduced the overall level of CD151 but did not diminish the 
level of CD151 recognized by antibodies to the integrin-binding domain. This observation 
suggests that distinct populations of CD151 are maintained on the cell surface. One of 
those populations is associated with integrins while the other is not. We will refer to 
these populations as CD151ITGA and CD151free respectively.
 Considering the epitope-specificity of antibodies, it is likely that antibodies which 
recognize distinct CD151-partner complexes can provide insight into the function and 
clinical relevance of that CD151 subpopulation.  We hypothesized that the inhibition of 
motility in response to mAB 1A5 was due to its ability to target a specific subpopulation 
of CD151 and affects its activity. Since a monovalent fragment of mAB 1A5 was unable 
to inhibit tumor cell motility, we predicted that this antibody mediated clustering of all, or 
a specific sub-population of CD151. Live-cell imaging was implemented to investigate 
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clustering in response to antibody binding. Using the flow cytometry approach developed 
by Yamada et. al. we determined that mAB 1A5 recognized the integrin-binding domain 
on CD151 and is therefore unable to interact with integrin-bound CD151. The analysis of  
tumor cell migration in vivo was used to investigate the ability of mAB 1A5 to control cell 
motility independent of integrin α3. These investigations were extended to other antibod-
ies that recognize the same integrin-binding domain (8C3 and 14A2.H1) or bind an unre-
lated site (11G5A). Finally, we determined if the presence CD151 not bound by integrins 
was relevant in prostate cancer progression by histological analysis of CD151free in tis-
sue from two cohorts of prostate cancer patients. 
Materials and Methods
Cell culture, reagents and antibodies
 HEp3 cells are perpetually maintained on the chick chorioallantoic membrane to 
retain metastatic and migratory potential (43-45). All cell lines were grown in media sup-
plemented with pen/strep, sodium pyruvate, non-essential amino acids and 10% fetal 
bovine serum and cultured at 37℃ in 5% CO2 incubator and passaged every 2-4 days. 
HEp3, NIH3T3 and HT1080 cells were maintained in DMEM. A549 cells were main-
tained in RPMI. The CD151 plasmids in the eGFP-N1 vector (Clontech) were received 
from received from Dr. Kiyo Sekiguchi (University of Osaka, Japan). Transfections of all 
cells were performed using Extreme Gene HD (Roche). The mAB 1A5 and the control 
antibody 29-7 was generated as described previously (46).The anti-CD151 antibodies 
11G5A and 14H2.1 were purchased from Abcam. Anti-C151 antibody 8C3 was gener-
ously provided by Dr. Sekiguchi. Anti-ITGA3 antibodies were purchased from Santa Cruz 
Biotechnology (P1B5) and Millipore. The smart pool RNAi specific to α3, PKCα, and the 
control siRNA was obtained from Dharmacon. 
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Tumor cell motility 
In vitro cell migration
  HEp3 and HT1080 cells were seeded in 6-well plates and allowed to attach over-
night in DMEM containing 10% FBS on the following day the cells were switched to se-
rum free/ insulin free media for an additional 24 hrs. On the day of the assay the conflu-
ent monolayers were scratched with a pipet tip in order to create a uniform wound after 
which the cells were washed with PBS to remove any floating cells. Cultures were re-
turned to full medium and the wound was documented at 0 hrs and 16 hrs post-scratch 
using a light microscope TMS-F (Nikon) equipped with a D90 SLR camera (Nikon). 
Wound closure (% surface area) was determined using T-scratch image analysis soft-
ware (47, 48). 
In vivo cell motility 
 Assays were performed as previously described (6). Briefly, cells to be injected 
were washed 2 times with PBS and detached with 2mM EDTA. The cells were resus-
pended in PBS and injected IV into Day 12 chick embryos. Four days post-injection the 
disseminated colonies were photographed using a Lumar V12 stereomicroscope (Zeiss) 
equipped with a Retiga Exi camera and controlled with Volocity image acquisition soft-
ware (PerkinElmer). Antibody treatments were introduced by intravenous injection one 
day after tumor cell injection. For visualization of the vasculature rhodamine-conjugated 
dextran was injected intravenously and allowed to circulate for 15 minutes prior to tissue 
collection. “Non-motile” colonies were defined as colonies comprised of 5 or more cells 
where individual cells remained in direct contact. Such non-motile colonies are compact 
while “motile” colonies contained a migratory cell populations dispersed in the CAM. 
Data is represented as the % of colonies within a single animal that demonstrated a mo-
tile phenotype.
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Flow cytometry
Standard flow procedure 
 Cells to be used in flow cytometry experiments were trypsinized with 0.25% 
Trypsin-EDTA and resuspended in cold Milytenyl FACs buffer (2mM EDTA, 0.5%BSA, 
PBS). For the analysis of cell surface expression of specific antigens the cells were 
washed 2 times with FACs buffer and then stained with the specific primary antibodies 
for 1hr on ice. Following incubation with the primary antibody the cells were washed 2 
times with cold FACs buffer and then incubated with species-specific, fluorophore-
conjugated secondary antibody.
Epitope mapping using flow cytometry
 NIH 3T3 were transfected with the CD151 human/mouse GFP substitution mu-
tants {Yamada, 2008, l92090} using Fugene HD (Roche). Transfected cells were pre-
pared for flow cytometry as described above 24 hr after transfection. Cells were stained 
with anti-CD151 antibodies (mAB 1A5, 8C3, 14A2H.1 and 11G5A) on ice for 1 hr fol-
lowed two washes and incubation with Alexa 647-conjugated secondary antibody (1 hr 
on ice). The stained cells were washed twice with cold FACs buffer resuspended and 
analyzed by two-color flow cytometry. Untransfected controls and empty vector (pEGFP 
N1) transfections were used as a no color and GFP only positive controls respectively. 
An isotype IgG was used for as a control for gating purposes. In order to analyze the 
GFP-positive and Alexa 647 double-positive populations, the cells were gated for GFP 
expression to identify GFP expressing cells which were subsequently analyzed for their 
binding of Alexa 647-conjugated antibody (which represents binding of the respective 
anti-CD151 antibody). The data is presented as dot plots with the detection of GFP 
graphed on the X-axis and the detection of Alexa 647 plotted on the Y-axis. 
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Immunoprecipitation, immunoblotting, and immunodepletion
Immunopreciptation
 HEp3 cells and A549 cells were lysed in either 1% (vol/vol) Triton X-100 lysis 
buffer or 1% (vol/vol) Brij-99 lysis buffer on ice for 30 minutes. The samples were cleared 
by centrifugation (14,000 rpm, 15 min) and cleared lysates were transferred to new 
tubes and stored at 4˚. Protein concentrations were determined by BCA (Pierce). Im-
munoprecipitations were performed by incubating 2 µg of the antibody with 1 mg total 
cell lysate over night at 4° with end-to-end rotation. The following day the protein/
antibody complexes were bound to Protein A/G sepharose beads (Fisher Scientific) for 4 
hours at 4° with end-to-end rotation. Beads were collected by centrifugation (8000 rpm, 
30 secs) washed with lysis buffer and stored together with unbound material for further 
analysis. Immunoprecipitated complexes were eluted in 100 µl Lamelli sample buffer and 
evaluated by immunoblot analysis. For each sample equal amounts of protein were 
loaded into SDS-PAGE and blotted onto polyvinylidene fluoride membranes (PVDF, Mil-
lipore). Protein detection was performed with enhanced chemiluminescence (ECL, 
Pierce) after blocking (5% non-fat milk from powder in  PBS, 0.05% Tween-20) and in-
cubation (O/N 4˚C) with antibodies prepared in blocking buffer. 
 Immunodepletion of mAB 1A5-bound CD151: 1) HEp3 or A549 cells were lysed 
in 1% Triton X-100 lysis buffer and incubated with 2 µg of antibody for two hr at 4˚ with 
end-to-end rotation. The immunecomplexes were then captured with Protein-G sepha-
rose beads for 1hr at 4˚. This process was repeated 3 times using the unbound lysate. 
Each immunodepletion was evaluated by immunoblotting as described above. 2) For 
immunodepletion  of mAB 1A5 bound to live cells HEp3 and A549 cells were treated 
overnight with mAB 1A5 or control antibody at a concentration of 2 µg/ml. Antibody-
bound cells were lysed 24 hr later and antibody-bound CD151 was immunodepleted with 
protein-G sepahrose beads. The unbound material was depleted 2 additional times with 
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protein-G beads and bound as well as unbound material was evaluated by immunoblot-
ting.
 Cell Surface Biotinylation: For cell surface labeling confluent HEp3 cells were 
treated with antibody for 1 hr on ice and then washed 3 times with cold PBS. Cultures 
were subsequently biotinylated with sulfosuccinimidyl-6-[biotin-amido]hexanoate using 
the EZ-Link Sulfo-NHS-Biotinylation Kit (Thermo Scientific) according to manufacturer’s 
instructions. Cells were lysed in either 1% Brij 99 followed by extraction of the insoluble 
material with RIPA buffer Immunoprecipitation was performed as described above. 
Biotinylated proteins were detected with peroxidase-conjugated strepavidin.
Live cell imaging and immunofluorescent staining
 In order to visualize CD151 localization HEp3 cells expressing GFP-tagged 
CD151 were imaged with a fully automated microscope (BX61, Olympus) equipped with 
a digital camera (Orca ER, Hammamatsu) every 5 minutes for 1hr. Cells were subse-
quently treated with Alexa 647-conjugated mAB 1A5 and imaging continued for an addi-
tional 3 hours. Movies were analyzed and complied using Volocity Image Acquisition and 
Analysis Software (PerkinElmer). 
 Immunofluorescent detection of anti-CD151 antibodies bound to cultured cells 
was accomplished by staining  paraformaldehyde fixed cells with Alexa 546-conjugated 
secondary antibody. Fibronectin fibrilogenesis was detected on paraformaldehyde fixed 
cells by immunofluorescent staining with rabbit anti-fibronectin antibody in conjunction 
with Alexa 546-conjugated anti-rabbit secondary antibodies. Images were captured with 
a fluorescent microscope using Volocity Image Acquisition and Analysis Software (Perkin 
-Elmer).
63
Platelet aggregation assay
 Platelet aggregation assays were performed as previously described (49). Blood 
to be used from donors was collected and mixed 1:10 with 3.8% Sodium Citrate Buffer 
and spun at 160 X g for 30 minutes. The platelet rich plasma (PRP) was counted and 
resuspended at a concentration of 2-4 X108 cells/mL. Aggregation of PRP was per-
formed on a BIO/DATA Corporation PAP-4 aggregometer at 37℃ with stirring (1200rpm). 
Individual treatments were added as outlined in the text and turbidity analyzed compared 
to the aggregation of platelet poor plasma (PPP). 
Cell clustering assay
 Suspension cultures of Jurkat and U937 cells were treated with control antibody 
or mAB 1A5 overnight using serum free culture medium. Clustering formation was 
documented at 100X magnification with a digital camera (Nikon D90) mounted to a 
phase-contrast microscope.
Collagen contraction assays
 HEp3 cells and their treatments were mixed with neutralized collagen solution (1 
mg/ml in 1X cell culture medium) at a concentration of 0.4 million cells/ml. The collagen/
cell mixture was placed in the wells of a 24-well plate, allowed to solidify at 37˚C and cul-
tured for 48 hrs before analysis. The collagen was subsequently released from the wall 
of the culture well using a metal spatula and contraction of the collagen plug was docu-
mented 1 hr after release. The collagen plugs were documented at 100X magnification 
with a digital camera (Nikon D90) mounted to a phase-contract microscope. 
Patients and samples 
 Two retrospective cohorts of patients with PCa were utilized in this study. The 
first cohort (cohort #1) of 99 cases underwent radical retropubic prostatectomy (RRP) 
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between 1994-1998 at the London Health Sciences Centre with pathological stage pT2 - 
pT3 PCa (Supplemental Tables 1 and 2). A second cohort (cohort #2) of 38 cases was 
comprised of diagnostic biopsy specimens from PCa patients at the same center who 
did not undergo RRP and developed metastatic disease during follow-up (Supplemental 
Table 3). Pathological staging was re-evaluated according to TNM criteria (AJCC 2002). 
Patient characteristics and disease-related outcomes were obtained from a review of the 
medical records (Supplemental Tables 1-3). This study obtained approval from an inde-
pendent local Ethics Committee (UWO REB #15084E) and obtained the informed con-
sent from all patients for the research use of their tissues.
Immunohistochemistry 
  Formalin-fixed, paraffin-embedded tissue blocks were cut into 4 µm sections and 
mounted onto positively charged glass slides. The tissue was deparaffinized and rehy-
drated using the xylene, graded ethanol, and water method. A two-step epitope retrieval 
was performed whereby tissue sections were boiled in the microwave in 10 mM Sodium 
Citrate, 0.05% Tween 20 pH 6.0. The slides were then allowed to cool down, washed 
with PBS 0.2% Triton-X (PBST), and incubated with pre-warmed pepsin (digest-all™ 3, 
Invitrogen) for 3 minutes. After washing with PBST, the specimens were stained using 
the UltraVision Detection System (Thermo-Scientific). CD151 mAb 1A5 was diluted 
1:800 in 1% BSA in PBS, CD151 mAb 11G5a (Abcam) was diluted 1:100 in 1% BSA in 
PBS and α3β1 antibody P1B5 was diluted 1:250 in 1% BSA in PBS. Samples were then 
counterstained with Hematoxylin and mounted with Cytoseal (Thermo-Scientific). Nega-
tive controls were prepared using the identical treatment with omission of the primary 
antibody. Non-immune mouse IgG was used as an additional negative control.
CD151 expression analysis
65
 CD151 expression in the RRP and biopsy cohorts detected by immunohisto-
chemistry was categorized as negative (score=0), weakly positive (score=1), moderately 
positive (score=2) or strongly positive (score=3) independently by two pathologists who 
had no knowledge of the patient’s clinical status. A consensus was reached where any 
discrepancy was identified. To determine the statistical significance of mAb 1A5 immuno-
reactivity, specimens were divided into negative (score=0) and positive (score=1-3). 
CD151 protein expression analysis was performed in cancerous areas as well as, be-
nign tissue adjacent and distant from areas of tumour. Biochemical recurrence after RRP 
was defined as two consecutive PSA measurements greater than 0.2 ng/mL. Bone me-
tastasis was defined as presence of metastatic lesions on a bone scan. 
 Profiling of CD151 mRNA expression in normal and prostate cancer tissue was 
accomplished using publicly available data obtained from the NCBI Gene Expression 
Omnibus (GEO) as well as The Cancer Genome Atlas (TCGA) via The cBio Cancer Ge-
nomics Portal (217). These included GDS2545 (n=171) (50), GDS1439 (n=19) (51), 
GSE6099 (n=102) (52) and the prostate adenocarcinoma dataset from TCGA. Datasets 
were categorized according to their clinical diagnosis and analyzed by ANOVA with post-
test analysis for linear trend. CD151 expression levels were extracted from publicly 
available expression dataset GDS3113 (n=3/tissue) (53) to demonstrate relative levels of 
CD151 expression in prostate compared to other tissues.
Statistical Analysis
 Statistical analyses were performed using SAS version 9.2 (SAS Institute Inc., 
Cary, NC), SPSS 20 (IBM), and Graphpad Prism (Graphpad software, La Jolla, CA). Ex-
perimental groups in migrations assays were compared to the control groups using a 
non-parametric Mann-Whitney test. The primary endpoint for cohort #1 is biochemical 
recurrence-free survival and the primary endpoint for cohort #2 is metastasis-free sur-
vival. Correlations between mAB 1A5 immunoreactivity and biochemical recurrence-free 
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survival in malignant areas compared to benign areas were analyzed by McNemar’s chi-
square test. Kaplan–Meier plots were used to assess biochemical recurrence-free and 
metastasis-free survival. Group comparisons were made using the log-rank test. The 
Cox proportional hazard model was applied for multivariable analysis. In all statistical 
analyses, a two-sided,p<0.05 was considered statistically significant. Graphical repre-
sentation of statistical significance included * (p< 0.05), ** (p< 0.01) and *** (p<0.001).
Image Processing and Analysis
 Included images are representative of at least three replicate experiments. Fluo-
rescent images are false-colored to represent specific labels. The brightness of images 
captured of in vivo experiments was uniformly adjusted for purposes of clarity. Where 
indicated the images were cropped and scaled without change in resolution. Quantitation 
of signal was performed on raw image files in Volocity Image Acquisition and Analysis 
Software (PerkinElmer) prior to creating the figures.
RESULTS
CD151 clusters and accumulates at areas of cell-cell contact in response to mAB 1A5 
binding
 Given that tetraspanins facilitate macromolecular organization within cellular 
membranes, we hypothesized that the ability of anti-CD151 antibodies to influence mi-
gration involved changes in CD151 localization. This possibility was evaluated by ana-
lyzing changes in CD151 surface distribution in response to antibody binding (Fig. 10). 
NIH3T3 cells transfected with human CD151-GFP exhibited a uniform surface distribu-
tion of CD151 when cultured at subconfluent densities (Fig. 10A and Bi/i’). Upon anti-
body binding CD151-GFP re-organized into punctate structures on the cell surface (Fig 
10A and Bii) and accumulated at areas of cell-cell contact (Fig. 10A and Biii). To confirm 
that antibody-bound CD151-GFP complexes were on the cell surface, a TRITC-
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Figure 10. Cell surface clustering of CD151 in response to mAB 1A5. The cell 
surface distribution of CD151 was visualized by fluorescent microscopy in NIH3T3 
cells after transfection with CD151-GFP and culture in the absence or presence of 
mAB 1A5 (2µg/ml) for 2hr. (A) CD151-GFP visualized in the absence (left panel) 
or presence of mAB 1A5 (right panels, 2µg/ml for 2hr). Surface bound antibody 
was detected using TRIC-conjugated anti-mouse IgG post fixation. Insets in A em-
phasizing general cell surface (i and ii) v.s. areas of cell-cell contact (i’ and iii) are 
magnified in (B). (C) Surface CD151 was detected in sequential Brij99 and RIPA 
extractions with avidin-HRP after biotinylation of surface proteins and immunopre-
cipitating the tetraspanin from HEp3 cells cultured in the presence of a control IgG 
or mAB 1A5 for 24hr. (D) Live cell imaging was used to evaluate changes in 
CD151 distribution in response to mAB 1A5 binding. A549 cells transfected with 
CD151-GFP (green) were imaged every 5 min for 2 hr with the addition of Alexa 
546-conjugated mAB 1A5 (red) added at t=60 min and flushed from the system at 
t=80 min. Data is representative of 3 independent experiments. Fluorescence 
quantitation across the indicated white dashed line was performed in Volocity and 
calculated as the mean fluorescence in intensity minus background. Quantitation 
is representative of >5 cells per experiment.- 
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conjugated secondary antibody was used to detect mAB 1A5 on the cell surface of intact 
cells fixed 2 hr after antibody treatment. Similar observations were made with HELA, 
HEp3, HT1080 and A549 cells. This data suggests that mAB 1A5 ligation of CD151 
promotes the formation of macromolecular (clustering) on the cell surface. Clustering of 
tetraspanins is known to cause a change in detergent solubility (1). To determine if 
antibody-mediated clustering induced a change in solubility we performed cell surface 
biotinylation and differential detergent extraction of HEp3 cells treated with mAB 1A5 
(Fig. 10C). Indeed, cell surface CD151 (biotinylated-CD151, arrow) became resistant to 
extraction by Brij99 and was solubilized by subsequent RIPA extraction. The increase in 
relative abundance of biotinylated CD151 in the RIPA re-extraction confirms that the 
clustered tetraspanin accumulated in detergent-resistant complexes on the cell surface.
 When cell densities were sufficient to allow for cell-cell contact, antibody-binding 
induced clustering of CD151 at areas of cell-cell contact (Fig. 10Biii) rather than at ran-
domly distributed surface aggregates. To further assess the recruitment of CD151 to ar-
eas of cell contact, live-cell microscopy of densely cultured A549 cells expressing 
CD151-GFP was performed during the addition of Alexa 546-conjugated mAB 1A5 (Fig. 
10D). A549 cells have intact cell-cell contacts (30) where CD151 is readily visible. Addi-
tion of mAB 1A5 caused rapid accumulation of both labeled antibody and CD151-GFP in 
areas of cell-cell contact (Fig. 10D “0 min” v.s. “120 min”). The accumulation of CD151 at 
areas of cell-cell contact was quantified by mapping pixel intensity from time 0 to 120 
min. in the GFP channel (CD151-GFP) and the Alexa 546 channel across a reference 
line. Although A549 cells have well established cell-cell contacts, similar observations 
were made for epithelial-derived cancer lines that lack stable cell-cell contacts such as 
the HNSCC HEp3 during in vitro culture (Fig. 11) and in vivo tumor growth (Fig. 12). 
Thus clustered CD151 accumulated at areas of cell-cell in all models and experimental 
settings.
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Fig. 11.Screen shot of movie depicting CD151 clustering at areas of cell-
cell contact in HEp3 tumor cells. HEp3 cells cultured to 80% confluency 
were monitored by time-lapse microscopy before, during and after treatment 
with 1µg/ml Alexa 488-conjugated mAB 1A5. Cell behavior was monitored by 
differential interference contrast (DIC) imaging while antibody localization was 
monitored by fluorescence microscopy.
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Figure 12. CD151 clustering at areas of cell-cell contact in vivo. Chick embryos 
bearing a tumor composed of HEp3 cells were treated with Alexa 488-conjugated 
mAB 1A5 (5 µg/animal). Accumulation of fluorescently-labelled antibody in the tu-
mor was document with time-lapse imaging of Alexa 488 fluorescence. The bottom 
panels represent the full micrograph at 0 and 340 minutes with the primary tumor 
outlined by the white dashed line. The central panel shows a full time-lapse of the 
cropped region (dashed white lines). The top panels are magnified to reveal accu-
mulation at intermediate time points. A white arrow highlights accumulation of mAB 
1A5 at the area of cell- cell contact between two tumor cells invading stroma adja-
cent to the tumor. Demonstrating that in migrating cells in vivo CD151 localizes to 
the areas of cell-cell contact in the presence of 1A5. Data is representative of 3 in-
dependent experiments >5 cells were tracked in each experiment. 
Antibody-induced clustering promotes an adhesive phenotype
 We previously observed that mAB 1A5 prevents detachment at the rear of mi-
grating cells thereby inhibiting tumor cell migration and metastasis in vivo (6). Evaluation 
of HEp3 migration at increasing concentrations of mAB 1A5 demonstrated a dose-
dependent inhibition of migration in vitro (Fig. 13A) and in vivo (Fig. 13B). In the pres-
ence of control antibody, GFP-expressing HEp3 form metastatic colonies comprised of 
widely spaced individual cells that are disseminating freely into the surrounding tissue. In 
contrast, treatment with mAB 1A5 limited cell motility resulting in compact colonies at 
concentrations as low as 0.5µg antibody/animal (Fig. 13B, upper right panel). The ability 
to immobilize tumor cells in vivo as such low antibody concentrations together with pre-
vious observed inhibition of detachment (6) suggests that the tetraspanin clustering me-
diates a gain of adhesive function.
 To confirm that CD151 clustering in response to mAB 1A5 induces adhesion, we 
evaluated a range of cellular behaviors dependent upon adhesion including collagen 
contraction, fibronectin fibrilogenesis, platelet aggregation and clustering of non-
adherent cells. Collagen contraction assays performed in the presence of mAB 1A5 
demonstrated that CD151 clustering promotes collagen contraction when compared to 
cells treated with the control antibody (Fig. 13C). This contrasts with the inhibition of col-
lagen contraction by agents that inhibit matrix remodeling by MMPs (GM6001) or block 
integrin-mediated adhesion to collagen (anti-α2β1 integrin). Fibronectin fibrilogenesis, an 
integrin-dependent process (31, 32), was evaluated in HT1080 cells. These cells exhibit 
very limited fibril assembly during routine culture but treatment with mAB 1A5 resulted in 
the formation of visible fibrils compared to the control IgG treated cells (Fig. 13 D). Plate-
let aggregation is an integrin-dependent process stimulated by collagen binding or 
thrombin-mediated protease activated receptors (PARs) (33). Platelets express an 
abundance of CD151 (34) where it contributes functionally to platelet aggregation via 
αIIbβ3 (17). Treatment with mAB 1A5 dose-dependent platelet aggregation which could
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Figure 13. Antibody-mediated clustering promotes an adhesive phenotype. (A) 
Dose-dependent inhibition of HEp3 cell migration in response to mAB 1A5 using an in 
vitro wound healing assay. (B) Dose-dependent inhibition of HEp3 cell migration in 
the CAM of chick embryos in response to mAB 1A5 treatment. (C) Collagen contrac-
tion by HT1080 cells in response to mAB 1A5 when compared to control IgG, inhibi-
tion of MMP activity (GM6001) and blocking of collagen binding (α2β1). (D) Fi-
bronectin fibrilogenesis in response to mAB 1A5 or control IgG treatment as detected 
by immunofluorescent staining of fibronectin fibrils. (E) Platelet aggregation in re-
sponse to mAB 1A5 treatment in the presence or absence of RGDS peptides to block 
integrin-mediated adhesions.Data is represented as SEM * (p<0.05), **(p<0.01), *** 
(p>0.001). Data is representative of 3 independent experiments. For in vivo coloniza-
tion in B data is representative of n>5 for each experiment.
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be prevented with integrin-blocking cyclic RGDS peptide suggesting ligand-specific ad-
hesion through integrins (Fig. 13E). Lastly, antibody-binding promoted clustering of lym-
phoma (U937) and leukemia (Jurkat) cells (Fig. 14A and B). Staining of suspended cells 
with mAB 1A5 after fixation demonstrates uniform surface distribution of CD151 (post-
fixation, . Fig. 14B). In contrast, treatment of the cells with mAB 1A5 prior to fixation in-
duced clustering of the cells and resulted in accumulation of the antibody-CD151 com-
plex at areas of cell-cell contact similar to what was observed for adherent cells (Fig. 
10). These observations consistently demonstrate the clustering of CD151 to promote 
cell adhesion.
MAB1A5 binds CD151 not associated with integrin α3 (CD151free)
 The ability of CD151 to contribute to adhesion and motility on laminin through 
direct interaction with the laminin-binding integrins α3β1 and α6β1 is well established(11, 
12). However, much of the adhesive behavior described above did not involve laminin 
and adhesion to collagen, assembly of fibronectin, and the aggregation of platelets (Fig. 
13 C-E) does not involve integrins that contain the α3 or α6 subunits. These observa-
tions suggest that CD151 clustering and biological activity in response to mAB 1A5 was 
independent of its association with laminin-binding integrins. Yamada et. al. (23) demon-
strated that several CD151 antibodies recognize the integrin-binding domain of CD151 
and only bind CD151 that is dissociated from its integrin partners (CD151free). Together, 
these observations suggest that an integrin-independent mechanism might be involved 
in the regulation of adhesion by CD151.To determine if mAB 1A5 selectively recognizes 
CD151free vs CD151ITGA, its ability to co-immunoprecipitate an integrin partner was 
evaluated.. A comparison was made with an antibody specific for the integrin binding 
domain which cannot precipitate thetegrins (8C3) and an antibody that binds outside this 
domain and readily precipitates the integrin (11G5A) (23). Since our principle tumor 
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Figure 14. Cell-cell adhesion in response to CD151 clustering. (A) Jur-
kat and U937cells cultured in the absence or presence of either control 
IgG or mAB 1A5. (B) MAB 1A5 (A and B) or control IgG (C and D) were 
added to Jurkat cells after (A and C) or 1 hr before fixing the cell with para-
formaldehyde. The antibody location was detected using Alexa 546-
conjugated anti-mouse IgG. Data is representative of 3 independent ex-
periments with >5 cells imaged per experiment in B.
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model (HEp3) is nearly devoid of α6, we evaluated integrin interactions primarily by 
monitoring α3. Immunoprecipitates were evaluated for the presence of α3 by immuno
munoblotting (Fig. 15A). The integrin subunit α3 co-immunoprecipitated with CD151 
bound by mAB 11G5A but not 1A5 or 8C3 (Fig. 15A). Similar observations were made in 
immunoprecipitations from HEp3 cells (. Fig. 16). To determine if mAB 1A5 bound the 
CD151/α3β1 complex in intact cells, we treated A549 cells overnight with mAB 1A5 (2µg/
ml) and lysed the cultures in Triton X-100 lysis buffer after removing all unbound anti-
body. The cell lysate was immuno-depleted with protein-G sepharose beads in three se-
quential incubations and the presence of α3 and CD151 was subsequently evaluated in 
both the bound and unbound fractions. Antibody-bound CD151 was removed in the first 
round of immuno-depletion while α3 remained in the unbound fraction. To confirm that 
the CD151 which remained in the unbound fraction remained associated with α3, we 
immunoprecipitated the integrin with mAB P1B5 and evaluated both bound and unbound 
fractions for α3 and CD151 (Fig. 15C). The majority of CD151 in the lysate co-
immunoprecipitated with α3. Since mAB 1A5 failed to co-precipitate α3 and the integrin 
remained associated with CD151 not bound by the antibody we conclude that mAB 1A5 
only binds CD151 that is not engaged with α3.
Monoclonal antibody 1A5 specifically recognizes the integrin-binding domain of CD151
 The integrin-binding domain of CD151 includes the 194QRD196 sequence of its 
large extracellular loop (12). Anti-CD151 antibodies that are unable to precipitate the 
CD151/α3β1 complex frequently bind this domain (35). Yamada and colleagues used 2-
color flow cytometry to map epitope-binding of human-specific anti-CD151 antibodies 
according to their reactivity with CD151 mutants in which twelve residues across the 
large extracellular loop (LEL) of the human protein were substituted with their mouse 
counterpart (23)(Figure 17A and B). We implemented a similar approach to determine 
which residues of CD151 are involved in recognition by mAB 1A5.
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Figure 15. MAB 1A5 binds to CD151 not engaged with integrin α3. (A) Immunoblot 
of α3 and CD151 after immunoprecipitation of the tetraspanin from A549 cell lysates (Tri-
ton X-100) using non-specific mouse antibody (cIgG) and three distinct antibodies 
against CD151 (1A5, 8C3, and 11G5a). (B) A549 cells were culture in the presence of 
mAB 1A5 for 24 hr. Cell lysates were generated with Triton X-100 and antibody bound 
CD151 was depleted from the lysate in three sequential incubations with immobilized 
Protein-G. Bound and unbound fractions were analyzed for α3 and CD151 by im-
munoblotting. (C) The integrin subunit α3 was immunoprecipitated from the unbound 
fraction of the 3rd depletion from (B) with anti-α3 (P1B5) and this sample was evaluated 
for the presence of α3 and co-precipitated CD151 by immunoblotting. “TCL” refers to To-
tal Cell Lysate while IgG refers to normal mouse included as a reference for the IgG 
band (*). Data is representative of 3 independent experiments.
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Fig. 16.MAB 1A5 binds to CD151 not engaged with α3 integrin in 
HEp3 cells. CD151 was immunoprecipitated from HEp3 cell lysates 
using three distinct anti-CD151 antibodies (1A5, 8C3 and 11G5A). The 
precipitated CD151 and the co-immunoprecipation α3 was detected by 
immunoblotting. Data is representative of 3 independent experiments.
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Monoclonal antibody 1A5 specifically recognizes the integrin-binding domain of CD151
 The integrin-binding domain of CD151 includes the 194QRD196 sequence of its 
large extracellular loop (12). Anti-CD151 antibodies that are unable to precipitate the 
CD151/α3β1 complex frequently bind this domain (35). Yamada and colleagues used 2-
color flow cytometry to map epitope-binding of human-specific anti-CD151 antibodies 
according to their reactivity with CD151 mutants in which twelve residues across the 
large extracellular loop (LEL) of the human protein were substituted with their mouse 
counterpart (23)(Figure 17A and B). We implemented a similar approach to determine 
which residues of CD151 are involved in antigen recognition by mAB 1A5.GFP-fusions 
of the human-mouse CD151 substitution mutants were transiently expressed in NIH3T3 
cells and subsequently stained with anti-CD151 antibody. Flow cytometry was used to 
detect cells positive for both GFP and Alexa 647 (Fig. 18). This analysis was performed 
for all substitution mutants (Figure 19). mAB 1A5 bound every substitution mutant except 
the 194QRD196 mutant in which the glutamine at position 194 is mutated to a lysine. This 
analysis was done in parallel with two antibodies previously shown to interact with this 
domain (8C3 and 14A2.H1) and contrasted to an antibody known not to bind to this re-
gion (11G5A, Fig. 18). We also used the remainder of the mutants for flow cytometry 
with 1A5 (Fig. 19).These observations confirm that mAB 1A5 binds CD151 through the 
integrin-binding domain containing the 194QRD196 sequence. In order to further verify the 
specificity of 1A5 binding to the integrin domain we also used the remaining mutants in 
flow cytometry using 1A5 (Fig. 19).
Antibodies that recognize the integrin-binding domain of CD151 can inhibit tumor cell 
motility in vivo
 Yamada et. al. (23) stratified anti-CD151 antibodies according their epitope 
specificity. MAB 1A5 belongs to “group I” which contains antibodies that specifically re
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Figure 17.MAb 1A5 recognizes the integrin-binding domain of CD151. (A) 
Schematic of CD151 highlighting the extracellular domains of the protein including 
the small extracellular loop (SEL) and the large extracellular loop (LEL). The LEL as 
depicted is divided into 2 regions a constant region and a variable region. The vari-
able region can be further divided into 3 subdomains denoted site 1, site 2 and site 3. 
(B) Representative flow cytometric dot plot of NIH3T3 cells gated for GFP and Alexa 
647. The three panels show NIH 3T3 cells the were mock transfected, transfected 
with a wildtype CD151-GFP, or transfected with mutant CD151-GFP not recognized 
by the antibody. (C) Table adapted from Yamada et. al (201) grouping the various 
anti-CD151 monoclonal antibodies including mAB 1A5 according to their abilities to 
bind to the CD151-LEL mutants as demonstrated by two-color flow cytometry. Data is 
representative of >3 independent experiments.
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Fig. 18. MAb 1A5 recognizes the integrin-binding domain of CD151. Two-color 
flow cytometry of the CD151 human/mouse substitution mutants was used to 
evaluate what epitope on CD151 is required for mAB 1A5 binding. NIH3T3 cells 
were transiently transfected with WT or mutant CD151-GFP constructs. Transgene 
expression was detected using GFP while antibody binding was detected using an 
Alexa 647-conjugate anti-mouse IgG. A comparison is made between WT CD151 
and the YT 27 (Q194K) mutant which disrupts binding with the α3 integrin subunit. 
mAb 1A5 is compared to two antibodies known for their inability to bind this mutant 
(8C3 and 14A2.H1) and one antibody whose binding is unaffected by this mutation 
(11G5A). A loss of antibody binding is represented by a decrease in the percentage 
of GFP and Alexa 647 double positive cells in quadrant (Q2). Data is representative 
of greater > 3 independent experiments.
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Fig. 19. MAb 1A5 recognizes the integrin binding domain of CD151. The re-
maining human/mouse substitution mutants were used in 2 color flow cytometry 
with 1A5.Data is representative of >3 independent experiments. 
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 cognize CD151free because they bind the integrin binding domain and fail to immunopre-
cipitate α3. Since mAB 8C3 and 1A5 share specificity we hypothesized that they might 
also share the ability to cluster the tetraspanin at areas of cell-cell contact. Live-cell im-
aging of A549 cells expressing CD151-GFP confirmed that mAB 8C3 but not 11G5A can 
cluster the tetraspanin (Figure 20). Since antibodies in “Group I” share both domain-
specificity and the ability to cluster CD151, we explored the possibility that these anti-
bodies specific for CD151free can control tumor cell migration. To achieve this, HEp3-
GFP cells injected I.V. into chick embryos were treated with antibodies specific for 
CD151free (8C3, 14A2.H1 and 1A5) and an antibody that binds outside this do-
mai(11G5A) or a control antibody (Fig. 21A). Metastatic colonies were allowed to form 
for 3 days before their morphology was documented and the number of colonies with a 
motile phenotype was quantified (Fig. 21B). At 0.5-5 µg/animal only mAB 1A5 inhibited 
tumor cell motility in vivo. However, at 20 µg/animal tumor cell motility was inhibited by 
8C3 and 14A2.H1 but not 11G5A or the control antibody. These data demonstrate that 
antibodies specific for CD151free are capable of inhibiting tumor cell migration by cluster-
ing CD151 not associated with integrins.
Tumor cell immobilization in response to CD151 clustering requires PKCα but not in-
tegrin α3
 To determine if α3 is required for the immobilization mediated by CD151, in vivo 
migration assays were performed following α3 knockdown. HEp3 cells were transfected 
with control or α3-specific siRNA and a ≥90% reduction in α3 expression after siRNA de-
livery was confirmed by immunoblotting (Fig. 22A). HEp3 cells bearing control or α3-
specific siRNA were subsequently injected into chick embryos and allowed to form 
metastatic colonies in the presence of mAB 1A5 or a control antibody (29-7). Knockdown
of α3 did not impair the migration of tumor cells as evidenced by the absence of coloni-
with an immobilized phenotype (Fig. 22B and C). Moreover, in the presence of mAB 1A5 
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 Fig 20. Antibodies that recognize  the integrin-binding domain of CD151 
mediate clustering at areas of cell-cell contact. A549 cells transiently trans-
fected with CD151-GFP were treated with the control IgG or the anti-CD151 
antibodies 1A5, 8C3 or 11G5A at 5 µg/ml. Localization of the tetraspanin was 
documented by fluorescent microscopy. *refer to those cells that are expressing 
high levels of CD151GFP. Data is representative of 3 independent experiments 
with >5 cells imaged per experiment. 
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Fig. 21. Clustering of CD151 through antibodies specific for the integrin-binding 
domain inhibits tumor cell motility in vivo. Changes in tumor cell motility in re-
sponse to anti-CD151 antibodies were determined by analyzing the formation of meta-
static colonies in the chorioallantic membrane. (A) The inhibition of tumor cell dissemi-
nation in the presence or absence of anti-CD151 antibodies (1A5, 8C3, 14A2.H1, and 
11G5A) was compared to the dissemination in the absence of tumor targeting antibod-
ies (untreated) or a control IgG. Images were taken after 4 days of treatment with 0.5, 
5, or 20µg or antibody (A) and the number of colonies with motile tumor cells were 
quantified (B). Data is represented as SEM *(p<0.05), **(p<0.01), ***(p<0.001). Data is 
representative of three experiments with n> 5 for each experiment. 
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Fig. 22. PKCα but not integrin α3 is required for the regulation of motility through 
CD151free. (A) Immunoblotting of Triton-X 100 lysates from HEp3 cells transfected with 
the control, integrin α3-specific or PKCα-specific siRNA to evaluate the efficacy of tar-
get gene knockdown. GAPDH is included as a loading control. (B) The analysis of tu-
mor cell motility in vivo after delivery of control, integrin α3 or PKCα siRNA. Tumor-
bearing animals were treated with control IgG or mAB 1A5 (5µg) 1 day after tumor cell 
injection. Images of metastatic colonies were taken 2 days after antibody injection. The 
immobilization of tumor cells in response to mAB 1A5 was quantified in (C). Data is 
represented as SEM *(p<0.05), **(p<0.01), ***(p<0.001). Data is representative of three 
experiments with n> 5 for each experiment.
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both HEp3 control- and α3-siRNA transfected cells form compact colonies demonstrating 
that the absence of α3 does not alter the ability of CD151-clustering to inhibit motility and 
colonization in vivo. PKCα is a known partner of CD151. To determine if PKCα is re-
quired for the inhibition of tumor cell motility upon CD151 clustering, in vivo migration 
assays were performed following PKCα knockdown (Fig. 22). The knockdown of PKCα 
did not affect tumor cell motility but did prevent immobilization in response to mAB 1A5 
induced clustering of CD151.
The integrin-binding domain of CD151 is detectable in prostate cancer and correspond-
swith poor patient outcome
 Antibodies specific for integrin-binding domain of CD151 define a subpopulation 
of this tetraspanin (CD151free) that is distinct from the tetraspanin bound to its integrin 
partner (CD151ITGA). The immobilization of tumor cells through clustering of CD151free 
(Fig. 21 and 22) and the subsequent inhibition of metastasis (6) demonstrates that 
CD151free may be relevant in the malignant progression of cancer. Recent work demon-
strated a specific role for CD151 in the progression of prostate cancer (36). We hypothe-
sized that detection of CD151free is altered during tumor progression and correlates with 
patient outcome. This relationship was evaluated in prostate cancer by comparing the 
detection of CD151free to biochemical recurrence (for patients who underwent radical ret-
ropubic prostatectomy (RRP): cohort #1, N=99) or metastasis (for patients who did not 
undergo RRP: cohort #2, N=38). See  tables 7-9 for patient information.
 Histological detection with the mAB 11G5A (which binds both CD151ITGA and 
CD151free) demonstrates abundant expression of CD151 in both normal and malignant 
prostate tissues. Conversely, mAB 1A5 (which binds only CD151free) exhibited weak 
staining of normal prostate glands but elevated detection of CD151free in tissue from 
prostate cancers (Fig. 23A). CD151 gene expression is relatively abundant in normal 
adult prostate tissue (. Fig. 24A). An analysis of CD151 mRNA expression in prostate 
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Table 7 Demographic information of patients  that underwent RRP at the 
London Regional Cancer Program between 1994 and 1998 (n=99) data un-
published collected by the laboratory of Dr. John Lewis
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Table 8. Pathological and clinical outcomes of patients that underwent 
RRP at the  London Regional Cancer Program between 1994 and 1998 
(n=99) data unpublished collected by the laboratory of Dr. John Lewis.
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Table 9.Demographic information of patients that developed metastasis during 
follow up at the London Regional Cancer Program between 1994 and 1998 
(n=38) data unpublished collected by the laboratory of Dr. John Lewis.
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Fig. 23. Detection of CD151free in prostate cancer corresponds with poor patient 
outcome. Immunohistochemical detection of CD151 was performed on two cohorts of 
prostate cancer patients (see methods). General expression of CD151 was detected 
with mAB 11G5A which recognizes all CD151 complexes while mAB 1A5 was used to 
detect CD151 not engaged with α3 (CD151free). (A) Micrographs of CD151 immunohis-
tochemistry with mAB 11GA or 1A5 on adjacent benign, adjacent normal and tumor 
tissue. human prostate cancer tissue while 1A5 does not. In the primary tumor how-
ever, similar to 11G5A, 1A5 positively stains the primary tumor. (B) Evaluation of gene 
expression in a TCGA data set of 216 patients with prostate adenocarcinoma. Arrows 
indicate integrin α3 (ITGA3) and CD151. (C) Immunohistochemical detection of integrin 
α3 (P1B5, left) CD151 (11G5A, middle), CD151free (1A5, right) and  in normal (top) and 
tumor tissue (bottom). (D) Immunohistochemical detection using polyclonal antibodies 
for CD151 (top row) and integrin α3 (bottom row) in normal and tumor tissue of the 
prostate, breast, colon and kidney obtained through ProteinAtlas.org. Each image is 
representative from a collection of 10-12 patients. (E) quantitation of staining intensity 
of prostate cancer patients in D. 
91
cancer studies available through The Cancer Genome Atlas (TCGA; CD151, Fig. 24) 
and NCBI GEO (. Fig. 24B-C) revealed no significant changes in CD151 gene expres-
sion. This observation is in accordance with histological assessment of CD151 protein 
detection with 11G5A (Fig. 23A). In contrast, 55% of the 216 prostate adenocarcinoma 
patients analyzed in the TCGA exhibited reduced expression of integrin α3 (ITGA3, Fig. 
23B). This observation suggested that the appearance of CD151free might coincide with 
reduced expression of integrin α3. Indeed, paired histological analysis of advanced pros-
tate cancer tumors reveals that CD151 is readily detected in the tumor tissue, adjacent 
normal and distant normal tissue. In contrast, integrin α3 expression is reduced in the 
tumor relative to normal tissue and CD151free is detectable only in the tumor (Fig. 23C). 
Independent histological evaluation of integrin α3 and CD151 available through the Hu-
man Protein Atlas confirms reduced expression of the integrin in tumor tissue compared 
to normal tissue not only in prostate cancer (Fig. 23D quantified in E) but also in cancers 
of the breast, colon and kidney (Fig. 23D). 
 To evaluate the correlation of CD151free with patient outcome in prostate cancer, 
we compared the levels of CD151free to biochemical recurrence (for patients who under-
went radical retropubic prostatectomy (RRP): cohort #1, N=99) or metastasis (for pa-
tients who did not undergo RRP: cohort #2, N=38). See tables 8-10 for cohort descrip-
tion. First, we dichotomized patients that underwent RRP (cohort #1) based on mAB 1A5 
staining (positive vs. negative). CD151free staining on benign tissue adjacent to the tumor 
( Fig. 25A) and normal tissue distant from the tumor ( Fig. 25B) failed to demonstrate an 
association with biochemical recurrence. In contrast, detection of CD151free (mAB 1A5 
positive) in tumor tissue corresponded to a significantly reduced time-to-biochemical re-
currence compared to tumor tissue with no detectable levels of CD151free (mAB 1A5 
negative, Fig. 26A; mean survival = 10.3 vs. 13.5; Log-Rank, p=0.023). Moreover, the 
detection of CD151free further stratified patients that were already stratified by high (≥8) 
and low (<8) baseline PSA levels in regards to biochemical recurrence (Fig.26B). Bio
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Fig. 24 Evaluation of CD151 expression in prostate tissue using the publicly 
available GDS3113 (n=3/tissue). Tissues are arranged according to expression 
levels following the universal human reference. The dashed line corresponds to 
the level of expression found in normal prostate. A comparison of CD151 expres-
sion in prostate cancer vs. normal or benign tissue was accomplished using 
GSE2545 (B, n=171) and GSE6099 (C, n=102) respectively.
93
Figure 25.CD151free detectable in benign and normal prostate tissue does not 
correspond with patient outcome. Kaplan-Meier curves of recurrence-free survival 
generated using the CD151free immunoreactivity in tissue sections of prostate tis-
sue obtained from patients that received a RRP after diagnosis whom were moni-
tored for biochemical recurrence (cohort #1, N=99). A analysis of CD151free staining 
on adjacent benign (A) and distant normal tissue (B).
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chemical recurrence-free survival is reduced in patients that are singly positive for either 
CD151free or high PSA compared to those negative for both (mean survival = 11.6 and 
12.3 years vs. no; Log-Rank, p=0.068) Furthermore, singly positive. patients have sig-
nificantly greater biochemical recurrence-free survival compared to patients that are 
double positive(mean survival = 11.6 and 12.3 years vs. 9.1 years; Log-Rank, p=0.017). 
Most importantly, in patients with high PSA, CD151free (positive vs. negative) is an inde-
pendent predictor of biochemical recurrence-free survival after adjusting for tumor stage 
(adjusted hazards ratio = 13.5; 95%CI 1.2-148.1; p=0.033). To determine if the presence 
of CD151free in the primary tumor could be indicative of future metastasis, we evaluated 
biopsy specimens from prostate cancer patients that did not undergo RRP and eventu-
ally developed metastasis (cohort #2). Patients were dichotomized according to 
absence/presence of mAB 1A5 staining and its relation to metastasis-free survival was 
visualized using Kaplan-Meier analysis (Fig. 26C). Patients with mAB 1A5 positive biop-
sies at time of diagnosis exhibited a greatly reduced metastasis-free survival (mean sur-
vival = 3.7 vs. 12.7; Log rank p=0.001). These observations indicate that CD151free is 
evident only in tumor tissues where its appearance coincides with reduced integrin α3 
expression and its detection is an independent negative predictor of biochemical-free as 
well as metastasis-free survival.
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Fig. 26. The expression of CD151free is a negative prognostic marker of metas-
tasis free survival and recurrance Kaplan-Meier curves of recurrence-free survival 
were generated using the CD151free immunoreactivity in tissue sections of prostate 
tissue obtained from patients that received a RRP after diagnosis whom were moni-
tored for biochemical recurrence (cohort #1, N=99). Log-Rank test-p=0.023. 
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CONCLUSIONS
! The tetraspanin CD151 is an established regulator of cell adhesion, migration 
and tumor cell metastasis (5, 14, 25, 36, 37). Its interactions with the integrin subunits α3 
and α6 have been shown to be important for adhesion, migration and morphogenesis on 
laminin (12, 13, 15, 20, 38). However, using immunoprecipitation and flow cytometry we 
demonstrate that there is a subpopulation of CD151 on the surface of tumor cells that is 
not associated with its integrin partner (CD151free). This population of CD151free can be 
detected with antibodies specific for the integrin-binding domain of CD151, including 
mAB 1A5, 8C3 and 14A2.H1.
 We previously demonstrated that anti-CD151 mAB 1A5 potently inhibits tumor 
cell migration and metastasis (6) by preventing de-adhesion at the rear of the cell. The 
inhibition of motility required a bivalent antibody suggesting that mAB 1A5 could mediate 
its activity by clustering the tetraspanin. Indeed, mAB 1A5, along with other antibodies 
specific for the integrin-binding domain of CD151 cluster the tetraspanin. Clustering of 
CD151free promotes cell adhesion and results in tumor cell immobilization, enhanced col-
lagen contraction, greater fibronectin fibrilogenesis, improved platelet aggregation and 
elevated cell-cell adhesion. Although many of these activities are integrin-dependent, 
they do not involve adhesion to laminin nor association with the laminin-binding integrins 
that are established integrin partners of CD151. Indeed, the immobilization of tumor cells 
in response to the clustering of CD151free does not require α3 expression (Fig. 22). We 
have previously demonstrated that the loss of CD151 does not lead to tumor cell immo-
bilization (6), thus the inhibition of tumor cell motility associated with the clustering of 
CD151free is likely a distinct mechanism for the control of cellular adhesion and migra-
tion. 
 These observations raise a number of questions including: a) what mechanism 
creates CD151free? b) does CD151free occur in normal tissue? c) is the mechanism by 
which CD151free controls motility distinct from the mechanism of integrin-associated 
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CD151? and d) is CD151free a tumor promoter? While fully answering these questions 
will require further investigation, significant insight is available from these and published 
studies. CD151free could become available when the stoichiometric balance with its in-
tegrin partners is altered. This alteration is evident when the expression of integrin α3 is 
significantly reduced in tumor relative to normal tissue (Fig. 7) but could also occur when 
CD151 expression is upregulated as reported for hepatic carcinomas {{Ke:2009be}. 
However, CD151free is also likely to occur in normal tissues when expression of the 
laminin-binding integrins is reduced or absent. This is evident in cardiac tissue which ex-
hibits little α3 and α6 expression but an abundance of CD151 that is detectable by anti-
bodies specific to the integrin binding epitope (11B1, 14A2.H1 (27). Even more evident is 
the presence of CD151free in the bone marrow, circulating hematopoietic cells and plate-
lets where the laminin-binding integrins have low expression and the surface expression 
of CD151free is readily detectable with any of the antibodies specific for integrin-binding 
epitope The ability of mAB 1A5 to promote adhesion in platelets and suspended hema-
topoietic cell lines (Fig. 1) is perhaps the first and most obvious evidence that CD151free 
can control an adhesive mechanism distinct from the laminin-binding integrins. The abil-
ity of CD151free clustering to inhibit tumor cell migration after the knockdown of α3 (Fig. 
22) suggests that CD151free can also regulate adhesion and migration of epithelial-
derived tumor cells through a mechanism independent of laminin-binding integrins. A 
preliminary evaluation of the CD151 signaling mechanisms revealed that neither Rac nor 
Rho activity was altered upon CD151free clustering. However, the canonical signaling 
partner of CD151, PKCα, was required for CD151free clustering to inhibit tumor cell motil-
ity. Although PKCα is generally thought of as a promoter of migration, PKCα was identi-
fied as an inhibitor of cell migration by the Brugge laboratory during an in vitro screening 
assay of normal epithelial migration (218).
 We hypothesize that the distinct mechanisms by which CD151 can regulate cell 
adhesion and migration are determined primarily by the nature of the associated partner 
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and the cellular context in which they function. In the context of a transformed cancer 
cell the CD151-integrin-laminin axis (“CD151ITGA“, 15, 16) participates in promoting tu-
mor cell invasion and metastasis (11, 12, 14, 38, 39) while in normal, quiescent epithelia 
the association of CD151 with the laminin binding integrins is required for cohesion and 
(non-motile) epithelial integrity (183,219). Clearly the loss of CD151 diminishes both 
normal epithelial integrity and cancer metastasis suggesting that both phenomena, 
which are on opposing ends of the motility spectrum, utilize the adhesion facilitated by 
CD151. Conversely, CD151free present on migratory/metastatic cells as well as non-
adherent cells (hemopoietic cells & platelets) can initiate/promote adhesion resulting in 
aggregation (platelets, Fig. 13; non-adherent cells, Fig. 14) or inhibition of migration (tu-
mor cells, Fig. 13 and (24) when clustered.
 Cell motility is directly linked to dynamic cycling of adhesion/de-adhesion (220). 
Firm adhesion as seen in normal epithelial cells on laminin-containing basement mem-
branes limits cell motility but promotes epithelial integrity (220-222). Uncoupling CD151 
from the laminin binding integrins would promote a less adhesive, more motile pheno-
type. This is not only supported by the reduction of integrin α3 in tumor cells but also the 
loss of the integrin during in vitro selection for matrix invasion (223). Considering the 
immobility of firmly anchored cells in normal epithelia, the creation of CD151free during 
tumorigenesis is a simple mechanism to promote motility. Furthermore, CD151free can be 
engaged (clustered) to stimulate adhesion (Fig. 13, l. Fig. 14 and (24) suggesting that 
the creation of CD151free would bias tumor cells towards a more dynamic cycling of ad-
hesion in favor of migration and thereby promote tumor metastasis. What remains to be 
determined is the identity of partners that control the switch of CD151free to its adhesion-
promoting state.
 In conclusion, our findings demonstrate that a subpopulation of CD151 exists on 
the surface of tumor cells that is not associated with integrin partners (CD151free) that 
regulate tumor cell migration (Fig. 27). Clinical correlation of CD151free with prostate can-
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cer progression demonstrates that it has independent prognostic value and suggests 
that this tetraspanin subpopulation may contribute to the disease and could be used to 
predict cancer progression (
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Fig.27. Summary two populations of CD151 exist on the cell surface. IA5 binds 
to the integrin QRD motif of CD151 and is unable to co-precipitate the CD151/integrin 
α3 complex from tumor cells. This allowed us to determine that there are two pools of 
CD151 on the cell surface integrin α3 associated CD151ITGA and integrin α3 non-
associated CD151Free. CD151ITGA inhibits migration by promoting laminin based ad-
hesion. The appearance of CD151Free is due to the loss of α3 expression in tumor 
cells and tissues. CD151Free is potentially a pro-migratory molecule and forms a com-
plex with an as of yet unknown cell surface protein.  
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Chapter V
CD151 AND ALCAM CONTROL MOTILITY VIA PKCα MEDIATED 
ACTIVATION OF RAP1
Summary
 The tetraspanin CD151 is a membrane scaffolding protein that forms macro-
molecular complexes with several transmembrane partners and is an important regulator 
of tumor cell motility. Much of the tetraspanin’s ability to regulate migration was initially 
linked to its association with laminin binding integrins. Recent work revealed that 
integrin-free CD151 (CD151free) is capable of promoting adhesion across many biologi-
cal systems. In tumor cells this adhesion inhibits migration leading to reduced invasion 
and metastasis. Using an antibody specific for CD151free we have investigated partners 
that associate with integrin-free CD151 as well as the signaling responsible for immobi-
lizing tumor cells upon clustering of this tetraspanin. Integrin-free CD151 was found to 
interact with Activated Leukocyte Cell Adhesion Molecule (ALCAM) and this association 
was required for CD151free to inhibit cell motility. Engaging the CD151/ALCAM complex 
through clustering with CD151 antibody or through ALCAM-ALCAM mediated adhesions 
promoted the activation of the GTPase Rap1A in a PKCα-dependent fashion. Finally, we 
demonstrate that Rap1A activation is sufficient to inhibit tumor cell motility in vitro and in 
vivo. These investigations demonstrate that CD151 can mediate signaling that controls 
tumor cell motility without direct integrin association by controlling the activation of the 
GTPase Rap1A. Together these observations suggest that CD151 signaling may switch 
to integrin-independent mechanisms for control of cell motility during tumor progression.
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Introduction
 While clinical progression to metastasis is a lethal aspect of cancer, the speed at 
which the malignancy progresses is very much dependent on the contribution of many 
individual molecular processes. This contribution is in large part dependent on the mo-
lecular integration of many individual mechanism with the biology of the cell and the 
neoplastic milieu (1, 2). Tetraspanins such as CD9 and CD151 are membrane scaffold-
ing proteins that are important regulators of cancer progression (3-5). They organize 
macromolecular complexes known as Tetraspanin-Enriched Microdomains (TERM) by 
facilitating interactions between themselves and their non-tetraspanin partners (6,7).
 CD151 has been shown to promote tumor cell motility and metastasis. Genetic 
ablation of this tetraspanin diminishes cancer metastasis in multiple models (8-10). Con-
versely, genetic loss of CD151 also disrupts epithelial integrity leading to physiological 
malfunction in kidney, lung, and the endothelium. CD151 has been proposed to facilitate 
the biological function of its integrin partners through interactions that ultimately regulate 
adhesion and migration (11, 12). Several CD151-specific antibodies have demonstrated 
the ability to augment cell migration (13-16). Recently we demonstrated that these 
migration-inhibiting antibodies engage integrin-free tetraspanin through its integrin-
binding domain, cluster the tetraspanin, promote adhesion and subsequently prevent 
metastatic dissemination by inhibiting migration (70). These observations demonstrate 
that CD151 can control migration through a mechanism distinct from its integrin partners 
by targeting an integrin-free population of CD151 (CD151free).
 We set out to determine what mechanism was employed by the clustering of 
CD151free to promote adhesion and prevent metastasis. To accomplish this goal we 
used mass-spectometry to identify proteins associated with CD151 immunoprecipitated 
by the anti-CD151 antibody 1A5 specific for CD151free. Molecular and genetic strate-
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gies revealed the cell-cell adhesion molecule ALCAM (Activated Leukocyte Cell Ahesion 
Molecule) to be a novel CD151 partner required for antibody-mediated clustering of 
CD151 to control cell motility. Further interrogation of this complex revealed downstream 
activation of the GTPase Rap1A to be responsible for controlling cell migration.
Materials and Methods
Cell Culture, Plasmids, Transfections, Inhibitors, and Antibodies
 HEp3 cells are perpetually maintained on the chick chorioallantoic membrane 
(CAM) to retain metastatic and migratory potential (65, 66). Cell lines were maintained in 
media supplemented with pen/strep, sodium pyruvate, non-essential amino acids and 
10% fetal bovine serum and cultured at 37°C in a 5% CO2 incubator. Plasmids used in-
cluded untagged wildtype CD151 (Clontech). CD151-GFP and ALCAM-GFP were kindly 
provided by Dr. Kiyo Sekiguchi (Osaka University) Dr. Josh Weiner (University of Iowa) 
respectively. HA-Rap1 expression vectors were kindly provided by Dr. Hans Bos (Uni-
versitair Medisch Centrum Utrecht, The Netherlands). Transfections of all cells were per-
formed using Extreme Gene HD (Roche), excluding Cho cells which were transfected 
using polyethylenimine (PEI). Signaling pathways inhibitors included small molecule in-
hibitors of Rho kinase (Y 297632,), PI3kinase (LY294002), PI4kinase, (Wortmanin), MEK 
(UO126), PKA (KT5720), PKC (Calphostin) and Rap (GGTI-298) obtained from Calbio-
chem. Knockdown of gene expression was achieved with siRNAs to PKCα, and Rap1 A 
and B and the control non-targeting siRNA purchased from Dharmacon. CD151 specific 
shRNA was obtained from Sigma Aldrich. ALCAM and GFP siRNA were purchased from 
Invitrogen (Grand Island, NY). Anti-CD151 (1A5) was generated as previously described 
(67)), ALCAM/CD166 (L50, Abcam and R&D systems). The control antibody 29-7 was 
generated in the same fashion as 1A5 (67).
Mass Spectrometry
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 HEp3 and HT1080 cells were lysed in 1% Brij99 lysis buffer as described above. 
Lysates were incubated with control antibody 29-7 or anti-CD151 antibody 1A5 overnight 
at 4°C and immunoprecipitated with protein-G sepharose beads. The immunoprecipi-
tated complexes were then resolved by SDS-PAGEG. Each lane was excised and pre-
pared for mass spectrometry analysis by the Vanderbilt University Mass Spectrometry 
Core. Mass spectrometry analyses were performed with a LCQ-Deca or LTQ-Orbitrap 
mass spectrometer (ThermoFinnigan). Tandem mass spectra were extracted from raw 
files and used to search the database. Only proteins identified from two independent ma-
trix preparations were considered as candidate components of the matrix.
Microarray and Gene Ontology analysis
 Gene Ontology analysis was performed with microarray data obtained from BLM 
melanoma cell lines were stably transfected with ΔN-ALCAM, sALCAM, or empty plas-
mid control as described previously (18). Samples were hybridized to Affymetrix 
U133Plus 2.0 microarray chip. Intensities were normalized by log2 transformation. Fold 
change was determined as compared to endogenous expression of wt ALCAM in BLM 
cells (empty vector control). P-value was determined using 2-tailed Student’s t-test with 
unequal variances. Fold change and p-value calculations were done in Microsoft Excel. 
Genes with a fold change of at least 2 and p-value of 0.001 or less were considered dif-
ferentially expressed. 260 gene probes were differentially expressed. Probe IDs of dif-
ferentially expressed genes were up loaded to Vanderbilt University’s WebGestalt ana-
lyzer(19). U133Plus 2.0 reference was selected. Gene ontology analysis was performed 
with default parameters. Enriched biological processes were highlighted in red and la-
beled with number of associated genes and adjusted p-value.
Cell Motility Assays
 In Vitro Wound Healing Assay HEp3 and HT1080 cells were seeded to conflu-
ence in 6-well plates with complete medium. After 24hrs the cells were switched to se-
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rum free/insulin free media for an additional 24hrs. At 48hrs after seeding the confluent 
monolayers were scratched with a pipet tip in order to create a uniform wound after 
which the cells were washed with PBS to remove any floating cells. Cultures were re-
turned to full medium and the wound was documented at 0hrs and 16hrs post-scratch 
using a light microscope TMS-F (Nikon) equipped with a D90 SLR camera (Nikon). 
Wound closure (% surface area) was calculated using Tscratch image analysis soft-
ware(68, 69).
 In Vitro Transwell Migration: Tumor cells in a single cell suspension were plated 
into the top chamber of 8µm transwell (Costar) inserts in the presence of serum free/
insulin free media. Cell culture media containing 10% fetal bovine serum was placed in 
the bottom chamber to serve as a chemoattractant. Migration assays were carried out 
for 12hrs in a 37°C cell culture incubator containing 5%CO. The top surface of the in-
serts was cleaned with a cotton swab soaked with PBS to remove the non-migrated 
cells. The transwell inserts were subsequently fixed in methanol and stained with 0.2% 
crystal violet. The number of migrated cells was counted in 3 independent fields under 
20x magnification with a light microscope.
 Two-Dimensional Migration: Tumor cell migration on soluble ALCAM-Fc was per-
formed by adhering it to tissue culture plates with protein-G. Briefly, protein-G (2µg/ml) 
was adhered to the culture plastic followed by rat tail collagen type 1 (100µg/ml). Un-
bound surface was blocked with BSA (0.5% in PBS) after which the surface was washed 
and incubated with ALCAM-Fc in 0.5% BSA. Control migration was performed on identi-
cal surfaces not incubated with ALCAM- Fc. Tumor cells were seeded at low density and 
tracked by live cell imaging every 10 minutes over a 6hr period with a fully automated 
microscope (BX61, Olympus) equipped with a digital camera (Orca ER, Hammatsu). 
Data acquisition and analysis was performed using Volocity image acquisition software 
(Perkin Elmer).
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 In Vivo Cell Motility: Assays were performed as previously described (15). Briefly, 
cells to be injected were washed 2 times with PBS and detached with 2mM EDTA. The 
cells were resuspended in PBS and injected intravenously into Day 12 chick embryos. 
Four days post- injection the disseminated colonies were photographed using a Lumar 
V12 stereomicroscope (Zeiss) equipped with a Retiga Exi camera and controlled with 
Volocity image acquisition software (PerkinElmer). Antibody treatments were introduced 
by intravenous injection one day after tumor cell injection. “Non-motile” colonies were 
defined as colonies comprised of 5 or more cells where individual cells remained in di-
rect contact. Such non-motile colonies are compact while “motile” colonies contained a 
migratory cell populations dispersed in the CAM. Assays were performed with 5 animals/
treatment and ≥ 5 fields/animal analyzed for colony formation. Data is represented as 
the percentage of colonies within a single animal that demonstrated a motile phenotype.
Flow Cytometry
Cells to be used in flow cytometry experiments were trypsinized with 0.25% Trypsin-
EDTA and resuspended in cold Milytenyl FACs buffer (2mM EDTA, 0.5%BSA, PBS). For 
the analysis of cell surface expression of specific antigens the cells were washed 2 times 
with FACs buffer and then stained with the specific primary antibodies for 1hr on ice. Fol-
lowing incubation with the primary antibody the cells were washed 2 times with cold 
FACs buffer and then incubated with species-specific, fluorophore-conjugated secondary 
antibody for 30 minutes on ice. After washing two times the cells were suspended in cold 
FACs buffer and subjected to flow cytometry.
Immunoblot and Immunoprecipitation Analysis
 Immunoblotting: For immunoblot analysis HEp3 , HT1080 or CHO cells were 
lysed in either 1% (vol/vol) Triton X-100 lysis buffer or 1% (vol/vol) Brij-99 lysis buffer and 
incubated on ice for 30 minutes. The samples were then cleared by centrifugation at 
14,000 rpm for 15 minutes and the cleared lysates were then transferred to fresh tubes. 
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Protein concentrations were determined by BCA assay(Pierce). Equal amounts of pro-
tein were loaded in to SDS-Page gels and subsequently transferred to polyvinylidene 
fluoride membranes (PVDF, Millipore). The membranes were blocked for 1hr in 5% non-
fat dry milk in phosphate buffered saline with 0.05% Tween-20 (PBSt). The membranes 
were incubated overnight at 4°C with specific antibodies prepared in blocking buffer after 
which the membranes were washed 3 times with PBSt and incubated with the appropri-
ate species-specific horse radish peroxidase-conjugated secondary antibodies for 1hr at 
room temperature. After washing, antibody binding was visualized by chemilumines-
cence.
 Immunoprecipitation: 1mg total cell lysate was incubated with 2µg of the im-
munoprecipitation antibody and the antibody lysate solution was incubated over-night at 
4°C with end to end rotation. In order to capture the protein/antibody complexes the 
lysates were coupled to protein G sepharose beads (GE Healthcare) for 4hr at 4°C with 
end to end rotation. The lysates were cleared by centrifugation at 8000 rpm for 30 secs 
and the unbound material saved for further analysis. The beads were washed 3 times 
with either Triton X-100 or Brij-99 lysis buffer accordingly and the immune complexes 
were then eluted in 100µl lamelli sample buffer and boiled for 5 minutes. The samples 
were then prepared for SDS-Page analysis. For GBP immunoprecipitations the lysates 
were incubated overnight with GBP conjugated beads with end to end rotation overnight 
at 4°C. After clearing the lysates were subjected to SDS- PAGE as described above.
 Cell Surface Biotinylation: For cell surface labeling confluent HEp3 cells were 
treated with 1A5 or control antibody for 1hr on ice and then washed with cold PBS. Cul-
tures were subsequently biotinylated with sulfoccinimidyl-6-[biotin-amido] hexanoate us-
ing the EZ-Link Sulfo-NHS-Biotinylation Kit (Thermo Scientific) according to manufac-
turer’s instructions. Cells were lysed in 1% Brij 99 followed by extraction of the insoluble 
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in 1% Triton X-100. Immunoprecipitation was performed as described above. Biotiny-
lated proteins were detected with peroxidase conjugated streptavidin.
 Metabolic Labeling: HEp3 cells were labeled overnight in methionine/cysteine 
free DMEM containing 35S-label. Cells were washed throughly with PBS and lysed in 
1% Brij 99 lysis buffer. The lysates were incubated with control antibody or monoclonal 
antibody 1A5 and immunoprecipitated as described above. The gels were dried and then 
exposed to film at -80°C.
Rap1 Activation Assays
 Rap1 activation was analyzed using the Rap1 activation kit (Chemicon). All 
treatments were performed in the presence of serum free/insulin free media. Cells to be 
assayed were washed with ice cold PBS and lysed in RIPA like Rap1 buffer (10% glyc-
erol, 50mM Tris/HCl, 150mM NaCl, 5mM phenylmethylsulfonyl fluoride, 1mM sodium 
orthovanadate). The lysates were pushed through a 25 gauge syringe and cleared by 
centrifugation at max speed at 4 degrees for 10 min. Equal amounts of lysates were im-
munoprecipitated with RalGDS RBD conjugated agarose beads for 45 minutes at 4 ̊C. 
After washing the beads where resuspended with sample buffer and boiled for 5 min-
utes. The immunoprecipitates were separated by SDS-Page as mentioned above, trans-
ferred to PVDF membranes, probed with the anti-Rap1 antibody and horse radish 
peroxidase-conjugated secondary antibody. After washing the membranes were devel-
oped by autoradiography.
Immunfluorescence
HEp3 cells grown to confluency on collagen coated coverslips were incubated with 1A5 
and then fixed in 4% formalin in PBS. The coverslips were blocked with 5% BSA in PBS 
for 30 minutes at room temperature and then stained with 1A5 and ALCAM primary anti-
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bodies overnight at 4°C. The coverslips were washed with PBS and then incubated with 
species specific fluorophore-conjugated secondary antibodies for 1hr at room tempera-
ture.). After staining the cells were washed with PBS and then counterstained with DAPI. 
The coverslips were then mounted onto glass slides with Fluorosave mounting media 
(Calbiochem). Pictures were taken with a BX 61 fluorescent microscope (Olympus) and 
analyzed using Volocity Image Acquisition Software (Perkin Elmer).
Statistical Analysis
 All statistical analysis was performed using Graph Pad Prism Analysis Software 
(La. Jolla California). For statistical analysis of migration experimental groups were com-
pared to the control groups using non-parametric Mann-Whitney test.
Results
Identification of CD151 associated proteins.
 The ability of tetraspanins to organize higher-order structures in the membrane 
leads to complex interactions of variable affinity with a variety of transmembrane and 
membrane proximal proteins (Fig. 28A, (6)). Immunoprecipitation of CD151 with the 
motility-inhibiting antibody 1A5 from lysates extracted with mild detergents (Brij) or strin-
gent detergent (TX-100) co-precipitates several proteins (Fig. 28B) visible after meta-
bolic labeling (S35), and cell-surface biotinylation (Biotin). In order to elucidate the com-
ponents of the CD151-TERM complex responsible for regulating tumor cell motility and 
metastasis, we used tandem Mass Spectrometry (LC-MS-MS) to identify CD151 part-
ners that co-IP with 1A5 (Fig. 28C). Specifically, the HNSCC cell line HEp3 was lysed 
with Brij-based lysis buffer to maximize possible protein- protein interactions. Immuno-
precipitations were preformed with the CD151free-binding antibody 1A5. Control sam
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ples included immunoprecipitations with an isotype-matched control IgG or protein-G 
only. The precipitated complexes were separated by SDS-PAGE, gel pieces were ex-
cised and subsequently analyzed by LC-MS-MS using a LCQ-Deca or LTQ-Orbitrap 
mass spectrometer (ThermoFinnigan). CD151-specific candidates were identified by 
eliminating targets precipitated with an isotype and protein-G respectively. Candidates 
identified by two or more peptides in two or more independent analyses were selected 
as viable targets. A total of 228 proteins were identified of which 51 candidates distrib-
uted across five phenotypic subgroups were detected repeatedly (Fig. 28C, pie chart 
and Table 10). We have recently demonstrated that anti-CD151 antibody 1A5 clusters 
the tetraspanin and promotes its accumulation at areas of cell-cell contact (70). Based 
on validated interactions from published studies and the observed cell-cell accumulation, 
a short list of potential candidates was developed (Fig. 28D, established and putative 
partners). Nearest neighbor analysis was performed on each putative candidate using 
the Broad Institute Cancer Cell Line Encyclopedia 
(http://www.broadinstitute.org/ccle/home, (17)). ALCAM was identified as the nearest 
neighbor of α3, one of the primary partners of CD151. To evaluate ALCAM’s role as a 
regulator of migration we evaluated changes in gene expression initiated upon expres-
sion of a dominant- negative ALCAM lacking the ligand-binding domain (18). Differen-
tially expressed genes were grouped by gene ontology (GO) association using Web-
Gestalt (http://bioinfo.vanderbilt.edu/ webgestalt/ (19) and enriched biological processes 
were displayed (Fig. 29). The primary processes identified were cell adhesion and mi-
gration. In addition to its association with cancer metastasis and migration, ALCAM has 
also been suggested to interact with PKCα, a key regulator of CD151 activity, supporting 
its potential as a bonafide partner in the regulation of tumor cell motility by CD151(20). 
ALCAM has broad expression in epithelial tissues and their corresponding tumors ( Fig. 
30 A). 
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Name Accession number
Signal transduction and cytoskeleton (20 %)
Alpha-actinin-1 IPI:IPI00013508.5
Alpha-actinin-4 IPI:IPI00013808.1
Calpain small subunit 1 IPI:IPI00025084.3
Cofilin-1 IPI:IPI00012011.6
F-actin capping protein subunit alpha-1 IPI:IPI00005969.3
Phosphatidylinositol 4-kinase type 2-alpha IPI:IPI00020124.1
Radixin IPI:IPI00017367.5
Villin 2 IPI:IPI00746388.1
Tropomyosin 1 alpha chain isoform 2 IPI:IPI00000230.6
Guanine nucleotide-binding IPI:IPI00217906.3
Protein G(i), alpha (isoform 2) IPI:IPI00033494.3
Cell-cell and cell-matrix adhesion (20 %)
CD151 antigen IPI:IPI00298851.4
CD63 antigen IPI:IPI00215998.5
CD166 antigen (ALCAM) IPI:IPI00015102.2
CUB domain-containing protein-1 IPI:IPI00290039.5
Claudin domain-containing protein-1 IPI:IPI00072743.3
EGF-like repeat and discoidin I-like domain IPI:IPI00306046.1
CD44 antigen precursor (isoform 12) IPI:IPI00297160.4
Integrin alpha-3 IPI:IPI00215995.1
Integrin beta-1 IPI:IPI00217563.3
Matrix metalloproteinase-14 IPI:IPI00218398.5
Plasminogen activator inhibitor 2 IPI:IPI00007117.1
Vesicle trafficking (30 %) 	  
Calnexin IPI:IPI00020984.1
Endoplasmin IPI:IPI00027230.3
Reticulon-4 IPI:IPI00021766.4
Caveolin-1(Isoform Alpha) IPI:IPI00009236.5
Lysosome membrane protein-2 IPI:IPI00217766.3
Ras-related protein R-Ras2 IPI:IPI00012512.1
Ras-related protein Rab-11B IPI:IPI00020436.4
Ras-related protein Rab-7A IPI:IPI00016342.1
Ras-related protein Ral-A IPI:IPI00217519.3
Serpin B4 IPI:IPI00010303.1
Synaptobrevin homolog YKT6 IPI:IPI00008569.1
Syntaxin-4 IPI:IPI00029730.1
Syntenin-1 IPI:IPI00299086.3
Vesicle-trafficking protein SEC22b IPI:IPI00006865.3
Secretory carrier-associated membrane protein IPI:IPI00306382.1
Protein, lipid and carbohydrate metabolism (20 %)
Cation-dependent mannose-6-phosphate IPI:IPI00025049.1
Fructose-bisphosphate aldolase C IPI:IPI00418262.4
Neutral alpha-glucosidase AB precursor (isoform 2) IPI:IPI00011454.1
Mannose-6-phosphate receptor-binding Protein-1 (isoform A) IPI:IPI00106668.4
Mannose-6-phosphate receptor-binding Protein-1 (isoform B) IPI:IPI00303882.2
Pyruvate kinase isozymes M1/M2 (isoform M2) IPI:IPI00479186.5
 Alpha-enolase IPI:IPI00465248.5
Lactoylglutathione lyase IPI:IPI00220766.5
Phosphoglycerate kinase-1 IPI:IPI00169383.3
Phosphoglycerate mutase-2 IPI:IPI00218570.6
Unknown (10 %)
Transmembrane emp24 domain-containing protein 10 precursor IPI:IPI00028055.4
Transmembrane protein 106B IPI:IPI00395903.1
Transmembrane protein 109 precursor IPI:IPI00031697.1
Hypothetical protein DKFZp686I04222 IPI:IPI00413451.1
Isoform 1 of Protein ZNF365 IPI:IPI00007274.6
Table 10. CD151 associated proteins identified by mass spectrometry
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Biological 
Process
Biological Adhesion
35 Genes
adjP=2.84e-07
Cellular Process
Localization
Multicellular 
Organismal Process
Response to stimulus 
119 genes 
adjp=7.22e-08
Single-Organism 
Process
Cellular Component 
Movement
Localization of Cell
36 Genes 
adjP=7.22e-08
Locomotion
43 Genes adjP=7.22 
e-08
Developmental 
Process
Single-Multicellular 
organism Process
Multicellular Organismal 
Development 86 genes 
adjP=2.79e-07
Cell Motility 
36 genes adjP=7.22e-08
Cell Migration 
35 genes adjP=7.22-08
System Development 
80 genes 
adjP=7.22e-08
Biological Adhesion
35 Genes
adjP=2.84e-07
Anatomical Structure 86 
genes adjP=2.05e-07
Fig. 29. ALCAM gene signature. Gene Ontology analysis performed with 
WebGestalt on genes differentially expressed after the introduction of a 
dominant-negative ALCAM.
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Continuous cell lines derived from these tumors continue to express ALCAM both at the 
level of gene transcription and protein translation (Fig. 30 B and C)
The IgG superfamily member ALCAM is a novel CD151 partner
 Clustering of CD151 with 1A5 promotes the localization of the tetraspanin to the 
areas of cell- cell contact leading to the inhibition of tumor cell migration and metastasis 
(previously published data (15) and (70). ALCAM and CD151 occupy the same areas of 
cell-cell contact and clustering of the tetraspanin causes ALCAM to co-localize exten-
sively with CD151 (Fig. 31A). To determine if CD151 and ALCAM were physically inter-
acting, the proteins were immunoprecipitated from mild (Brij) and stringent (TX-100) de-
tergent lysates obtained from the HNSCC HEp3 using the antibodies 1A5 and AZL50 
respectively and the resulting precipitations were immunoblotted for its possible partner 
(Fig. 31 B and C respectively). CD151 and ALCAM did indeed co-immunoprecipitate in 
their reciprocal precipitations. Since 1A5 drives CD151 clustering and promotes an in-
teraction between CD151 and ALCAM, we pursued an independent validation of the in-
teraction between CD151 and ALCAM using affinity purification of GFP-tagged proteins. 
ALCAM-GFP and CD151-GFP were co-transfected with untagged CD151 or ALCAM re-
spectively into CHO cells. GFP-tagged protein was precipitated from TX-100 lystates 
using a GFP-binding protein (Fig. 31 D and E). ALCAM indeed co-precipitated with 
CD151-GFP and CD151 co-precipitated with ALCAM-GFP. These four independent pre-
cipitations demonstrate that CD151 forms a complex with ALCAM and that ALCAM is a 
component of the CD151-TERM. Importantly, this complex is stable under stringent de-
tergent conditions (TX-100) suggesting that the stability of the CD151-ALCAM interac-
tion is similar to those observed previously for CD151-α3.
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Fig.30. ALCAM expression in cancer and cultured tumor cells. (A) The human pro-
tein ATLAS (HPA) was queried for the expression of ALCAM and demonstrates that it is 
expressed in a number of different tumor tissues (B) mRNA expression analysis of the 
NCI-60 dataset demonstrates that the expression of ALCAM varies, however, epithelial 
derived cancer cell lines have the highest expression (C) Western blot analysis of com-
monly used cancer cell lines was performed and probed for the expression of ALCAM 
using the anti-ALCAM antibody and demonstrates that ALCAM is expressed in a num-
ber of different cell lines and cell types GAPDH was used as a loading control
117
Fig 31.Physical association of CD151 with ALCAM. (A) Immunofluorescent 
staining of CD151 and ALCAM in HEp3 cells treated with control IgG or 1A5 dem-
onstrates to evaluate their relative distribution. (B) Co-immunoprecipitation of AL-
CAM by anti-CD151 antibody 1A5. Proteins immunoprecipitated from HEp3 cells 
lysed in either Brij 99 or Triton X-100 containing lysis buffer by anti-CD151 antibody 
were immunoblotted for ALCAM. (C) Co- immunoprecipitation of CD151 by anti-
ALCAM antibody. Proteins immunoprecipitated from HEp3 cells lysed in either Brij 
99 or Triton X-100 containing lysis buffer by anti-ALCAM antibody were im-
munoblotted for CD151. (D-E) Co-precipitation of ALCAM and CD151 after pull-
down of GFP-tagged partner. GFP-tagged CD151 (D) or ALCAM (E) were transfect 
into Chinese Hamster Ovary (CHO) cells together with with myc-tagged ALCAM or 
untagged CD151. GFP- tagged protein was pulled down with GFP-binding protein 
(GBP) conjugated beads and subsequently evaluated by immunoblotting for 
CD151 and ALCAM. (CD151*= untagged CD151that co-precipitates with CD151-
GFP). Data is represented of 3 independent experiments.
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ALCAM and CD151 cooperate in their ability to regulate migration
 The physical association of CD151 and ALCAM demonstrates that ALCAM is a 
component of the TERM complex. To determine the relevance of this interaction in cell 
motility, the ability of CD151 and ALCAM to regulate migration was evaluated after RNAi-
mediated depletion in HT1080 and HEp3 cells (Fig. 32, and Fig. 33). CD151 clustering 
induced by the antibody 1A5 inhibits HT1080 tumor cell migration (Fig. 32 A). After 
RNAi-mediated depletion of ALCAM, tumor cells are no longer sensitive to the immobili-
zation by CD151 (Fig. 32 B and C). Engaging HT1080 cells in ALCAM-ALCAM interac-
tions can be accomplished by seeding cells on ALCAM- Fc coated surfaces (Fig. 32 D 
and (21). Similar to anti-CD151 treatment, engaging ALCAM- ALCAM interactions can 
inhibit tumor cell motility in a wound-healing assay. The inhibition of cell motility upon 
ALCAM-ALCAM binding is enhanced by 1A5-induced clustering of CD151 (Fig. 32 E, 
white bars). Conversely, shRNA mediated knockdown of CD151 in HT1080 cells not only 
eliminates sensitivity to the anti-CD51 antibody 1A5 but also prevents the inhibition of 
motility by ALCAM-ALCAM ligation (Fig. 32 E, black bars). Similar observations were 
made for the HNSCC HEp3 (. Fig. 33.) These data clearly demonstrates that CD151 and 
ALCAM cooperate with each other to control tumor cell motility.
CD151 and ALCAM control tumor cell migration through PKCα activation of Rap1A
 A targeted pharmacological screen was performed in an attempt to identify mo-
lecular mechanisms that might contribute to the inhibition of motility mediated by CD151 
and ALCAM (Fig. 34 A). Tetraspanins regulate intracellular signaling events by interact-
ing directly or indirectly with key signaling molecules including protein kinase Cα (PKCα) 
and phosphatidylinositol 4 kinase type IIa (PI4kinase Type IIa) (22-24). Rho and PI3 
knase have also been associated with CD151-mediated regulation of tumor cell motility 
(25). MEK, Erk, and Rap1 were targeted as established mediators of cell motility (26, 
27). Transwell migration assays were performed in the presence or absence of each in-
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Fig 32. CD151 and ALCAM cooperate in the regulation of tumor cell migra-
tion. (A) Schematic representation of migration in response to clustering of 
CD151 by antibody 1A5 (I) which results in enhanced adhesion (II) and subse-
quent inhibition of migration. (B) Transwell migration of HT1080 cells in the 
presence or absence of 1A5 after transfection with control siRNA (white bars) or 
ALCAM siRNA (black bars). (C) The knockdown of ALCAM was confirmed by 
immunoblotting and immunofluorescent staining of cultured cells. (D) Schematic 
representation of migration in response to ALCAM-ALCAM interactions. 
ALCAM-Fc was bound to protein-G coated plates as described in the materials 
and methods. ALCAM-Fc engages cell- surface ALCAM (III) which impacts ad-
hesion and subsequent migration (IV). (E) Analysis of cell migration on ALCAM-
Fc by single-cell tracking. Migration velocity is determined after transfection with 
control shRNA (white bars) or CD151 shRNA (black bars). The impact of 
ALCAM-ALCAM interactions was evaluated in the presence of the anti-CD151 
antibody (1A5). (F) The knockdown of CD151 was confirmed by immunoblotting 
and immunofluorescent staining of cultured cells.The data is represented as 
SEM * (p> 0.05), ** (p>0.01), *** (p>0.001) Data is representative of 3 inde-
pendent experiments. Migration assays in B and E performed in triplicate.
***
***
**
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Fig. 33. ALCAM and CD151 cooperate in the regulation of tumor cell migration. 
(A) Schematic representation of migration in response to clustering of CD151 by an-
tibody 1A5 (I) which results in enhanced adhesion (II) and subsequent inhibition of 
migration. (B) Schematic representation of migration in response to ALCAM-ALCAM 
interactions. ALCAM- Fc was bound to protein-G coated plates as described in the 
materials and methods. ALCAM-Fc engages cell-surface ALCAM (III) which impacts 
adhesion and subsequent migration (IV). (C) Transwell migration of HEp3 cells ex-
pressing the control or ALCAM specific siRNA in the presence of the control antibody 
or 1A5. (D) Immunofluorescence of HEp3 cells expressing the control or ALCAM-
specific shRNA grown on glass coverslips. (E) Analysis of cell migration on ALCAM-
Fc by single-cell tracking. Migration velocity was determined in the presence (white 
bars) or absence of anti-CD151 antibody 1A5 (black bars). Data represented as SEM 
* (p>0.05), **(p>0.01)***(p>0.001). Data is representive of 3 independent experi-
ments. Migration assays in C and D performed in triplicate.
121
hibitor together with or without the anti-CD151 antibody 1A5. The MEK inhibitor (U0126) 
and PI3 kinase inhibitor (LY294002) inhibited migration independent of anti-CD151 anti-
body treatment (1A5) while the PI3 kinase inhibitor (Wortmannin) did neither influence 
the migration of untreated cells nor did it prevent the inhibition of migration by 1A5. Con-
versely, the PKC inhibitor (Chelerythrin) and the RAp1 inhibitor (GGTI-298) allowed for 
migration of untreated cells but prevent 1A5 from inhibiting migration. RNAi-mediated 
ablation (siRNA) of PKCα and Rap1A confirm that these proteins are required for CD151 
to inhibit motility (Fig. 34 B). Rap1A is a GTPase well known for its ability to promote ad-
hesion upon activation (28). We hypothesized that Rap1A was activated in response to 
CD151 clustering as well as ALCAM-ALCAM ligation. To evaluate this possibility, HEp3 
cells were treated with 1A5 or seeded on ALCAM-FC for up to 48hrs. Active Rap1A in 
the cells was evaluated by immunblotting of GTP-bound Rap1A affinity purified from 
lysates with Ral-GDS beads. Both CD151 clustering and ALCAM-ALCAM binding re-
sulted in rapid and persistent activation of Rap1A (Fig. 34 C). Activation of the GTPase 
Rac was evaluated as a control to confirm the specificity of Rap1A activation (Fig. 34 D). 
PKCα is known to associate with CD151 (22) and ALCAM (20). Moreover, it has also 
been demonstrated to mediate activation of Rap1 (29). Together with the observed con-
tribution of PKCα to the regulation of migration (Fig. 34 A and B), these published reports 
suggest that PKCα might mediate activation of Rap1A by CD151 and ALCAM. To deter-
mine if PKCα signaling is required for Rap1A activation by CD151, GTPase activity as-
says were performed in HEp3 cells after PKCα was disrupted with Chelethyrine or 
PKCα-specific siRNA (Fig. 34 E). In control transfected or untreated cells 1A5 promotes 
activation of Rap1A, however, when PKCα is knocked down by genetic manipulation or 
inhibited by pharmacological means, 1A5 is unable to promote Rap1A activation. This 
data clearly demonstrates that downstream of CD151 clustering, Rap1A is activated in a 
PKCα-dependent manner.
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Fig 34. CD151/ALCAM signaling mechanism involves PKC and the small GTPase 
Rap1. (A) Transwell migration of HEp3 cells in the absence (white bars) or presence of 1A5 
Anti- CD151 (black bars) was analyzed in the presence of different pathway inhibitors. The 
potential pathways that were interrogated for their abilities to regulate cell motility in the 
presence of 1A5 by chemical inhibition include; MEK (U0126), PI3 kinase (LY294002), PKA 
(KT5720), PKC (Chelerythin), and Rap1 (GGTI-298). Only the inhibition of PKC and Rap1 
rescued the inhibition of migration associated with the engagement of CD151 by 1A5. (B) 
Wound healing migration of HEp3 cells expressing siRNAs specific for ALCAM, PKCα, and 
Rap1 further demonstrate that the expression of these proteins is required for the inhibition 
mediated by CD151 clustering. (C) Rap1 activation HEp3 cells were serum starved overnight 
and then treated with 1A5 in culture for the indicated time points. Rap1 activation was deter-
mined using a commercial Rap1 activation kit. In untreated cells Rap1 is not activated as 
demonstrated by the absence of GTP bound Rap1. Within five minutes of treatment however, 
we observed a robust activation of Rap1 that is sustained for 48hr post treatment. In order to 
demonstrate the specificity of GTPase activation by 1A5 we also analyzed the activation 
status of the small GTPase Rac1 which in the presence of 1A5 was not activated above ba-
sal levels. (D) Plating HEp3 cells on ALCAM-Fc activates Rap1 in a time dependent manner 
but has not impact on the activation of state of the small GTPase Rac1. (E) 1A5 treatment 
activates Rap1 in a PKCα-dependent manner. Data represented as SEM * (p>0.05) ** 
(p<0.01) *** (p>0.001) Data is representative of 3 independent experiments. Migration as-
says in A and B performed in triplicate.
Rap1 activation is sufficient to immobilize tumor cells in vitro and in vivo
 Rap1A serves as a molecular switch capable of regulating cell motility by control-
ling adhesion (30, 31). We have demonstrated that the inhibition of tumor cell motility in 
response to CD151 and its partner ALCAM involves the activation of Rap1A. We hy-
pothesized that Rap1 activation was sufficient to inhibit tumor cell motility. To address 
this question we transfected GFP- expressing HEp3 cells with dominant negative Rap1A 
(Rap1N17) or the dominant active Rap1A (Rap1V12 (32). The expression of the con-
structs was verified by western blot analysis (Fig 35 A). Migration assays were subse-
quently performed in order to determine if Rap1A activity was sufficient to impact on tu-
mor cell migration in vitro. Dominant negative Rap1A (Rap1N17) had no significant im-
pact while the dominant active Rap1A (Rap1V12) reduced migration (Fig. 35 B). This 
observation extended to in vivo migration. HEp3-GFP cells transfected with dominant 
negative Rap1A (Rap1N17) or dominant active Rap1A (Rap1V12) were injected intrave-
nously into D12 avian embryos and metastatic colony formation was analyzed at 4 days 
post injection. Colony size can reflect tumor cell growth while the local dispersion of 
metastatic tumor cells reflects on their motility (15). All of the transfected cells demon-
strated efficient colony formation. However, HEp3 cells expressing dominant active 
Rap1A (Rap1V12) formed compact colony indicative of reduced motility while mock and 
Rap1N17 transfected cells exhibited exhibited a dispersed, highly motile colony appear-
ance(Fig. 35 D) and quantitated in (Fig. 35 C) as the percent (%) motile colonies.
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Fig. 35. Rap1 activation is sufficient to inhibit tumor cell motility in vitro and in 
vivo. HEp3 cells were transiently transfected with empty vector (Control) dominant 
negative Rap1 (N17) or dominant active Rap1 (V12). (A) Transgene expression was 
verified by immunoblotting for the HA-tagged protein. (B) In Vitro cell migration was 
performed with transiently transfected cells in a wound-healing assay. (C) and (D) 
HEp3 cells were injected into 12 day old chicks and the migratory phenotype of 
metastatic colonies was evaluated (see methods for details). The number of motile 
colonies was quantified (C) from images taken of the chorioallantoic membrane con-
taining metastatic colonies (D). Data is representative of three experiments with n≥5 
for each experiment. Data is represented as SEM ** (p=0.01). Migration assay in B 
performed in triplicate.
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Conclusions
 The regulation of migration is a complex process that relies on the integration of 
many molecular processes. Molecular scaffolding through the tetraspanins is one of the 
means by which signal integration can be accomplished. Many of these mechanisms 
can both promote as well as inhibit migration. The best example of this is the regulation 
of adhesion. Too much or too little adhesion can limit migration while an optimal balance 
of adhesion and de-adhesion promotes motility (Fig.4). There have been several investi-
gations into the molecular mechanism(s) by which the tetraspanin CD151 regulates cell 
motility (reviewed in (33, 34)and(35)). The characterization of direct interaction with 
laminin-binding integrins evolved to define the ability of CD151 to promote integrin activ-
ity and thereby promote adhesion and migration. Consistent with this hypothesis is the 
reduction of migration on a laminin substrate (36) and the reduction in metastasis seen 
with CD151 knockout mice (37). However, recent work has revealed that direct interac-
tions with laminin-binding integrins may not be responsible for some of the molecular 
activity of CD151 (70). Moreover, the loss of α3β1 in prostate cancer cells promotes, 
rather than inhibits metastasis (38, 39) suggesting that CD151 may regulate cell motility 
independent of this integrin. Indeed, α3β1 expression is frequently reduced during car-
cinogenesis while integrin-free CD151 becomes detectable in the tumor tissue and is 
prognostic of cancer progression and patient survival (70).
CD151 and ALCAM as partners in the regulation of tumor cell migration.
 In the present study we identify ALCAM as a novel CD151 partner that can asso-
ciate with integrin-free CD151. ALCAM is a cell-cell adhesion molecule belonging to a 
small subgroup (VVC2C2C2) of the immunoglobulin superfamily (Ig-SF). Though initially 
identified and primarily expressed in activated leukocytes as the only known ligand for 
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CD6, ALCAM is in fact expressed broadly in human tissues and cells with predominant 
expression in neuronal cells, immune cells, epithelial cells, and stem cells of hemato-
poietic and mesenchymal origin (Fig. 28). It is functionally associated with many cell ad-
hesion events including T-cell activation, endothelial adherence junction, neuronal guid-
ance, and epithelial integrity (40, 41). ALCAM expression and function has been associ-
ated with many solid cancers and their progression (40). While the molecular mecha-
nism of action had not been defined, its expression has been broadly recognized to be 
altered during cancer progression (42, 43)(Fig. 28). We recently demonstrated that the 
ectodomain of ALCAM is shed during cancer progression and that ALCAM shedding is 
prognostic of disease progression and patient survival (44). Since ALCAM- ALCAM in-
teractions are responsible for mediating the activation of Rap1A and inhibiting motility, it 
is reasonable to hypothesize that ALCAM shedding offers a mechanism by which tumor 
cells can control Rap1A-mediated adhesion and migration.
Molecular integration of CD151, ALCAM, PKCα and Rap1A.
 PKCα binding to the C-terminal tail of CD151 allows the tetraspanin to serve as a 
linker between PKCα and the integrins α3β1 (22) and α6β4 (45) thereby regulating in-
tegrin signaling. It appears that CD151 performs the same function for ALCAM but that 
the ultimate target of this signaling is Rap1A. PKCα has been previously identified as an 
inhibitor of cell migration by the Brugge laboratory during an in vitro screening assay of 
normal epithelial migration (46). Since PKCα has many substrates, these results suggest 
that divergent signaling mechanisms may be initiated depending on what partner CD151 
interacts with. The elevation of integrin-free CD151 in cancer (70) is likely to divert sig-
naling from integrins to other tetraspanin partners. Both CD151 clustering and homotypic 
ALCAM-ALCAM interactions mediated promote tumor cell adhesion and control motility 
by activating the small GTPase Rap1A. Rap1A was first identified in revertants after Ras 
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transformation of fibroblasts leading to its initial description as Krev (47, 48). Since then 
many lines of evidence demonstrate that Rap1 can influence cancer progression (49). 
The most prominent of these may be the identification of SIPA1, a Rap1 GTPase activa-
tors (Rap1GAP) as the mediator of differential metastatic ability associated with Polyoma 
Middle T antigen initiated breast cancer (50-52). Metastatic virulence in breast cancer 
appears to be associate with specific Single Nucleotide Polymorphisms (SNPs) in Si-
PA1(53). These lines of evidence suggest that active (GTP-bound Rap1) limits meta-
static dissemination. Indeed, our data demonstrates that the activation of Rap1A (gener-
ating the GTP-bound state of Rap1A) promotes adhesion and thereby limits dissemina-
tion. The activity of Rap1 is regulated by a large number of regulators including Gua-
nidine Exchange Factors (GEF), GTPase activators (GAP) and effectors that mediate 
the activity of the GTPase (28, 54). While it is extremely challenging to determine the 
specific molecular entities response for regulating the activity of Rap1A, we demonstrate 
a requirement for PKCα in the activation of Rap1 by CD151 and ALCAM. In the absence 
of PKCα, neither 1A5 treatment nor ALCAM adhesion is able to activate Rap1, which 
suggests that the signaling mechanisms associated with immobility require PKCα to ac-
tivate Rap1A. Indeed, PKCα can activate Rap1 in platelets and subsequently promote 
adhesion through integrin activation(29). CD151 was initially identified as a platelet cell 
surface antigen and its clustering can induce platelet activation (70) suggesting that this 
mechanism may apply broadly outside the regulation of tumor cell motility.
 The ability of Rap1 to control adhesion is seen across many biological systems 
and adhesive interactions. The GTPase can control adhesion to extracellular matrix (55), 
cell-cell adhesion in epithelial cells (56, 57), endothelial cells (58, 59) and hemopoietic 
cells (60) in addition to platelet adhesion (29). Considering the many regulators and ef-
fectors of Rap1A, there are multiple mechanisms by which the activity of the GTPase 
can be regulated. Many of the adhesive properties propagated by Rap1 occur via in-
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tegrins but are initiated by non-integrin mechanisms including cytokine stimulation and 
non-integrin adhesion receptors. Indeed, the IgG superfamily member CD31 can control 
the activity of Rap1 and thereby regulate leukocyte adhesion via beta1 (VLA-4) and be-
ta2 (LFA-1) integrins (61). Although ALCAM is also involved in leukocyte adhesion (62), 
it has global expression (Fig. 28) and could convey the ability to control Rap1 activation 
to epithelial cells.
 Tetraspanin interactions with, and organization of, seemingly unrelated and di-
vergent proteins and signaling molecules allow them to function as molecular integrators 
of cellular behaviors. In the present study we aimed to determine the mechanisms by 
which the clustering of CD151 is able to promote adhesion and control tumor cell motil-
ity. As motility is required for metastasis tetraspanins are considered attractive targets in 
the design of anti-metastatic treatment (1, 34, 63). The data demonstrates that clustering 
of integrin-free CD151 leads to the activation of Rap1A which subsequently promotes 
cell adhesion and inhibits tumor cell migration (Fig. 36). Considering that the regulation 
of Rap1 is a endogenous mechanism that controls cellular and influences the virulence 
of metastasis (49, 64), this mechanism is an attractive target for limiting tumor cell dis-
semination.
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Fig.36. Summary: CD151Free associates with ALCAM/CD166. In the absence of 
α3β1 integrin CD151Free associates with ALCAM/CD166 (CD151ALCAM) to form a 
pro-migratory complex. When CD151ALCAM is clustered in the presence of 1A5 cell 
motility is inhibited in a PKCα Rap1 dependent fashion. Clustering of CD151ALCAM 
promotes cell-cell adhesion (through ALCAM mediated mechanisms) and cell-matrix 
adhesion (through Rap1 mediated mechanisms). Rap1 activation regulates the bind-
ing of β1 containing integrins to the ECM to inhibit migration, non-integrin proteins 
could also be involved as well.
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CHAPTER VI
DISCUSSION AND FUTURE DIRECTIONS
Summary
 The data presented within this thesis provides insight into the mechanism by 
which CD151 controls tumor cell motility. CD151 is principally considered a promoter of 
tumor cell metastasis and dissemination. This is supported by a wealth of data and re-
cently it was demonstrated that the global loss of CD151 diminishes metastasis in a 
mouse model of prostate cancer (224). I demonstrate herein that clustering of CD151 by 
the 1A5 antibody is able inhibit migration and metastasis further supporting the idea that 
CD151 is potentially a pro-migratory molecule. Clustering of CD151 ultimately promotes 
associations with proteins that are able to inhibit migration. Presently, it is not known if 
CD151 promotes or inhibits migration. Ultimately, the answer to this question will depend 
on the cellular context in which CD151 is expressed. As a member of the tetraspanin 
family, the principal role of CD151 is to organize other tetraspanins and tetraspanin-
associated proteins into macromolecular signaling complexes on the cell surface. These 
complexes known as Tetraspanin Enriched Microdomains or TERMs give tetraspanins 
the ability to associate with and regulate the activity of cell surface partners and intracel-
lular signaling molecules. In chapters 1 and 2 I presented the idea that there are five key 
factors that regulate cell motility including; soluble factors, cell autonomous factors, cell-
cell adhesion, cell-matrix adhesion, and molecular integration of two or more of the other 
four factors. In chapter 3 we focused primarily on the roles and functions of CD151. In 
chapter 4 we presented data to demonstrate that 1A5 binds to the α3β1 recognition epi-
tope of CD151 and therefore; binds to integrin free CD151 (CD151free). Furthermore, we 
reveal that the ability of CD151 to control tumor cell migration through the clustering of 
CD151 can be independent of α3β1. Using histological staining of prostate cancer tis-
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sues with anti-CD151 antibodies we demonstrate that the expression of CD151free is a 
clinical indicator of prostate cancer progression. Based on our new-found understanding 
of integrin-free CD151, we demonstrate in chapter 5 that CD151 can function as molecu-
lar integrator of migration by promoting the formation of a cell surface signaling complex 
that triggers both cell-cell and cell-matrix adhesion. This complex contains the novel 
CD151 associated protein ALCAM and signals to activate the small GTPase Rap1A. We 
also demonstrate that the expression of Rap1A in tumor cells can inhibit motility in vitro 
and in vivo. This work adds clarity to the mechanism by which CD151 can control tumor 
cell migration and metastasis. These findings not only provide mechanistic insight and 
possible clinical application, they also provide a basis for us to propose further investiga-
tion into the function of tetraspanins and their contribution to cell migration and cancer 
metastasis.
Therapeutically targeting CD151 in cancer
 In recent years, the potential of targeting tetraspanin proteins like CD151 has 
garnered a lot of attention (155). This is primarily due to the published role of CD151 as 
an integrator of molecular mechanisms important for tumor cell migration and metasta-
sis. There are essentially three proposed mechanisms by which these antibodies are 
potentially exerting their effects: 1) by promoting antagonistic effects and preventing tet-
raspanin association with lateral partners, 2) by promoting agonistic effects and activat-
ing membrane associated partner proteins and 3) by mediating antibody-dependent cell 
cytotoxicity (ADCC). The only way that we can truly figure out the mechanisms of action 
is to take an approach similar to the one outlined in this thesis. The data that we have 
collected demonstrates that 1A5 and antibodies like 1A5 can function in multiple ways 1) 
by antagonizing partner proteins in the case of ITGA3 and 2) by promoting agonistic af-
fects and mediating signal transduction via partner proteins to control cellular processes 
as we demonstrate for ALCAM/CD166.
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Anti-CD151 antibodies that recognize the integrin-binding (QRD) motif can inhibit motility
 Our work is the first to demonstrate that anti-CD151 antibodies that bind to the 
integrin motif are able to control tumor cell migration by clustering the tetraspanin not 
associated with its integrin partner (CD151free). Monoclonal antibody 1A5 is able to in-
hibit in vitro migration and in vivo motility at low micro molar concentrations. The other 
antibodies specific for CD151free can also inhibit motility and cluster CD151 albeit in the 
presence of much higher concentrations of antibody. Further investigation into the effi-
cacy of 1A5 is necessary to explain these results. It maybe a simple function of affinity 
but it is also possible that 1A5 recognizes a distinct epitope or structure of CD151 that is 
functionally important for the activity of clustered CD151. The affinity of individual anti-
bodies could be determined using Biacore analysis with purified CD151. This system 
would allow us to calculate association constants (Ka) and dissociation constants (Kd) 
and also rank the anti-CD151 antibodies according to their calculated binding affinities. 
Although it has been demonstrated that the QRD motif of CD151 determines the ability 
of CD151 to form a complex with integrin alpha 3, the differences in the abilities of the 
antibodies that recognize CD151free and inhibit migration suggest that the actual epitope 
may be composed of more than these three epitopes or that the epitope maybe inacces-
sible due to the presence of other amino acids or chemical modifications in and around 
the epitope that may diminish antibody binding-efficiency. One of the best ways to ana-
lyze the differences in antibody binding to CD151 would be to perform antibody docking 
experiments combined with X-ray crystallography which would allow us to look at the 
chemical interactions of these antibodies with CD151. Unfortunately, the crystal structure 
of CD151 has not been determined because transmembrane proteins are extremely dif-
ficult to crystalize. Nevertheless, the extracellular domain of CD82 has been crystalized 
suggesting that the same could be done with CD151 with and without bound antibody. 
Comparison of physical interactions and structural changes upon antibody binding would 
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give further insight into the differential activity of these antibodies and how that might re-
late to the natural activity of CD151.
Expression of CD151free regulates PCa progression
 We demonstrated in a retrospective study of metastatic prostate cancer that the 
detection of CD151free is increased during the progression of metastasis as evidenced by 
positive staining with the 1A5 antibody. Together with the diminished metastasis in the 
absence of CD151 this suggest that CD151free is a positive regulator of metastasis. In-
terestingly, we demonstrate that clustering of CD151free leads to enhanced adhesion via 
Rap1A activation and subsequently reduces migration. This would suggest that 
CD151free can certainly act as an inhibitor of metastasis. These seemingly contradictory 
results, leave us to conclude that it is not yet clear if CD151free is necessary and/or suffi-
cient to promote metastasis. Further evaluation of its specific activity would require the 
generation of CD151free. Is it possible to dissociate CD151 from α3β1 integrin and de-
termine the contribution of CD151free to migration and metastasis? Chometon et. al re-
ported that the anti-CD151 antibody TS151r is capable of dissociating CD151 from its 
integrin partner and that this leads to an increase in migration on laminin matrices. Is this 
a means to generate CD151free? Interestingly, TS151r binds to the same epitope as 1A5 
however, unlike 1A5 treatment of cells with this antibody promotes instead of inhibits cell 
motility. TS151r could be used as a tool to dissociate CD151 from α3β1 and migration 
analyzed in the presence of 1A5 treatment allowing us to look at the affect on migration 
mediated by clustering of CD151free It is possible that the effect of TS151r is specific for 
migration on laminin matrices since it was not tested on other substrates or in vivo. Is it 
possible to disrupt CD151 integrin association in vivo without clustering the tetraspanin? 
Soluble extracellular domain (EC2) or competing peptides or single-chain antibody might 
be useful for this purpose. Our laboratory demonstrated that monomeric Fab fragments 
of 1A5 continue to bind CD151 but fail to inhibit migration. This observation suggests 
that the detection of CD151free maybe the product of uncoupling CD151 from its integrin 
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partners. In tissues that express CD151free I demonstrated that they do have reduced 
levels of integrin α3β1 suggesting that loss of integrin expression correlates with the ap-
pearance of CD151free. We demonstrate that the subsequent association with other part-
ners such as ALCAM and the activation of downstream signaling is what controls its con-
tribution to cell migration. This suggests the need for further structure-function investiga-
tion of CD151free  in order to determine its contribution to migration. This is potentially 
challenging. because it has been demonstrated that the forced expression of CD151 can 
promote migration and metastasis of cancer cells (224,225). Nevertheless, further inves-
tigations into the protein-protein associations of CD151 will be needed to fully extrapo-
late its contribution to cancer metastasis and possibly reveal a therapeutic target that 
can be used to inhibit metastasis. The laboratory has initiated a large-scale cloning pro-
ject to generate a molecular tool kit that enables my colleagues to rapidly build fluores-
cent constructs. It may be possible to build a variety of FRET or BRET probes that make 
it possible to follow the molecular interactions that CD151 engages in as it contributes to 
cell migration along the metastatic cascade.
 Clinically it will be important to determine at what stage during disease progres-
sion CD151free become available. To determine this, we will have to perform a more 
comprehensive analysis of CD151free across the clinical spectrum of prostate cancer and 
other tumors. A particular emphasis would have to be placed on early stage disease 
where know evidence of invasive properties are detectable by classic histology. If the 
detection of CD151free correlates with disease progression for early stage patients, it 
could serve as a means to determine disease stage prior to the development of visible 
metastasis or be used as a means to guide early clinical intervention.
The ALCAM/CD151 immobility complex
 In Chapter 5 I used a proteomic based approach to identify the protein compo-
nents of the CD151 TERM complex mediated by clustering of CD151 on the cell surface. 
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When clustered in the presence of the anti-CD151 antibody 1A5 the tetraspanin local-
izes to the areas of cell-cell contact and associates with the immunoglobulin protein 
ALCAM/CD166. I demonstrated further that ALCAM is required for clustered CD151 to 
regulate cell motility. The physical association of CD151 and ALCAM clearly demon-
strated that ALCAM is a protein component of the TERM. Even though, this complex ex-
its on the cell surface it is not known whether this association is direct or indirect. I dem-
onstrated that the complex is relatively stable due to the fact that it can be precipitated 
under both mild and stringent detergent extraction conditions. In order to determine if the 
complex formation is through direct interactions with CD151, chemical cross linking ex-
periments could be performed with a cell impermeable cross-linker such as 3′,3′-
dithiobis(sulfosuccinimidyl propionate (DTSSP) in the presence of the 1A5 antibody. Al-
though covalent cross-linking is a commonly used technique there is the risk of cross-
linking protein complexes with CD151 due to their membrane proximity and not due to 
their direct physical association with CD151. As I have eluded to previously, protein-
protein interactions with tetraspanin proteins involve amino acid residues contained in 
the hypervariable region of the LEL, therefore it is not difficult to speculate that these 
same regions are involved in the formation of the CD151/ALCAM complex. In order to 
determine if the LEL is required for the ability of CD151 to associate with ALCAM 
CD151it would be necessary to generate CD151 chimeras containing mutant LELs from 
other tetraspanin proteins. Co-immunoprecipitations can then be performed to determine 
if the CD151 LEL is required for the formation of the complex with ALCAM. I could also 
potentially use the CD151GFP human/mouse LEL substitution mutants introduced in 
Chapter 4 of this thesis. Clustering of CD151 promotes the localization of both CD151 
and ALCAM to the areas of cell-cell contact and while we were able to visualize the lo-
calization of CD151GFP in live cells in the presence of 1A5 we were unsuccessful in im-
aging the localization of ALCAM-GFP after 1A5 stimulation. This was primarily due to the 
fact that, upon transfection, ALCAM-GFP localized  to the areas of cell-cell contact and I 
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was not able to visualize any further localization. Indeed, it is at present not clear wether 
CD151 brings ALCAM into areas of cell-cell contact or the converse. The data presented 
in chapter 4 of this thesis demonstrates that the antibody 1A5 binds CD151free which is 
associated with ALCAM. This raises the possibility that in the absence of α3 CD151 may 
preferentially associate with ALCAM. Co-immunoprecipitation analysis of alpha3 knock-
down cells for the CD151/ALCAM complex could allow us to answer this question.
 Traditional scratch assays were used to demonstrate that ALCAM was required 
for the inhibition of migration mediated by clustering of CD151. Interestingly, when I ana-
lyzed the migration of CD151 knockdown cells on ALCAM Fc the inhibition of migration 
mediated by plating on ALCAM Fc was rescued. These data suggested to us that CD151 
and ALCAM are mutually required to control cell motility. The exact molecular and struc-
tural relationship between ALCAM and CD151 remains poorly understood. I demon-
strated that CD151 is required for ALCAM to activate Rap1A however, the role of CD151 
in the regulation of migration is likely to be more complicated than that. The tetraspanin 
is likely to control the incorporation of ALCAM into macromolecular complexes and even 
its availability on the cell surface. The ability of ALCAM to connect with tetraspanin en-
riched microdomains, the cytoskeleton and its availability are also likely to influence the 
status of post-translation modifications of ALCAM including ubiquitination and shedding 
(226). These mechanisms could possibly be regulated by the association of ALCAM with 
CD151. Published work with other tetraspanins have suggested that all of these mecha-
nisms might be available for CD151 to control ALCAM. Some of these regulatory 
mechanism, including control of post-translational modifications have been recorded for 
the functional regulation of α3 by CD151 (206). Further structure-function analysis of the 
ALCAM-CD151 interaction will help guide future experiments that investigate how this 
relationship can control down stream signaling and its control of cell migration.
Requirement for Protein Kinase Cα and Rap1A 
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 The inhibition of cell migration mediated by CD151 and ALCAM is accomplished 
via signaling through Protein Kinase C Alpha (PKCα). CD151 associates with PKCα and 
serves an adaptor role between the kinase and integrin α3 (200). It not unreasonable to 
suggest that ALCAM is a substrate of PKCα. Although it has been demonstrated that 
ALCAM homotypic adhesion requires PKCα signaling, the lack of a serine or threonine 
residue in the C-terminal tail of ALCAM challenges the idea that ALCAM is a PKCα sub-
strate (227). Activation of the small GTPase Rap1A in the presence of CD151 clustering 
and ALCAM mediated adhesion ultimately controls adhesion. The activation of small 
GTPases like Rap1A is ultimately determined by Guanine Nucleotide Exchange Factors 
(GEFs) which promote the addition of a phosphate group to the GDP bound small 
GTPase to promote activation and the initiate of intracellular signaling events. The small 
GTPase remains activated in the GTP bound state until it is hydrolyzed by the activity of 
GTPase activating enzymes. There are a number of GEFs that could possibly activate 
Rap1A to control adhesion and it is likely that PKCα can mediate the activity of one or 
more regulators of Rap1. In a study performed by Letschka et. al it was determined that 
another isoform of PKC, PKCθ associates with and phosphorylates the guanine ex-
change factor RapGEF2 also known as PDZ-GEF2. PDZ-GEF2 activates Rap1A and 
controls the adhesion of T-cells. Protein Kinase C isoforms are only active when associ-
ated with the membrane and while we have determined a role for PKCα in the regulation 
of motility by CD151 it is not known if CD151 clustering is able to activate PKCα. While 
we could perform protein kinase activation assays, one of the easiest ways to analyze 
activation of PKC would be to image the localization of GFP tagged PKCα in live cells in 
the presence of 1A5 treatment. This experiment will answer two important questions: 1) 
does 1A5 clustering promote PKCα activation and 2) does activated PKCα localize to 
similar membrane complexes as CD151? ALCAM is not a PKCα substrate but it is likely 
that one or more molecular participants in the signaling cascade is. In order to investi-
gate this a targeted screen in which known regulators of Rap1A are knocked down by 
139
RNA could be performed. The knock down that prevents activation of Rap1A by CD151/
ALCAM is likely to be a downstream target of PKCα. Alternatively, we could perform ra-
dioactive labeling assays in the presence and absence of PKC inhibitors. Comparative 
analysis of phosphorylated proteins could reveal the proteins targeted by phosphoryla-
tion by PKCα in response to CD151 clustering.
Rap1 Activation controls motility
 Our data demonstrated that the activation of Rap1A can inhibit motility. Similarly, I 
demonstrated that the expression of the constitutively active non-hydrolyzable Rap1V12 
can similarly inhibit cell migration. Our data conflicts with data generated using other 
cancer cell types and models that suggest that the activation of Rap1 promotes tumor 
cell metastasis and invasion . Specifically, Bailey et. al has shown that the activation of 
Rap1 promotes metastasis of PC3 cells. Mechanistically, they demonstrate that stromal 
derived factor 1 (SDF-1) is involved in the progression of metastasis which is inhibited 
when PC3 cells expressing Rap1GAP (GTPase activating protein) are used (228). In 
another study, McSherry et. al demonstrated that Junctional Adhesion Molecule-A (JAM-
A) can promote the migration of MCF-7 breast cancer cells in a Rap1A-dependent fash-
ion (229). These studies imply that the ability of Rap1A to control migration is both stimu-
lus and cell type specific. Most of the current literature focuses on the activation of 
Rap1A being an positive regulator of migration and metastasis. Our work is one of the 
first to suggest that the activation of Rap1 could potentially act as an inhibitor of cancer 
motility and metastasis. It is possible that Rap1 plays opposing roles in cell-matrix adhe-
sion and cell-cell adhesion. While the activation of Rap1 can promote migration by regu-
lating matrix interactions, it may inhibit tumor cell migration by regulating cell-cell adhe-
sion. In Drosophilla, Knox et al. demonstrated that the expression of Rap1 is sufficient to 
maintain adherens junctions and promote cell-cell adhesion a process that is important 
for proper wing development. Interestingly, one of the key in vitro phenotypes associated 
with clustering of CD151 is a promotion of platelet cell-to-cell adhesion. In tumor cells I 
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also demonstrate that clustering of CD151 promotes the localization of CD151 and AL-
CAM to areas of cell-to-cell contact. The ability to localize GTP-bound Rap1 would allow 
us to determine if Rap1 is similarly localized with CD151 and ALCAM to similar subcellu-
lar locations.
 One significant distinction between the inhibition of cell motility and metastasis 
seen in our studies vs. the promotion of motility seen in other studies is the nature and 
duration of Rap1 signaling. Most studies investigate dynamic activation of Rap1 in re-
sponse to a soluble ligand, activation which is normally short in duration. In contrast, the 
activation that we have investigated in response to cell-surface adhesion promotes per-
sistent (chronic) activation of Rap1. The activation of Rap1 mediated both by CD151 
clustering and ALCAM-ALCAM adhesion is robust and maintained for more than 48 
hours post-stimulation. Is it possible that the perpetual activation of Rap1 inhibits migra-
tion while cycling of Rap1 from the GDP bound to the GTP bound state is able to pro-
mote migration? Our in vitro and in vivo data associated with the expression of the 
Rap1V12 suggests that this is indeed the case. Further support for this possibility comes 
from work done by Freeman et. al who demonstrated that the expression of Rap1V12 is 
able to inhibit the migration of B16 by altering focal adhesion turnover. They further 
demonstrated that focal adhesion turnover and migration is dependent on 1) Rap1 acti-
vation and 2). Rap1 cycling between the GDP bound and GTP bound states. Stabiliza-
tion of focal adhesions is also seen in response to CD151 clustering. In vivo Freeman et. 
al. also show that the activation of Rap1 is able to inhibit the metastasis of B16 cells to 
the lungs in murine experimental metastasis assays (230). Further analysis of Rap1 ac-
tivation in scenarios of cell-cell contact might reveal its contribution to cell migration. It is 
highly likely that the transient activation of Rap1 in response to soluble ligands is func-
tionally and spatially distinct from the activation in response to adhesive interactions. To 
visualize Rap1 activation in live cells treated with 1A5 or plated on ALCAM-Fc, FRET 
analysis could be performed in HEp3 cells expressing pRaichu-Rap1, a commonly used 
141
biosensor of Rap1 activation (231). A comparison of Rap1 activation in response to cyto-
kines vs tetraspanin-mediated adhesions could provide some guidance on future inves-
tigations of this signaling mechanism. Furthermore, detailed investigation of Rap1 in the 
migration of non-transformed cells is warranted to determine how the GTPase contrib-
utes to migration prior to oncogenesis. There maybe distinct changes that occur as a 
function of oncogenic transformation and the mode of  tumor cell migration (ie. epithelial 
vs mesenchymal) might determine the ultimate contribution of Rap1 during metastasis. 
Subcellular localization of the components of the immobility complex
 I have presented data demonstrating that the tetraspanin CD151 controls the mo-
tility and metastasis of tumor cells through the formation of a cell surface complex con-
taining a number of very diverse proteins. The order of events as presented here sug-
gests that clustering of CD151 forms a complex with ALCAM on the cell surface. The 
formation of this complex ultimately activates small GTPase in a PKCα-dependent man-
ner. All of the proteins that we have found to be involved in this mechanism are organ-
ized on the cell surface and their activity is likely to be controlled at least in part by their 
spacial orientation. This is at leas in part supported by the fact that migration in 3D and 
in vivo is inhibited much more by anti-CD151 antibodies than it is in vitro. Visualization 
all of the proteins involved in this mechanism will be important for determining how the 
spatial orientation of the cell and its cell-surface interactions will influence cell migration. 
Our fluorescent tool kit currently under construction may help facilitate new experimental 
imaging of these molecules in 3D and in vivo. Many of the discoveries presented in this 
thesis were made in the chick chorioallantoic membrane (232). Imaging the spatial dis-
tribution of CD151, ALCAM, Rap1 and other participants may greatly clarify how the or-
ganization of these complexes can control tumor cell motility and their subsequent me-
tastasis.
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The integrated model of motility regulation by CD151free
 Chapter 4 of this thesis demonstrated that there are two pools of CD151 ex-
pressed on the tumor cell surface integrin associated (CD151ITGA) and integrin free 
CD151 (CD151free). Additionally, I demonstrated that the ability of CD151 to control motil-
ity is independent of α3β1 integrin and that CD151free is potentially a metastasis pro-
moter. In tumor tissues I also demonstrated that the presence of CD151free is concomi-
tant with the loss of α3 expression. The identity of the protein associating with CD151free 
was answered in chapter 5 where I demonstrated that CD151free associates with 
ALCAM/CD166 (CD151ALCAM) and that this complex promotes migration. The clustering 
of CD151ALCAM by 1A5 inhibits motility in a PKCα and Rap1A dependent manner. Collec-
tively the data generated in these chapters allows me to generate the integrated model 
of motility regulation by CD151 (Fig.37). 
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Concluding Remarks
 The data presented within this dissertation highlights the role of the tetraspanin 
CD151 as a molecular integrator of migration and metastasis. I demonstrated that clus-
tering of CD151 with the migration and metastasis inhibitory antibody 1A5 functions in-
dependently of the integrin α3β1 to control migration. I also show that anti-CD151 anti-
bodies that bind to the integrin-binding motif are able to inhibit migration by clustering 
integrin free CD151 (CD151free). The most exciting aspect of this work is that I was able 
to apply a basic molecular mechanism of migration to an enhanced understanding of the 
progression of metastatic prostate cancer. Mechanistically, clustering of CD151 pro-
motes both cell-matrix and cell-cell adhesion to control migration. This data supports the 
idea that the primary roles of tetraspanins are to function as scaffolding proteins that are 
able to regulate cellular processes by promoting the association of diverse signaling pro-
teins and processes. Clinically we demonstrated that CD151free is present in advanced 
cancers,and can independently predict recurrence and metastasis free survival. This 
data demonstrates that the dissociation from the integrins is clinically relevant. Collec-
tively, the work presented herein highlights a number of key findings: 1) the tetraspanin 
CD151 functions as a master integrator of cell migration and metastasis 2) clustering of 
CD151 is sufficient to control both cell-cell and cell-matrix adhesion 3) there are poten-
tially two pools of CD151 integrin associated (CD151ITGA) and non-integrin associated 
(CD151free) and 4) the expression of CD151free has clinical significance to the progres-
sion of metastatic cancer. In addition to improving our understanding of tetraspanins and 
associated microdomains I elucidated a large part of the mechanism by which the anti-
CD151antibody 1A5 functions to control migration and metastasis. Understanding the 
function of CD151 could ultimately aid in the creation of therapeutics targeting cell motil-
ity in the treatment of metastatic disease.
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 Both CD151 clustering and ALCAM-mediated adhesion trigger Rap1 activation 
and are sufficient to promote tumor cell immobility in vitro and in vivo. Ultimately, I dem-
onstrated that CD151free forms a complex with ALCAM and clustering through tetras-
panin antibodies or ALCAM binding both lead to down stream activation of Rap1A Rap1 
activation has been suggested to promote metastasis however, our data suggests the 
opposite. I demonstrated that perpetual activation of Rap1 is able to inhibit motility by 
promoting adhesion. In addition to the clarity of molecular signaling and the clinical rele-
vance of both CD151free and ALCAM, this work could be useful in the design of therapies 
designed to target motility in metastasis. This work demonstrates that persistent and 
stable adhesions mediated by Rap1 signaling inhibit invasion and metastasis. This im-
plies that cells which lose such stable adhesions are prone to become metastatic. While 
this has been demonstrated for E-cadherin, this thesis suggests that ALCAM maintains a 
positive feed-forward loop that maintains stable adhesions. This loop can be disrupted 
by temporarily or permanently disabling ALCAM. The laboratory is actively investigating 
the regulation of ALCAM. Interestingly, the loss of ALCAM inhibits metastasis suggesting 
that it indeed contributes to dissemination. This role is supported clinically by the findings 
that ALCAM expression not only persists but is frequently upregulated in tumor tissues. 
Conversely, at the protein level ALCAM is subjected to shedding by ADAM17 and ubiq-
uitination by a, currently unknown, E3 ligase. ALCAM shedding elevates greatly during 
cancer progression and this shedding corresponds with poor patient outcome(17). Our 
current interpretation of these observations is that dynamic regulation of ALCAM-ALCAM 
interactions allows tumor cells to engage adhesive properties via Rap1 activation when 
needed. Disabling these same interactions can disable the feed-forward loop, reduce 
adhesion and promote dissemination. Future therapeutic targeting of this process could 
be successful by simply limiting the turnover of ALCAM or limiting the inactivation of 
Rap1. There are likely to be several approaches that could accomplish this. While target-
ing CD151 is likely to have many off-target effects in normal homeostasis, targeting AL-
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CAM shedding or Rap1 (in)activation may provide a means to limit metastatic tumor cell 
migration more specifically. 
 Ultimately this work suggests that metastasis is facilitated by the dynamic regula-
tion of migration not a mere activation of motility. Therefore, in order to truly make in-
roads into the treatment of metastatic disease, it will be necessary to develop a deeper 
understanding of motility and accomplish greater control over the mechanisms that drive 
tumor cell migration.
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A.
APPENDIX
A. RAP1 ACTIVATION IS POTENTIALLY A GLOBAL TETRASPANIN 
MECHANISM
 In chapter 5 of this thesis we determined the identity of the components of the 
immobility complex mediated by the clustering of CD151 on the cell surface. These data 
demonstrated that ALCAM is component of the TERM complex and is functionally re-
quired for the clustering of CD151 to inhibit cell migration. This inhibition of motility was 
dependent on the downstream activation of the small GTPase Rap1A in a PKCα de-
pendent fashion. Like CD151, ALCAM is involved in the regulation of cell motility. Inter-
estingly, when we stimulated ALCAM-ALCAM homotypic interactions by plating tumor 
cells on ALCAM Fc, it also leads to the activation of Rap1 in a PKCα dependent manner. 
Independent of CD151 clustering and ALCAM mediated adhesion, perpetual Rap1 acti-
vation inhibits cell motility in vitro and in vivo. We focused on the role of CD151 in the 
regulation of motility; however, as mentioned earlier CD151 is not the sole cell motility 
and cancer associated tetraspanin. CD9, CD63, CD82, and CD81 are associated with 
motility and monoclonal antibodies to these tetraspanins have been used as tools to 
cluster the tetraspanin. We first verified the expression level of these tetraspanins on the 
cell surface of HEp3 cells by flow cytometry and demonstrated that they are all ex-
pressed albeit at varying levels. In order to determine if the clustering of these tetraspan-
ins  regulates migration we performed transwell migration assays in the presence of 
these antibodies. Cell migration was inhibited significantly in the presence of antibodies 
to all of the tetraspanins except CD63. We then analyzed Rap1 activation levels in the 
presence of all of these antibodies including MAb 1A5 (anti-CD151) and demonstrated 
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that Rap1 is activated in the presence of the migration inhibitory antibodies. This data 
clearly suggests that the activation of Rap1 to control migration mediated by tetraspanin 
clustering is potentially a global mechanism (Fig. A1). This data motivates a number of 
key questions; 1). is PKCα signaling involved in the activation of Rap1 and the inhibition 
of motility 2). are some of the same partner proteins associated with the regulation of by 
CD151 involved and 3). if these tetraspanins do not associate specifically with ALCAM 
do TERM complexes generated by the clustering of these molecules contain CD151 and 
by association ALCAM? Interestingly, in a recent paper by Gilsanz et al it was demon-
strated that CD9 forms a complex with ALCAM in T-cells and that this interaction is im-
portant for regulating activation, proliferation and adhesion of T-cells (233) 
 Rap1 activation is the common mechanism of CD151 clustering and ALCAM me-
diated adhesion. The demonstration that the activation of Rap1 is sufficient to control 
migration and metastasis by Freeman et. al strongly supports the data presented in this 
thesis. The decrease in focal adhesion turnover, combined with an an increase in paxillin 
localization in Rap1V12 expressing cells further supports the role of adhesions in the 
regulation of migration and subsequent metastasis(230). Interestingly, CD151 clustering 
also leads to increased focal adhesion formation as evidenced by an increase in paxillin 
staining in 1A5 treated cells (Fig. A2). It would interesting to determine if the clustering of 
CD151 is able to control migration through the regulation of focal adhesion turnover(24). 
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